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Zusammenfassung: 
In dieser Doktorarbeit wurde der 5-Methylcytosin (mC) Gehalt von Zellen, die von Pavel 
Bashtrykov mit verschiedenen DNA-Methyltransferase 1 (DNMT1) Mutanten transfiziert 
wurden, mittels einer LC-MS/MS Isotopen-Verdünnungsmethode bestimmt. Dabei konnte 
gezeigt werden, dass eine Mutation der Aminosäuren 572 und 575 von Glutamat bzw 
Aspartat zu Arginin einen erhöhten Level an mC zeigt. Dies konnte durch den 
Kooperationspartner mit einer in vitro-Aktivitätsbestimmung bestätigt werden, in der die 
Mutante sogar noch deutlich höhere Aktivitäten als der Wildtyp zeigten.[1]  
Dadurch konnte eine Hypothese bestätigt werden, nach der das Enzym durch die Bindung 
einer N-terminalen Proteindomäne über ionische Kontakte an den katalytischen Teil des 
Proteins im C-Terminus reguliert wird (Abb. 1).[2]  
 
 
Abbildung 1: A) Schematische Sicht der allosterischen Selbstregulation der RFTS Domäne von DNMT1 
und der Mutationsseiten (rot) B) Darstellung des 5-Methylcytosin Gehalts in genomischer DNA der 
Kontrolle und des Wildtyps (blau) und der verwendeten Mutante (rechts, rot). Hierbei sind leicht erhöhte 
Werte der Mutante erkennbar. 
 
Seit 2009 ist die Oxidation des mCs durch die ten eleven translocation (TET) Proteine zu 
5-Hydroxymethyldesoxycytidin (hmC) bekannt und ein oxidativer Weg zur aktiven 
Demethylierung wurde vorgeschlagen.[3-5] Mittels einer LC-MS Isotopen-
Verdünnungsmethode, die insbesondere von Daniel Globisch entwickelt wurde, konnte in 
dieser Doktorarbeit der Gehalt von hmC in einigen Hirntumorgeweben bestimmt werden.[6] 
Es konnte gezeigt werden, dass diese Modifikation in den untersuchten Tumortypen stark 
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reduziert ist und ein geringer hmC-level als Tumormarker in Betracht gezogen werden 
könnte. 
In einem anderen Teil dieser Arbeit konnte gemeinsam mit Toni Pfaffeneder eine weitere 
Oxidationsstufe des Cytidins (dC) in der DNA von embryonalen Mäusestammzellen (mESC), 
das 5-Formyldesoxycytidin (fC), mit Hilfe modernster Massenspektrometrie entdeckt und 
grob quantifiziert werden (Abb. 2).[7] Es wurde vorgeschlagen, dass es sich hierbei um ein 
weiteres Intermediat der oxidativen aktiven Demethylierung handelt und von den TET 
Proteinen gebildet wird. Darüber hinaus konnte es erfolgreich chemisch modifiziert werden, 
was unter anderem dazu beitrug die genomische Verteilung der Modifikation zu bestimmen.[8] 
 
 
Abbildung 2: A) Illustration des oxidativen aktiven Demethylierungsvorgangs. B) Spektrum des in mESC 
DNA neu entdeckten 5-Formylcytidins. 
 
Diese Entdeckung konnte kurz darauf von einer anderen Gruppe unabhängig bestätigt 
werden.[9]  
Darüber hinaus wurde in einem Isotopen-Verfolgungsexperimentes ein Oligonukleotid mit 
einem stabil markierten Isotopolog des 5-Carboxylcytidins (caC) synthetisiert, mit 
Kernextrakt von mESCs inkubiert und anschließend durch Affinitätsaufreinigung 
wiedergewonnen. Dabei konnte markiertes dC massenspektrometrisch und damit auch erste 
Hinweise auf eine aktive Decarboxylierung nachgewiesen werden (Abb. 3).[10] Ein in dieser 
Arbeit synthetisiertes stabil markiertes Isotopolog des dC diente dabei als Standard.  
Dieser Standard wurde auch bei weiteren Experimenten genutzt die die Decarboxylierung 
untermauerten. Hierbei wurden von Dr. Stefan Schiesser katalytische Zentren möglicher 
Enzyme durch die Verwendung von beteiligten Aminosäuren simuliert. Durche hohe 
Konzentration von Thiolen in Anwesenheit von Katalysatoren konnte eine Decarboxylierung 
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beobachtet werden. Die exakten Mengen der Decarboxylierung wurden anschließend über 
eine neue Fragmentierungsmethode an einem Triple-Quadropol LC-MS/MS Gerät, die von 
Toni Pfaffeneder entwickelt und für die im Rahmen dieser Dissertation interne Standards 
hergestellt wurden, bestimmt. Es konnte gezeigt werden, dass unter den getesteten 
Bedingungen durch C(5)-C(exo) Bindungsbruch bei caC bis zu 30% dC entstand. Der 
Bindungsbruch bei fC lag bei nur 1/10 verglichen mit caC und bei hmC war er 
vernachlässigbar gering.  
 
 
Abbildung 3: A) Illustration des Arbeitsschemas zur Verfolgung eines caC markierten Oligonukleotids. Y 
ist Biotin-desoxy-Uridin, das zur Affinitätsaufreinigung genutzt wurde B) Darstellung des Spektrums von 
dC nach Inkubation mit Kernextrakt von mESCs (links), oder der Kontrolle (rechts). Stabil markiertes 
dC in der Anwesenheit von natürlichem dC in der mit Kernisolat behandelten Probe (grün). C) 
Darstellung der Effiziens des CC Bindungsbruchs der verschiedenen Oxidationsprodukte nach der 
Inkubation mit einer hohen Thiolkonzentration. 
 
Desweiteren wurde der Einbau von Triphosphaten der neuen Cytidin-Derivate, die von Dr. 
Stefan Schiesser und Barabara Steigenberger synthetisiert wurden, durch diverse 
Polymerasen etabliert und massenspektrometrisch verifiziert (Abb. 4).[11] Dadurch stehen 
nunmehr lange DNA Fragmente mit den neuen epigentischen Basen zur Untersuchung der 
verschiedenartigen biologischen Prozesse zur Verfügung. 
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Abbildung 4: A) Darstellung des Gels von PCR Fragmenten nach der Inkorporation der Triphosphate. 
1&2: Negativ Kontrolle ohne Templat und ohne dCTP, 3: positiv Kontrolle mit dCTP, 4: hmCTP, 
5: fCTP, 6: caCTP. B) LC-MS/MS Analyse von Fragment 5 nach Totalverdau. Klar zu erkennen ist die 
Detektion von fC sowohl mittels UV-Detektor (links) als auch mittels MS/MS  Fragmentierung(rechts). 
 
Mit Hilfe der bereits erwähnten LC-MS/MS Methode konnte durch Toni Pfaffeneder mit 
5-Hydroxymethyluridin (hmU) ein weiteres DNA-Nukleosid als Oxidationsprodukt der 
TET-Enzyme in Stammzellen entdeckt und quantifizert werden. Dieser DNA-Baustein wurde 
im Rahmen der aktiven Demethylierung bisher mit einer Deaminierung von hmC in 
Verbindung gebracht und galt als ein weiteres mögliches Intermediat, da es von speziellen 
Glykosylasen erkannt wird. Darüber hinaus konnten einige Proteine indentifiziert werden, die 
an diese spezielle DNA-Base binden (Abb. 5).  
 
 
Abilldung 5: Illustration der Generierung von hmU aus dT durch die TET Proteine und mögliche 
Beteilung an diversen biologischen Prozessen. 
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Summary: 
In this thesis the level of 5-methylcytidine (mC) in cells, that were transfected by Pavel 
Bashtrykov with different DNA-methyltransferase 1 (DNMT1) mutants, was determined 
using an LC-MS/MS isotope dilution method. It could be shown that the level of this mutant 
was elevated when the residues 572 and 575 in the protein were mutated from a glutamate and 
an aspartate to arginine residues. Additional in vitro activity studies by the collaboration 
partner confirmed a higher methylation activity of the DNMT1 mutants. This confirmed a 
hypothesis of self-regulation.[1] In this theory the protein is regulating its own activity by 
binding of an N-terminal domain via ionic contacts to the catalytic domain at the C-terminus 
(Fig. 1).[2] 
 
 
Figure 1: A) Schematic view of the allosteric self-regulation of the N-terminal domain (blue) and the 
mutation sites (red dots). B) Illustration of the 5-mC content in the genomic DNA of the control, the 
wildtype (blue bars) and the mutant enzyme (red). Slightly enhanced methylation in the mutant version 
compared to the wild type enzyme. 
 
Since 2009 the oxidation of mC by the ten eleven translocation (TET) proteins to 
5-hydroxymethylcytidine (hmC) is known, leading to the hypothesis that an oxidative 
pathway for active demethylation exist.[4-5] Using a stable isotope dilution LC-MS method, 
developed by Daniel Globisch, the content of this modification in the tissue of brain tumors 
was determined.[6] It was shown that hmC was strongly reduced in the investigated tumor 
types. This result might allow using hmC-levels as tumor markers.  
In another part of this thesis another cytidine modification, 5-formylcytidine (fC), was 
discovered, together with Toni Pfaffeneder, in the genomic DNA of mouse embryonic stem 
cells (mESCs) using highly sophisticated mass spectrometry (Fig. 2).[7] It is proposed that it is 
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a further intermediate in the active demethylation cycle and that this modification is also 
generated from hmC by the TET enzymes. Furthermore a method for chemical modification 
of fC was developed, that was later used by another group to determine the genomic 
distribution of this modification.[8] 
 
 
 
Figure 2: A) Illustration of the active demethylation cycle. B) Spectrum of the newly discovered 
5-formylcytidine in mESCs. 
 
The discovery of fC in genomic DNA of mESC was confirmed later on by another group. 
They could also identify the last proposed intermediate of the active demethylation cycle, 
namely 5-carboxylcytidine, as a product of the TET enzymes in mESCs.[9]  
Moreover an isotope tracing experiment with an isotopically labeled 5-carboxycytidine (caC) 
in an oligonucleotide was performed in this thesis. After incubation with nuclear extracts of 
mESCs the oligonucleotide was re-isolated using affinity purification and enzymatically 
digested to the nucleoside level. The isotopically labeled dC was discovered, which provided 
evidence for the existence of a decarboxylase activity (Fig. 3).[10] A labeled nucleoside 
standard of dC was synthesized and used as a standard for the MS experiments. 
Additionally this standard was used by Stefan Schiesser to perform chemical decarboxylation 
experiments to validate the earlier finding. Active sites of possible decarboxylases were 
mimicked by using different amino acid combinations. High concentrations of thiols in the 
presence of catalysts lead to the same signal of labeled dC.  
The exact amount of the chemical decarboxylation was then determined using a new low 
resolution fragmentation method on a triple-quadruple LC-MS/MS machine. This method was 
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Figure 3: A) Illustration of the workflow for the tracing of the oligonucleotide carrying the marked caC. Y 
is biotin-desoxyurdine, which was used for the affinity purification. B) Illustration of the spectrum of dC 
after the incubation with nuclear extracts of mESCs (left), or of dC in the control experiment (right). The 
traced stable isotope of dC is marked in green. C) Illustration of the efficiency of the C-C bond cleavage of 
the different oxidized mC derivatives after incubation with high concentrations of a thiol. 
 
developed by Toni Pfaffeneder and used several standards, that were synthesized or purified 
in this thesis. It could be shown that the C(5)-C(exo) bond cleavage of caC was the most 
efficient reaction under the tested conditions , it resulted in up to 30% dC formation. 
Furthermore the incorporation of the triphosphates of the new cytidine derivatives using 
polymerase chain reaction was established and confirmed by LC-MS/MS (Fig.4).[11]  
 
 
Figure 4: A) Illustration of the agarose gel containing the PCR fragments after incorporation of the newly 
synthesized triphosphates. 1&2: negative controls without template or without dCTP, 3: positive control 
with dCTP, 4: hmCTP, 5: fCTP, 6: caCTP. B) LC-MS/MS analysis of fragment 5 after total digest. The 
incorporated fC is clearly detectable using UV light (left) or MS/MS fragmentation (right). 
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The triphosphates were synthesized by Stefan Schiesser and Barbara Steigenberger. Now 
long DNA fragments containing the new epigenetic bases are available for investigations of 
epigenetic processes. 
Using the earlier mentioned LC-MS/MS method, Toni Pfaffeneder identified 
5-hydroxymethyluridine (hmU) as a product of TET-enzymes in the DNA of mESCs (Fig. 5). 
This nucleotide was connected with the deamination of hmC and was suggested to be another 
intermediate of active demethylation, as it is recognized by special glycosylases. Furthermore 
specific readers for this novel DNA-base were identified.  
  
 
Figure 5: Illustration of the generation of hmU from dT by TET proteins and of the biological processes it 
might be involved in. 
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I. Introduction 
1. Pluripotent cells in modern medicine 
Understanding cellular differentation on the molecular level is one of the main challenges of 
the 21st century. The life of a vertebrate organism starts with the fertilization of an egg by a 
sperm cell resulting in a zygote.[12] Out of this zygote, the whole multicellular organism 
develops by cell division and cell differentiation. The ability of these cells to found a whole 
organism is called totipotency.[13] After a few cell divisions, the blastocyst is formed. It 
consists of the inner cell mass and the outer trophoblast. The cells of the inner cell mass begin 
to differentiate and are no longer able to form an individual on their own anymore, however, 
they can still differentiate into any of the three germ layers (endo-, meso-, ectoderm)-this state 
is called pluripotent.[14] In 1981 the first cultured embryonic stem (ES) cells could be isolated 
from the inner cell mass of a mouse embryo and expanded in vitro.[15-16]  
 
“Pluripotential embryonic cells appear to give rise to both rapidly differentiating cells and 
others which like themselves, remain undifferentiated.” – LeRoy Stevans and Clarence 
Little.[17] 
 
In 1954 this definition of an ES cell was stated by LeRoy Stevans and Clarence Little and is 
valid until today. Because of their ability to develop to any kind of cell type and tissue, these 
cells are of interest for modern medicine. They promise to replace non-healthy tissue by a 
new tissue generated from stem cells. However stem cell therapy has a number of drawbacks 
still to overcome, as it is difficult to control the differentation of stem cells to a certain tissue 
and many differentiation pathways are to date unknown. The major problems are the 
availability of stem cells due to the ethical dilemma of the death of an embryo when isolating 
ES cells and the immune response to foreign cell material. To avoid this it has been tried to 
gain pluripotent cells from other sources. In 2012 the Nobel Prize was awarded to John B. 
Gurdon and Shinya Yamanaka, two pioneers in the area of nuclear transfer and induced 
pluripotent stem cells (iPSC). These cells derive from somatic cells that are reprogrammed by 
several factors to the pluripotent state. These so called Yamanaka factors, Oct4, Sox2, Klf4 
and c-Myc, are part of a complex regulatory network, the so called pluripotency network that 
is unique to pluripotent cells.[18-19] A core network of more than a dozen transcription factors, 
including three of the Yamanaka factors, which tightly regulate each other’s expression is 
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responsible for the pluripotent state of the cell (Fig. 6). Other methods for reprogramming 
have been shown, most recently a still controversially debated method that induced 
reprogramming by external stimuli, such as low pH.[20-22]  
These iPSCs are very similar to ES cells, as they are able to divide indefinitely and are able to 
differentiate, however they have some disadvantages such as the low efficiency of 
generation.[23]  
Understanding the reprogramming processes and the unique genomic properties of pluripotent 
cells on the molecular level, has the potential to contribute to modern medicine. A current 
example of stem cell therapy is the stand alone growth of live murine teeth.[24] This technique 
has in principle the capability to replace protheses and give rise to new teeth. Volponi et al. 
have summarized the ongoing research in a review.[25] 
 
 
Figure 6: Illustration of the core transcription factor network for pluripotency. Yamanaka factors are in orange. 
C-myc is not a part of the core pluripotency network. 
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2. Epigenetics  
In order to understand the process of reprogramming, it is important to understand the 
reversible process of cell differentiation. As described a neuron and a lymphocyte derive from 
the very same totipotent cell (Fig. 7). The diversity of cell types is thus dependent on 
regulations beyond the genetic code. These regulations are taken together in the scientific 
field of epi-genetics (greek: epi- beyond).[26] 
Necessary for the diversity is a “switch” on of the transcription of cell specific genes and 
hence different expression patterns. These genes include the pluripotency network, which is 
downregulated upon environmental signals and furthermore tissue type specific genes that are 
upregulated. Consequently the cell is epigenetically programmed to differentiate. Not only 
tissue cells differ in their epigenetic status. Comparing ES cells cultured with different signal 
pathway inhibitors, Nichols and Smith established in 2009 the concept of “naïve” and 
“primed” cells.[27] They differ on the molecular level in their epigenetic status and are 
therefore developmentally and functionally different. 
The molecular level of these regulations is established by specific promoters and enhancers on 
the DNA-level, together with a set of special transcription factors on the protein-level. These 
levels are so called cis- and trans-elements. In the environment of our genetic code, the 
chromatin, these elements control gene expression.  
 
 
Figure 7: Possible differentiation of stem cells to distinct cell types. 
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The genetic information is converted into messenger RNA (mRNA) and ultimately translated 
into proteins. The different repertoire of proteins at a certain location and time point, the 
proteome, is controlled by several processes such as proteosomal degradation, however only 
epigenetic marks can, just like the DNA sequence, be stably inherited.[28] Epigenetic 
mechanisms play a major role in the chromatin environment and work, in part, via its physical 
properties. One of two major epigenetic mechanisms is the dynamic regulation of the 
nucleosome structure. 
 
2.1 Histone modifications 
DNA is wrapped around histones, forming the nucleosomes, to gain the extreme compaction 
necessary to store the huge genetic information of our genome into the nucleus. There exist 
four core-histones, H2A, H2B, H3 and H4 as well as a huge number of special histone 
variants.[29-30] 
The Nucleosomes are built up out of one H3/H4 tetrameric complex and two H2A/H2B 
dimers forming a histone octamer.[31] These octamers have several positive charges on their 
outside and therefore attract DNA. They act as spools on which the DNA is wrapped around 
and therefore stored in a very compact form. At certain amino acid side chains in their long 
N-terminal ends, the so called tails, histones can be covalently modified. As these 
modifications have been investigated for several decades we have been able to gain a broad 
knowledge about them. More than 100 different modifications have been described, which 
range from well-known ones such as lysine acetylation, lysine methylation and 
serine/threonine phosphorylation to less understood ones such as crotonylation or poly-ADP 
ribosylation.[32-33] 
In 1961 histone acetylation has been discovered and investigated ever since.[34] Lysine 
residues can be acetylated by histone-acetyltransferases (HATs) using acetyl-CoA and 
deacetylated by histone-deacetylases (HDACs).[35-36] HATs, HDACs and histone 
hyperacetylation have been reported early to associate with high transcriptional activity.[37] 
In vitro and in vivo studies have supported the idea that neutralization of the positive charge 
of lysine residues by acetylation leads to weakened DNA binding.[38-39] Thus promoter- and 
enhancer-DNA is physically better available for the transcription machinery and other 
biological processes such as DNA repair. The half-life of acetylation marks is in the range of 
a few minutes and thus acetylation and deacetylation is a highly dynamic process, to ensure 
quick recovery of a more densely packed chromosome.[40] 
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Histones can also be phosphorylated by distinct kinases or poly-ADP ribosylated by 
poly-ADP ribosylation polymerase (PARPs) on serine and threonine side chains, leading to a 
negative charge on histone tails and therefore presumably to charge repulsion with the DNA 
backbone.[41-42] Similar to acetylation, the resulting looser packed DNA has enhanced 
availability. The major processes associated with poly-ADP ribosylation are DNA repair and 
heat shock response, whereas phosphorylation is mainly involved in cellular development and 
regulation of other histone modifications.[43-45] 
Another well investigated modification is mono-, di- and tri-methylation of lysines.[46-48] It is 
carried out by histone methyltransferases (HMTs) using S-adenosyl methionine (SAM) as 
cofactor.[46,49-50] About 60 different HMTs have been annotated in the human genome and 
most of them harbor a Su(var)3-9, Enhancer-of-zeste, Trithorax (SET) domain, the catalytic 
active domain.[51] The exposure time of lysine residues to SET domains is important for the 
methylation state and is regulated by chromatin remodeling and other histone modifiers.[52] It 
has been suggested that methylation has indirect effects on nucleosome dynamics by 
interaction with different partners, rather than a general direct mechanistic effect.[53] Some of 
the recognizing elements of the three lysine methylation states are the Chromo-, PWWP-, 
plant homeo- (PHD) and Tudor-domains frequently found in cis-regulatory elements and 
chromatin associated factors.[54-55] 
Methylation of different lysine residues therefore has different effects on transcriptional 
regulation. A mark generally associated with active transcription is H3K4 trimethylation, 
which is found at transcription starting sites (TSS) in eukaryotes. Its presence correlates 
positively with active transcription.[56] However there are also bivalent marks such as H3K27 
which depending on its methylation status and surrounding histone marks can either activate 
transcription or repress it. Mono- and di-methylation marks on H3K27 are only observed in 
combination with phosphorylation of H3S28 and are associated with active transcription, 
whereas trimethylated H3K27 is only observed in the absence of H3S28P and associated with 
repression.[56-57]  
In the younger history of histone research, conserved histone demethylases have been 
identified in yeast and humans.[58-59] They contain a jumonji C (JmiC) domain that is able to 
oxidize the methyl groups using FeII and -oxogluterate (2-OG) to hydroxymethyl-lysines. 
The oxidized methylgroup is then released as formaldehyde. Demethylases are reported to act 
strictly dependent on the methylation status, as JHDM1A is only able to demethylate di-
methylated H3K9 whereas JHDM3A is able to demethylate tri-methylated H3K9.[59-60] 
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The heavy intra- and inter-crosstalk of histone modifications and modifiers indicates the tight 
regulation and strong dynamics of these processes (Fig. 8). Their improper activity can lead to 
several diseases, especially to cancer, as the expression of several oncogenes can be 
altered.[61] Correct dynamic histone modifications are also important for the developmental 
status and pluripotency of cells. Bivalent marked genes, so called “poised” genes are 
associated with pluripotent cells and are necessary for their rapid differentation.[62] Another 
very important crosstalk of histone modifications for pluripotency, is the connection of 
histone modifications and modifiers to the second major mechanism of epigenetics, DNA 
methylation. [63-64] 
 
 
Figure 8: Illustration of chromosome arrangement and dynamic regulation of histone modifications. 
Recognizing elements of different biological processes are indicated with arrows. 
 
2.2 DNA methylation 
Histone modifiers and modifications can recruit DNA-Methyltransferases (DNMTs) to 
specific gene loci.[65] DNA methylation in eukaryotes was first discovered in 1948 by 
Hotchkiss and is involved in several cellular events, such as cellular development, gene 
expression, chromatin remodeling and regulation of parental imprinting as well as 
stabilization of X chromosome inactivation.[66-71] DNA methylation occurs at several DNA-
sites, however the most important and abundant site is the so called CpG site. Of CpG sites 
about 60-80% are methylated, which corresponds to about 4-6% of all cytosines.[72] If the 
observered frequency of a CpG site on 200 base pair length is higher than statistically 
expected, these regions are defined as CpG islands (CGI). The CGIs occur mainly in promoter 
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regions and can be found in about 70% of all human genes.[73-74] CGIs are classified in high-, 
medium- and low-density CGIs, depending on the frequency of CpG sites. In promotors high 
density CGIs are usally unmethylated, whereas especially low density CGIs seem to be more 
frequently methylated.[75-76] The CG dinucleotides are in comparison to the other 
dinucleotides statistically underrepresented, because deamination of 5-methyldesoxycytidine 
(mC) to desoxythymidine (T) is about 4 times faster than deamination of C to T and its repair 
is not as efficient as for other mutations.[77-78] Therefore during evolution, it is thought that 
many CG sites were lost.[72] Several enzymes can bind methylated cytosine via a methyl-CpG 
binding domain (MBD) because the methyl group is pointing into the major groove of the 
DNA.[79] These proteins can either make promoters unavailable for transcription factors or 
directly recruit inhibitors of transcription.[80]  
 
 
Figure 9: Conserved mechanisms of DNA methyltransferases: Briefly an attack of a cysteine residue on 
the C(6) of cytosine leads to formation of a covalent enzyme-substrate intermediate. After attack of the 
formed enamine on the methyl group of S-adenosyl-methionine (left box; up), syn-elemination leads to the 
product 5-methyldesoxycytidine and S-adenosyl-homocysteine (left box; bottom) 
 
Therefore mC is strongly correlated with transcriptional repression. As described DNMTs can 
be recruited by histone modifiers, however, also the inverse recruitment is known and leads to 
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chromatin remodeling.[81] Aberrant mC levels can lead to serious diseases, the best 
investigated of them being cancer. Wrong methylation patterns can, just like aberrant histone 
modifications, lead to upregulation of oncogenes and downregulation of tumorsupressors, 
which may lead to unregulated cell growth and tumorogenesis.[82]Methylation patterns are 
also important for cell differentation as each cell type is methylated at specific sites.[83] 
Methylation is carried out by DNMTs using a highly conserved mechanism. The catalysis is a 
nucleophilic attack of a cysteine residue in the active site at the C(6) position of cytosine, after 
flipping the target base into the active site.[84] This leads to a covalently bound DNA-protein 
intermediate and a double bond at the C(4)-C(5) position forming an enamine. This enamine 
attacks the methyl group of the co-substrate SAM in an SN-type reaction. After syn-
elemination of the cysteine residue 5-methylcytosine (mC) is released (Fig. 9) . 
 
2.2.1 DNA Methyltransferases 
There are three types of mammalian methyltransferases sharing a similar structure and 
catalyze the same reaction, the maintenance methyltransferase DNMT1 which is responsible 
of copying methylation marks to newly synthesized DNA together with its interaction partner 
ubiqutin-like plant homeodomain and RING finger domain (UHRF1) and two de novo 
methyltransferases DNMT3a and DNMT3b. 
Mouse DNMT1 comprises 1620 amino acids and its N-terminal region harbours several 
interaction and regulation domains.[72] It contains the nuclear localisation singal (NLS) and 
the CXXC zinc finger domain, which is a common DNA binding motif.[85] Also a sequence to 
target the enzyme to replication foci (RFD) and a PCNA binding domain (PBD), both guiding 
the enzyme to the newly synthesized DNA substrates at the replication fork, are located 
there.[86-88] To achieve localistation there, UHRF1 interacts with the RFD domain and acts as 
a molecular chaperone of DNMT1, guiding it to CpGs at the replication fork by binding hemi-
methylated DNA over its SET and RING finger-associated (SAR) domain (Fig. 10).[89-90] It 
can discriminate between fully methylated DNA and hemi-methylated DNA by steric 
repulsion and flips out mC into its active site, were specific contacts are made.[91-92] At the 
hemimethylated sites DNMT1 has a high processivity and methylates long stretches of DNA 
without dissociating or swaping the DNA strand.[93] The polybromo homology domain of 
DNMT1, whose function is to date unknown, as well as an autoinhibitory domain, that has 
recently been discovered and shown to prevent de novo methylation, are haboured in the 
N-terminus.[94] The C-terminal region contains the MTase domain and is seperated from the 
N-terminal region by GK repeats (Fig. 10). 
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Figure 10: A) Schematic view of the structure of mouse DNMT1 and human UHRF1. B) Crystal structure 
of mDNMT1. The binding of the RFTS domain (yellow) to the DNA binding pocket of DNMT1 that is 
located in catalytic part (dark green) is stabilized by several hydrogen bonds and ionic contacts (indicated 
by arrows) and leads to intrinsic supression. Important contacts of the RFTS domain are labeled (light 
green). Residues of the catalytic domain and the CXXC domain involved in interaction with the RFTS 
domain are shown in pink. These images have been prepared using the crystal structure (PDB code: 
3AV4) published by Takeshita et al. (2011) and was taken from Bashtrykov et al.[1] 
 
UHRF1 comprises of 793 amino acids and can enhance DNMT1´s activity by about 5-fold.[95] 
Additionally, UHRF1 connects DNA methylation directly to histone modifications, as its 
PHD and Tandem Tudor domain recognize H3K9-trimethylation.[95-96] Other binding partners 
are histone deacetylase 1, histone acetyltransferase and PCNA.[90,97-98] Due to its interaction 
 10 
 
partners, it is therefore proposed that it is part of a multiple enzyme complex that is 
responsible for the epigenetic code replication machinery.[99]  
It is the most important regulator of DNMT1 and is also involved in proteasomal degradation 
of DNMT1 by acting as E3 Ligase.[100] In UHRF1 double knock-out mES cells and mouse 
embryos the global methylation drops as much as in a DNMT1 double knock-outs.[90,101] Thus 
as it stands UHRF1 and DNMT1 together are responsible for the correct inheritance of 
methylation patterns.  
While the C-terminal catalytic part of DNMT3a/b are very homologous, the regulatory N-
terminal part contains different domains. A cysteine-rich plant homeo domain (PHD), also 
known as ATRX-DNMT3-DNMT3L (ADD) domain, binds zinc and is known to take part in 
various protein-protein interactions, such as with the nucleosome associated proteins myc, 
SETDB1, BRg1 and HDAC1 (Fig. 11).[65,102-104] 
A conserved proline-tryptophane motif (PWWP domain) is also located at the DNMT3a/b N-
terminus. It is part of the royal domain super-family that is known to bind to histone tails with 
various marks.[55] These interactions lead to pericentromeric chromatin localisation and 
enhanced activity.[105-106] 
DNMT3L, another member of the DNMT-family in mammals, is catalytically not active as 
the C-terminal part lacks serveral motifs of the methyltransferase domain and cannot bind the 
cofactor SAM. The N-terminal part just like DNMT3a/b contains the PHD domain which is 
necessary for the interaction of the DNMT3s.[107-108] Via these interactions it plays despite its 
inactivity an important role in de novo methylation, which is described later in this chapter. 
Genetic studies on DNMT knock-out mice prove their significant role in cellular 
development, as all DNMT knock-outs are lethal and mutations in these genes lead to severe 
diseases. But they also show the differences in the contribution to DNA methylation.  
DNMT1 knock-out mice die shortly after gastrulation, show loss of genomic imprinting and 
X-chromosome inactivation.[109-111] Dnmt3a knock-out mice develope to term, but die shortly 
after birth, while DNMT3b deficient mice die in utero at embryonic day E9.5. These 
phenotypes indicate that the enzymes despite their structural and biochemical similiarties 
cannot complement each other.[112] The indispensable role of DNMTs in mammalian 
development makes it necessary to control their activity and location tightly. 
Maintenance methyltransferase DNMT1, that is highly expressed in dividing cells, has a 
preference to bind to double stranded hemi-methylated CG-sites in a CG rich context, 
however it also binds to poly-(dA), -(dT), -(dG), -(dG/dC) DNA, poly (ADP-ribose), fully 
methylated double stranded DNA (dsDNA) as well as methylated single stranded DNA 
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(ssDNA).[113-118] However binding does not correlate with the kinetics of methylation, as most 
of the binding partners show slow methylation kinetics or are even unsuitable as 
substrates.[119]  
 
 
Figure 11: A) Schematic view of DNMT3 proteins. B) Crystal structure of the DNMT3a/L tetrameric 
complex. Zoom into the interaction sites of DNMT3a (purple) with another DNMT3a molecule over polar 
contacts of aminoacid residues H869, H872 and R881. Interaction site of DNMT3a with DNMT3L (both 
salmon) is comprised of residues F768, F728 of DNMT3a and F301 and F261 of DNMT3L. SAH in spheric 
illustration. PDB code: 2QRV.[120] 
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through a network of hydrogen bonds and form the DNA binding site (Fig. 11).[139] 
Interaction over hydrophobic contacts with DNMT3L seems to introduce a conformational 
change that increases binding to SAM, and hence its activity.  
Additionally, the complexity of the regulation of DNA-methylation is greatly enhanced by 
post-translational modifications, such as sumoylation or phosphorylation, by the existence of 
different isoforms of DNMTs and distinct localisation during the cell cycle and embryonic 
development. [72] 
DNA methylation, however, is not only tightly controlled, as evidence occurs that it is 
reversible too, and thus like histone modification a dynamic process during mammalian 
development. 
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2.3 DNA Demethylation 
As the transcriptional requirements upon cell specification change very fast, a dynamic and 
flexible epigenome is necessary. In contrast to that DNA methylation was thought to be a 
stable epigenetic mark and the only possibility to remove it was by diluting it during DNA-
replication (Fig. 12), recent studies suggest a more dynamic picture. The loss of methylation 
marks has been observed genome-wide and locus specific upon different stimuli. Comparing 
the methylation levels during embryonic development they appear strongly altered. Only 4-8 
hours after fertilization the mC-levels of the paternal pronucleus drop rapidly.[140-141] As the 
first cell division is not thought to take place at that time and this change was shown to 
happen in the presence of a replication inhibitor, a passive demethylation by impaired 
DNMT1 activity is unlikely.[141]  
 
 
Figure 12: Schematic view of the mC levels during early cell development (box); Overview of possible 
proceedings with methylation marks: maintenance of methylation (orange mark) after replication on the 
left site, passive demethylation after replication and inhibited DNMT1 activity in the middle and active 
removal of mC on the right.[142] 
 
Another wave of active genome-wide demethylation occurs in primordial germ cells. Here 
almost all methylation patterns including the one of imprinted genes are removed.[143] 
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Additionally locus specific demethylation has been reported in non-dividing neurons, in T-
lymphocytes and during hormone-regulated gene activation.[144-146] 
It is hard to imagine that one single mechanism is responsible for these very different 
demethylation events. Therefore a number of pathways and mechanisms have been proposed 
and investigated. 
 
2.3.1 Base excision repair of mC 
In plants base excision repair (BER) of mC is thought to be the major pathway of active 
demethylation and it is carried out by the family of Demeter (Dme) nucleases.[147]  
BER has two mechanisms: 
1. The short patch mechanism of BER starts with the recognition of the damaged base. It 
is then flipped out of the DNA into the active site of the enzyme and the nucleobase is 
removed via a SN1-type reaction after the attack of a water molecule. Then an 
endonuclease cuts the resulting abasic site (AP-site) moiety out of the DNA leading to 
a single strand break. In case of a bivalent nuclease the endonuclease is not necessary, 
as this step is carried out by the nuclease.[148-149] PARPs bind to these nicks and recruit 
a DNA polymerase and a ligase to fill in the gap.[150] 
2. The alternative long patch mechanism involves the excision of 3-5 bases upstream by 
strand displacement of the polymerase followed by ligation.[148-149] 
Both pathways result in the replacement of mC by C. 
DNA-methylation in plants is not restricted to CpG sites as CpNpG and CpNpN 
(N = A, T or C) can be methylated as well.[66] The Dme family members are able to recognize 
and remove mC in this context in vitro.[151] A mutation in one of the family’s genes leads to 
hypermethylation in vivo in all sequence contexts, however, at distinct genomic loci, 
suggesting an individual function for each of them.[151-154] 
Despite the lack of Dme orthologes in mammals, the same pathway has been reported here as 
well. The first reports proposed Thymine DNA Glycosylase (TDG) as a glycosylase for mC, 
however, its activity on mC was 30-40 fold lower than on T-G mismatches.[155-157] Another 
enzyme proposed to excise mC is the methyl-CpG-binding protein MBD4.[158] Yet again its 
activity is 30-40 fold slower than on T:G mismatches. In addition MDB4 null mice are vital 
and exhibit normal demethylation of the zygotic paternal pronucleus, however, they show an 
increased number of C to T mutations.[159-160] These facts show that the biological relevance 
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of the excision of mC is presumably very low as impaired active demethylation should lead to 
developmental defects and no glycosylase with high activity for mC excision in mammals has 
been found to date. 
 
2.3.2 Deamination of mC 
Another pathway thought to play a role in active demethylation was deamination of mC and 
removal of the resulting T-G mismatch by the earlier mentioned TDG and MBD4. Cytosine 
deaminases as well as DNMTs have been proposed to play a role in the first part of this 
pathway. The most prominent members of cytosine deaminases are activiation-induced 
deaminase (AID) and the apolipoprotein B pre-mRNA editing enzyme, catalytic polypeptide 
(APOBEC).[161-162] They have several important biological functions, such as antibody 
recombination in B-Cells, RNA editing and retroviral defense.[163] They are both capable of 
deaminating mC to T in single stranded DNA in vitro and in an E.coli assay.[164] As a 
consequence of their genomic location in a pluripotency gene cluster, AID and APOBEC are 
expressed in mouse oocytes, ES cells and primordial germ cells (PGCs). [164]  While a large 
scale bisulfite sequencing study indicates a small contribution to active demethylation in 
PGCs, the global methylation level shows that the main factors of demethylation are yet to be 
identified.[165] Studies in zebra fish embryos could reveal that coexpression of AID and 
MDB4 leads to T-G mismatches that are repaired so rapidly that they could only be observed 
using a catalytic mutant of MDB4. When decreasing the expression of AID and APOBEC to a 
level which does not allow demethylation, the addition of growth arrest and DNA-damage-
inducable 45 (Gadd45a) protein was able to restore demethylation, indicating cooperative 
effects of the three proteins.[166] However, AID and APOBEC1 null mice do not show 
developmental defects, are vital and fertile.[167-170] Additionally, dsDNA cannot be deaminated 
in vitro by AID which is surprising if this mechanism was responsible for global DNA 
demethylation.[164] Also DNMTs have been reported to deaminate mC in vitro and in vivo on 
the promoter level. For rapid dynamics of methylation and demethylation using the same 
enzyme with two opposite activites would make perfect sense.[146] Chemically the saturation 
of the C(5)-C(6) bond in the covalent DNMT-DNA intermediate would facilitate the 
nucleophilic attack of water at the C(4) position. The stabilized amino group would act as a 
leaving group and its substitution would lead to either desoxyuridine or T depending on the 
presence of SAM (Fig. 13). DNMTs are known to associate with TDG and to stimulate each 
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other’s activity.[171] Methylation activity of DNMT3a is reduced upon TDG interaction, 
whereas TDGs activity is enhanced. 
 
 
Figure 13: Proposed deamination mechanism in DNMT-DNA intermediates with (right) and without (left) 
SAM; nucleophilic attack of water on the C(4)-atom leading to the substitution of the stabilized amino 
group.[119] 
 
However, in this report deamination was only proved indirectly by a Ligation-mediated-PCR 
assay after potential deamination and AP-site cleavage and took place at very low SAM 
concentrations.[146] Therefore the biological relevance of this setup remains unclear, as SAM 
is ubiquitous in the cell and necessary for various biological processes, while this process 
would require rapid changes in the SAM-level.[4] 
 
2.3.3 Oxidation of mC 
Demethylation of histones is carried out by oxidation of the methyl group and subsequent 
release of formaldehyde.[60] A smiliar mechanism for DNA was proposed early as AlkB, a 
member of the DNA and 2-OG dependent dioxygenases family, has been shown to be 
involved in bacterial response to alkylation damage.[4] They are able to carry out the 
demethlyation of 3-mC and 1-methyladenine using 2-OG, FeII and molecular oxygen and 
release formaldehyde by a similar mechanism as histone demethylation.[172]  
Oxidation of thymidine in various organisms is well known and studied. In trypanosomes a 
glucose moiety is attached to 5-hydroxymethyluridine (hmU), the oxidation product of T, to 
produce base J. The enzymes J-binding protein 1 and 2 (JBP1 and JBP2) were identified as 
the dioxygenases responsible for its formation.[173] The Rao group was able to identify 
homologues of these enzymes in mammals, when they found the ten eleven translocation 
(TET) family of proteins in 2009.[3] This discovery had a huge impact in the field of active 
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DNA demethylation as it identified a long time searched enzyme to perform the putative 
oxidative demethylation reaction. 
 
2.3.3.1 TET  
Three TET-family proteins were discovered in the mouse genome, TET1, 2 and 3.[9] The 
transcription of these proteins is tightly controlled as their expression is crucial for the 
development status of the cell.[174] TET1 and TET2 are positively regulated by Oct4 and their 
mRNA as well as their protein levels decrease during differentiation. On the other hand TET3 
is upregulated during that process.[175-176] Thus TET proteins are directly connected to the 
pluripotency network and are crucial to maintain ES cell identity, as demonstrated by Ito et al. 
in knock-down approaches.[174] A recent study suggests miRNA-22 to downregulate 
TET2.[177] Also recently Zhang and coworkers were able to show that Calpain-proteases are 
responsible for the degradation of TET proteins.[176] Several proteins and also metabolites 
have been found to regulate TET activity. UHRF2 and also L-ascorbate show positive 
stimulation of TET proteins either by direct interaction or indirect effects such as substrate 
targeting.[178-179] On the other hand CXXC5 and inhibition of the Dvl and Axin complex 
(IDAX) negatively stimulate TET activity.[180] 
Computational screens revealed that IDAX was detached from TET2 by a chromosomal 
inversion.[181] It contains, like TET1 and TET3 a CXXC domain, a common DNA binding 
motif with three subfamilies.[181] TET proteins originated from a JBP-like gene that fused with 
a gene containing a CXXC domain.  CXXC subfamily 1 recognizes specifically unmodified 
CpGs in DNA and targets the enzymes, such as DNMT1, MLL and KDMA, to it.[182-185] 
Subfamily 2 has yet only been identified in the first two CXXC domains of MDB1 and has 
not been shown to bind DNA or possess any other function.[182] Subfamily 3 includes the 
domains of IDAX, TET 1 and TET3.[181] Interestingly the TET1 CXXC domain is reported to 
not bind DNA at all, while the TET3 CXXC domain is reported to preferentially bind 
unmodified CpGs.[186-187] The CXXC domain of IDAX binds preferentially to unmethylated 
CpGs in vitro and is enriched at CpG islands and CpG-sites in vivo.[180] 
Even though IDAX was detached during evolution it is targeting TET2 for caspase-dependent 
degradation. If key DNA binding residues are mutated in the CXXC domain, this negative 
regulation cannot occur. This finding supports the idea that IDAX recruits TET2 to certain 
gene loci before degradation occur.[180] While TET1 is reported to act mainly at TSS but also 
in the gene body, TET2 oxidizes mC in the gene body. The activity on the TSS has been 
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reported to negatively correlate with gene expression, while enzymatic activity in the gene 
body is positively correlated.[188] Consistently, TET1 has also been proposed to play a role in 
poised promoters, as its depletion leads to both the activation as well as the repression of 
some of its target. While the activation is proposed to depend on its catalytic activity, 
presumably in the gene body, the repression may be related to its interaction with the SIN3A 
repressor complex, but in any case not to its catalytic activity.[189-190] TET2 and also TET3 are 
able to recruit O-linked -N-acetylglucosamine (GlcNAc) transferase (OGT) to the chromatin 
by a strong direct interaction. The formed complex leads to increased glycosylation of 
histones at TSS and also leads to increased methylation of H3K4.[191-193]  
 
 
Figure 14: A schematic view of the TET proteins; B crystal structure of TET2 catalytic domain and zoom 
into the active site. The substrate (yellow) is flipped out of the DNA and recognized by H1904 and D1384. 
The FeII (orange sphere) is coordinated by D1384, H1382, H1881 and cofactor 2-oxogluterate. Zinc ions in 
black sphere. PDB code: 4NM6.[194] 
 
In the core catalytic domain at their C-terminus all proteins possess a Cys-rich motif that is 
coordinating zinc ions and allows DNA binding.[194] Also the C-terminus contains a double 
stranded -helix and a less conserved low complexity insert.[3,181] The active site consists of a 
conserved His-X-Asp/Glu motif specific for dioxygenases, an additional conserved 
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His-residue is also involved in coordinating FeII together with the cofactor 2-OG (Fig. 14). 
The cofactor is stabilized over ionic contacts to an Arg residue. Recently, the crystal structure 
of TET2 catalytic domain in complex with dsDNA has been solved and gave insight into the 
mechanism of action (Fig. 15).[194-195] 
Base recognition of mC in the dsDNA by TET2 is achieved by two hydrogen bonds from 
H1904 and N1387 to the endocyclic N-atoms of mC and by base stacking to Y1902. The 
target base is flipped into the active site, which brings it near the iron cofactor which leads to 
a DNA torsion of 40°. 
 
 
Figure 15: Reaction mechanism of 5-methylcytosine oxidation by TET proteins. Upon binding of 
molecular oxygen (blue), 2-oxogluterate is decarboxylated and an oxo-ferryl species is generated. Stepwise 
single electron transfer mechanisms lead to the oxidation of the C-H bond and regeneration of the FeII 
center.[194-195] 
In this structural study, mutations in the aminoacids responsible for base recognition lead, as 
expected, to decreased mC oxidation but not to significant DNA interaction changes. 
Investigation using oligonucleotides with dC in different sequence contexts shows that while 
mCpA DNA had less than 2%, mCpC DNA showed up to 10% and mCpG DNA at least 85% 
oxidized mC thus indicating a strong preference for mCpG-sites. However as the methyl 
group does not show any contacts to the catalytic site the preference cannot not be expanded 
to binding, conclusively mCpG and CpG have similar binding affinity. Hu et al. speculate that 
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this might be due to the different characteristics of the oxidation products compared to mC. 
Stabilization of the methyl group by a hydrophobic contact would block the interaction of the 
oxidation products that contain hydrophilic groups.[194]  
The products are generated by decarboxylation of the cofactor upon binding of molecular 
oxygen and oxidation of FeII to FeIV (Fig. 15). The resulting oxo-ferryl species is able to 
oxidize the nearby C-H bond by a single electron transfer generating a methyl radical and an 
FeIII specie as intermediates. The O-atom is transferred with another single electron transfer to 
the methyl radical and the FeIII is accepting the electron to recover the FeII center and close 
the enzymatic cycle by the release of the product, 5-hydroxymethylcytosine (hmC).[196-197] 
 
2.3.3.2 Hydroxymethylcytosine 
This oxidized mC was already discovered in 1952 in phages and 1972, at suspicious high 
levels, in mammals and was later believed to be an oxidative damage.[198-200] However, as its 
(re-)discovery revealed it as a product of dioxygenases, it was opening the road to an active 
demethylation cycle.[4] The level of hmC is dependent on the expression-level of TET 
proteins. It was shown that the already mentioned genome wide loss of mC in the male 
pronucleus after fertilization is not a conversion to dC but is going hand in hand with TET3 
expression and the oxidation to hmC.[201] The highest levels of hmC, with 0.7% of all 
cytosines, have been detected in the brain, which corresponds to about 12% of all CpGs.[202] 
In mESC the level is about 0.2% of all cytosines and upon differentiation the level is 
decreasing.[7] Aberrant levels of hmC are correlating with several diseases, especially in the 
brain.[203] In astrogliomas hmC is significantly reduced and might be used as a marker for 
classification of tumors into the World Health Organization (WHO) grades.[6] In psychotic 
disorders hmC and TET1 levels are significantly higher.[204]  
To determine the genomic distribution, different genome-wide mapping approaches of hmC 
have been performed and revealed its accumulation in gene bodies, promoters and TSS.[189-
190,205-206] The location of hmC suggests a role in transcription, however, this role is so far not 
completely understood. It is possible that it activates transcription by blocking the binding of 
MBPs.[207] On the other hand it is reported that in patients with psychotic disorders, increased 
hmC-levels at the TSS of the GAD67 promoter, leads to reduced mRNA levels.[204] Consistent 
with that is the earlier mentioned finding of enhanced transcription after depletion of TET1, 
which is mainly generating hmC at TSS.[188] Further research effort has to be done to reveal 
the exact role of hmC in transcription.  
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Recently, two oxidative variants of bisulfite sequencing have been established for base 
resolution sequencing of hmC. In principle they rely on computational comparison of bisulfite 
sequencing before and after an oxidation step, carried out by either TET (TET-assisted BS) or 
chemically with a KRuO4 complex.
[208-209] This is possible due to the different chemical 
behavior of further oxidized cyotsines and hmC during sequencing. 
With a proteomic approach, proteins that bind hmC have been identified, among them are the 
glycosylases NEIL1 and MBD2, the factor necessary for maintenance methylation UHRF1 
and several proteins with a yet unknown function such as UHRF2, Wdr76 and C3orf37. In 
this study UHRF2 was shown to have a positive effect on TET-activity and to rise the hmC 
level by a factor of 1.2.[178] It was shown that UHRF1 binds hmC over its SET and RING 
finger associated (SRA) domain with a similar affinity to mC, opening a possible way for 
hmC inheritance.[210] However evidence from pre-implantational embryos suggests that hmC 
is passively removed through replication. Unlike DNMT1, DNMT3a and DNMT3b have been 
shown to methylate opposite hemi-hmC DNA than unmethylated DNA in a similar rate.[211] 
Conclusive with that de novo methylation has been shown to play the major role in hmC 
production.[212] Even though hmC inheritance therefore is in principle possible, there is no 
direct evidence for it. 
It has been reported that hmC can be deaminated to hmU, which would lead similar to the 
earlier mentioned deamination of mC to a mismatch and DNA repair. [213]  In the study AID 
and TET1 overexpression lead to the detection of hmU, however, recent work in our group 
could show that TET1 catalytic activity is not restricted to mC but can also take place on dT. 
This explains the detection of hmU even though deamination is still possible. 
 
2.3.3.3 Other oxidized pyrimidine species 
During this work we were able to discover the further oxidation product of hmC, 
5-formyldesoxycytidine (fC) in the genomic DNA of mESC, and estimated a level of 0.02% 
of all Cytosine derivatives.[7] Shortly thereafter, the discovery and the connection to TET 
enzymes could be confirmed by the Zhang group, who together with the Xu group were also 
able to detect 5-carboxyldesoxycytidine (caC) as the last product of mC oxidation 
cascade.[9,214] The reaction rate to these 2 products are significantly lower than the production 
of hmC and the levels of fC are only 1/10 respectively 1/100 for caC of the hmC level.[9] This 
is about 3.5 caC per 106 nucleotides and about 1000 molecules per genome, in comparison 8-
oxo-guanosine, a known marker for oxidative damage is reported to occur in 1 per 106-7 
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nucleotides.[215] Despite their low abundance, they might play an important role in active 
demethylation and epigenetic regulation, because these modifications occur mainly at CpG 
islands and are considered transient intermediates.  
The hydrophilic properties of these new epigenetic bases are similar to those of hmC and 
contrary to mC. However the carbonic acid of caC which should be deprotonated under 
physiological conditions, allows ionic contacts and therefore, theoretically tighter binding or 
repulsion. 
By LC-MS based approaches several selective readers for these new DNA modifications have 
been identified, however, in comparison to caC much more is known about fC, which might 
be due to its higher abundance.[178,216] Interestingly some of the readers, such as FOXK1 and 2 
are known as transcriptional regulators.[216] The genomic distribution of fC was initially 
determined by a chemical ligation of the aldehyde with an aldehyde reactive probe (ARP), a 
technique that was first introduced by us (Pfaffeneder et al.).[7] The fragments containing the 
ligated fC-ARP product were enriched using streptavidin beads. Sequencing revealed that like 
hmC fC is enriched around the TSS, H3K4 trimethylated histones and is frequently bound to 
RNA polymerase II.[8] The findings of this study strongly corelate fC to transcription, 
however, the function is not 100% clear. When fC and caC are located in the gene body in 
vitro, the fidelity of RNA polymerase II is impaired and the polymerase is stalled.[217] In vivo 
this would lead to pre-terminated RNA fragments. The authors of the study therefore suggest 
a role in transcriptional regulation and mRNA processing, as e.g. splicing. It has been also 
recently reported that caC is enriched in euchromatic regions in follicular cells, also 
suggesting a role in transcriptional regulation.[218] 
Recently, two chemical modification variants of bisulfite sequencing (BS) were established 
for base resolution sequencing of fC and caC. During BS, dC, fC and caC are deaminated to 
dT while mC and hmC are not. Like the base resolution sequencing of hmC they rely on 
computational comparison of bisulfite sequencing before and after the chemical modification 
of fC/caC, as the modification prevents fC and caC from deamination to dT.[219-220] The 
different chemical behavior of dC derivatives during bisulfite sequencing, was investigated by 
Jin et al. in the detail.[221] These new technique might give insights on the exact genomic 
location and function of the newly discovered bases.  
An antibody study in mouse embryos could show that fC and caC are generated in 
pre-implantational mouse embryos and are then diluted through replication.[222] The authors 
also state that due to the behavior of caC in BS, earlier studies reporting demethylation have 
to be reinvestigated.[222] The levels of these modifications during early mESC differentiation 
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have also been studied, and the kinetics of the nucleosides have been compared in a cluster 
analysis. This revealed that fC and caC behave similar, with and peak early in their levels. In 
comparison hmC behaves differently and could not be correlated with them. This finding 
supports the idea of hmC as a stable epigenetic base and fC/caC as intermediates in an active 
demethylation cycle. In this study also hmU as a product of T oxidation by TET enzymes has 
been discovered, and some direct and indirect binders have been identified using a proteomic 
approach. However, further studies have to be made to elucidate biological functions of this 
new modification. 
 
2.3.3.4 Excision of new epigenetic bases by BER  
Shortly after the discovery of fC and caC, it was reported that they are substrates for TDG and 
it was proposed that active demethylation would occur by BER.[214,223] In fact TDG knock-out 
cells show an increase of around 40% in fC and of about the same increase in caC. The 
activity of the enzyme on fC is 1.5 fold faster than on T:G and 4 fold slower on caC, hmC was 
found not to be a substrate for TDG.[223] It was also reported that hmU is excised by TDG 
with significant but lower activity.[224-225]  A crystal structure of caC and hmU containing 
DNA was obtained by different groups and gave insights into the molecular mechanism and 
discrimination of the different substrates (Fig. 16).[225-226] Several amino acids, such as 
Ser271, Ser272, His151, Asn157, Asn191 and Asn230, interact with the accommodated base 
in the cage of the active site and are able to act as hydrogen-donors or acceptors.  
The catalytic activity is established by the activation of a water molecule by Asn140, which 
leads to a putative oxacarbenium ion intermediate.[227-228] The conserved Tyrosine residue 152 
stacks with the AP-site in the postreactive complex.  For caC Asn191 seems to be the most 
important contact, where as it is not necessary for TDG activity on fC (Fig. 16). It is proposed 
that it stabilized the N3-protonated species of caC, whose excision is unlike fC pH-
dependent.[229] A mutation of Asn230 or Asn157 results in greatly reduced activity on hmU, 
but does not affect caC excision significantly. While mutations in both abolish excision of 
caC but not of hmU.[230] 
While fC and caC seem to be exclusively excised by TDG, hmU is recognized and removed 
by 3 distinct glycosylases. Next to the earlier mentioned activity of TDG, MBD4 and SMUG1 
are able to catalyze the hydrolysis to an AP-site, with a 6-10 fold reduced activity on hmU:G 
compared to TDG.[224,231] 
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Due to the high activity TDG has on the newly discovered fC and caC bases in vitro and in 
vivo, as well as the fact that TDG knock-out mice are not viable and show developmental 
 
 
Figure 16: Crystal structure of human TDG catalytic domain mutant N140A in complex with A:caC 
mismatch dsDNA. Zoom into the active site showing caC coordinating amino acids and hydrogen bonds. 
PDB code: 3UO7.[226] 
 
defects, it is conclusive to see this as a likely pathway for DNA demethylation.[232-233] 
However the generation of abasic sites (naturally occurring 1 per 105 nucleotides) in all fC 
and caC-sites would lead to an about 4-fold increased number of AP-sites and therefore to a 
greater genomic instability, which is in respect to embryonic development very 
unfavorable.[234] 
 
2.3.3.5 C-C bond cleavage pathway 
An attractive alternative for the BER pathway is the cleavage of the C(5)-C(exo) bond of the 
oxidized dC-derivatives by an enzyme. A mutant of the bacterial DNA methyltransferase 
HhalI has been reported to reversibly add/remove aldehydes using different substrates, to 
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result among others in hmC.[235] In 2012 DNMT3a and 3b but not DNMT1 were reported to 
have the same enzymatic reactivity depending on their redox state and the presence of SAM. 
A catalytically inactive enzyme did not show this activity and thus DNMTs were suggested to 
act as bidirectional enzymes.[236] Shortly thereafter the same group reported that all three 
human DNMTs are able to directly demethylate mC dependent on CaII.[237] Very recently 
Klimasauskas and coworkers were able to show similar effects of methyltransferases on hmC 
and caC.[238] Interestingly in this thesis, it was possible to break the C-C bond by using thiols 
and basic amino acids, mimicking active sites which contain these amino acids like 
DNMTs.[10,239] It was shown, that incubation of hmC with high concentrations of 
-mercaptoethanol and imidiazole leads to breakage of the C-C bond and formation of dC. 
However, the cleavage of hmC is very slow and resulted in a yield below 1%, which is far 
below the yield of dehydroxymethylation reported by DNMTs or photohydration.  
Higher yields were detected for the cleavage of fC, resulting in formic acid (2.5%) and for 
cleavage of caC which leads to the formation of carbon dioxide (28%). Mechanistically, the 
acid catalyzed addition of a thiol to the C(6) atom of the cytosine derivatives results in a 
saturated C(5)-C(6) bond and facilitates the elimination of the leaving groups. For fC the 
aldehyde has to be attacked nucleophilically by a thiol or water before acting as a leaving 
group. Interestingly, during a proteomic approach a specific binder for fC was discovered 
bearing a formyltransferase activity, which might be a putative deformylase by transferring 
the formyl group on metabolites, as for an example tetrahydrofolate.[216] Quantum chemical 
calculations showed, that saturation of the C(5)-C(6) double bond results in a far lower energy 
of a potential vinyl anion intermediate after the release of carbon dioxide from the molecule. 
According to the calculations the energy barrier would drop by about 40 kcal/mol, which 
could enable a very fast decarboxylation process.[239] 
Decarboxylation is a very frequent process in nature and very well understood, therefore a 
quite convincing candidate-pathway for demethylation of mC. It takes places in various 
metabolic pathways, in which organic acids need to be converted such as fatty acid synthesis 
or the thymidine salvage pathway. This is managed by decarboxylases of which at least 90 
different classes according to IUPAC are known. A great variety of mechanisms involve 
different cofactors such as organic biotin or pyridoxalphosphate (PLP) or inorganic cofactors 
such as metal complexes.[240] 
However, some decarboxylases do not need any cofactors. Interestingly one of these is 
isoorotate-decarboxylase in the thymidine salvage pathway, an enzyme the proposed caC-
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decarboxylase could be very similar to. IDcase is the enzyme with the highest rate 
enhancement known to date, accelerating the reaction 1017 fold.[241] 
The crystal structure of IDcase has recently been solved and subsequently more insight into 
the mechanism is gained (Fig. 17).[242] The active site consists of three histidines and one 
aspartate coordinating a zinc ion and several other conserved residues coordinating water. 
Two models for the mechanism have been proposed upon mutational studies:[242] 
1. In the first model the aspartate acts as a nucleophile to attack the C(exo) and form an 
unstable tetrahedral intermediate (Fig. 17). Upon elimination from the aromatic ring a 
vinyl anion that is quickly protonated is formed. This is followed by elimination of 
hydrogen carbonate after attack of a water molecule on the aspartate-carboxyl 
intermediate. Then the product is released and the enzymatic cycle can be restarted.  
2. In the second model, the nucleophilic attack is carried out by a water molecule after 
activation by the aspartate. Again a tetrahedral intermediate is formed and the C-
C(exo) bond is polarized and broken. After quick protonation of the vinyl intermediate 
and release of hydrogen carbonate, the product is released.  
 
 
Figure 17:A) Crystal structure of IDcase with U in the active site; zoom into active site and aminoaacids 
involved in the catalytic activity indicated with stick illustration and zinc in light orange as sphere 
illustration. PDB code: 4HJW.[242] B) Proposed mechanism of IDcase with a tetrahedral intermediate, 
stabilized by N262. 
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In each of the model mechanisms the N262 residue is stabilizing the water molecules and 
intermediates during the process. Interestingly the authors of the study could show that the 
enzyme was capable of forming cytidine from carboxycytidine. They suggest that a putative 
caC-decarboxylase might consist of a similar active site but would interact differently with 
metal ions as the amino group is a stronger electron donor. Additionally a DNA binding motif 
must exist as caC is only formed in dsDNA in vivo, resulting in a larger enzyme. 
Bioinformatic research could help to identify such an enzyme.[242] 
In this thesis the decarboxylation activity of nuclear extracts of mESC was studied using MS-
based isotope tracing in dsDNA. An oligo containing double 15N labeled caC was incubated, 
reisolated and analyzed after total digestion, resulting in a signal for the labeled dC. Even 
though the study could not identify a decarboxylase, it shows that the existence of such an 
enzyme can be proven by analysis on the molecular level.[10]  
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II. Aim of thesis 
DNA methylation and active DNA demethylation are processes with high relevance to 
modern medicine. While DNA methylation has been in the focus of research since decades, 
active demethylation is a relatively young scientific field. Several pathways of demethylation 
have been investigated, but with the discovery of hmC as a product of TET enzymes, the 
oxidative demethylation pathways have been in the focus. 
The search for intermediates of this DNA-demethylation pathway in the brain did not lead to 
the identification of fC or caC. The main goal of this thesis was to determine the fate of hmC 
in the cell, to continue the search for the intermediates of DNA demethylation and to 
investigate the process of DNA methylation/demethylation. This process is thought to take 
place mainly in pluripotent cells, such as mESC. Therefore they are a reasonable biological 
system for the investigation. The study was designed to give more insights into the pathways 
of active demethylation and their functions. To investigate the dynamics of 
DNA-methylation/demethylation the development of biochemical tools and analytical 
methods was necessary. 
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III. Conclusion and Outlook 
The investigation of cytosine dynamics is still ongoing and after the discovery of fC and caC 
more and more insights are gained. Even though the formation of mC has been investigated 
for decades, the very complex methyltransferase enzymes are still not fully understood. In this 
thesis a recently stated self-regulation mechanism of DNMT1 could be confirmed.  
The pathway of combined oxidation and excision of mC-derivatives (Fig.18) was 
convincingly proven in vitro and in vivo, but the selectivity of genomic location still needs to 
be addressed. The C-C bond cleavage pathway needs further validation, as especially 
decarboxylation seems to be very attractive. First hints for this process could be found in this 
thesis but yet no decarboxylase has been identified. The bivalent function of DNMTs are yet 
to be confirmed on the molecular level, however quick dynamics and tight regulation could be 
a challenge in vitro as well as in vivo. 
Additionally deamination of mC and hmC might play a role for the dynamics of cytidines and 
might couple them to those of uridines (Fig. 18).  
 
 
Figure 18: Overview of active demethylation pathways with chemical properties (middle) and relative 
abundancies (left bar).  
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Nature invests energy into the generation of fC, caC and hmU and removes them indirectly 
under the pressure of genomic instability. Different biological processes that involve the 
different cytosine modifications might make the variety of intermediates and pathways 
necessary, but yet we are not at the point of understanding them completely. 
These processes include gene regulation, in which the role of the demethylation intermediates 
is yet not fully understood. However, hints for bivalent roles of modified CpGs arise. In this 
context also the crosstalk of histone modifications and new cytosine modifications would be 
interesting. Also the effects on trans-elements is yet not investigated, however the different 
chemical behavior of caC and mC could lead to different DNA-histone/protein interactions 
upon modification change and could trigger gene regulation (Fig. 18). 
The metabolism of the newly discovered bases is also unknown, therefore it might be 
interesting to include urine samples and metabolized cytosine modifications, for example 
glucose-conjugated caC, in the investigations. The negative charge would need to be 
neutralized in order to pass the cell membrane and degrade caC after its excision, therefore a 
metabolization is very likely. 
Due to the different chemical behavior in bisulfite sequencing older data has to be 
reconsidered and confirmed. 
Further research using modern tools in biochemistry, such as next generation sequencing, LC-
MS and isotope tracing as well as established methods as genetic manipulations should be 
able to shed light into cytosine dynamics and its effects on biological processes. 
Understanding the pathways and functions could help us to gain more insights in cellular 
development, reprogramming and altered expression levels of oncogenes and ultimately to 
contribute modern medicine. 
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Introduction: 
As described in Chapter I.2.3.3 the discovery of hmC as a product of the TET enzymes had a 
huge impact in the field of active demethylation. The proposed cycle of active demethylation 
however included the existence of the higher oxidized cytidine derivates, fC and caC. These 
intermediates could not be identified in mouse tissue in an earlier study, despite the high 
levels of the first putative intermediate hmC. As DNA demethylation was however thought to 
take place especially in early cell development, the search was successfully extended to 
mESCs in this manuscript. 
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discovered and characterized fC using MS/MS and chemical modifications. We also 
determined the values of mC and hmC, and estimated the amount of fC by a coinjection 
study.  
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Christian A. Deiml, Christian Hagemeier, and Thomas Carell*
Cellular development requires the silencing and activation of
specific gene sequences in a well-orchestrated fashion. Tran-
scriptional gene silencing is associated with the clustered
methylation of cytosine bases (C) in CpG units of promoters.
The methylation occurs at position C5 of cytosine to give 5-
methylcytosine (mC) with the help of special DNA methyl-
transferases (DNMT).[1] The DNA methylome is significantly
reprogrammed at various stages during early development,[2]
during the development of primordial germ cells,[2c,3] or later
in a locus-specific way at postdevelopmental stages.[4]
Decreasing levels of mC can be established passively by
successive rounds of DNA replication in the absence of
methyltransferases. Active demethylation, in contrast, is
proposed to be a process in which the mC bases are directly
converted back into unmodified cytosines in the genome.[5]
The recent discovery that mC can be further oxidized to
hydroxymethylcytosine (hmC) with the help of TET
enzymes[6] has led to the idea that hmC is connected to
epigenetic reprogramming,[7] maybe as an intermediate in an,
as yet controversial, active demethylation process.[4,5,8] Indeed
recent data suggest that active demethylation in postdeve-
lopmental phases may proceed through deamination of hmC
to give 5-hydroxymethyluridine (hmU), which is then
removed from the genome with the help of the base excision
repair (BER) system.[9] Chemically, an attractive alternative
mechanism for a more global active demethylation could be
envisioned through further oxidation of hmC to give either 5-
formylcytosine (fC) or 5-carboxylcytosine (caC) followed by
elimination of a formyl or carboxyl group, respectively
(Scheme 1).[5a,10] Although such an oxidative active demethy-
lation pathway with hmC as the starting point has been
frequently postulated,[5a,10] none of the further oxidized bases
(fC, caC) have so far been detected.[10a]
To examine the question of whether hmC is the only
oxidized base present in genomic DNA or if other higher
oxidized species may be present as well, we performed an
HPLC-MS study using synthetic fC and caC material as
Scheme 1. A) Putative cycle of methylation and oxidative demethylation
of cytidine derivatives. B) Details of the demethylation reaction via
vinyl carbanions.[11] I : Deformylation of fC to C. II : decarboxylation of
caC to C.
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standards.[10a,12] Specifically, we used DNA isolated from
mouse embrionic stem cells and embyoid bodies (mEBs) after
two and three days of differentiation for the study. In mES
cells, CpG-rich gene promoters are actively maintained in a
hypomethylated state and differentiation of mES cells
induces a wave of gene-specific de novo methylation that
involves repression of TET1 and TET2 expression as well as
reduction of global hmC and an increase in the global mC
levels.[7d] In addition, we analyzed DNA isolated from nerve
cell tissue, which features the highest levels of hmC in mice.
Indeed, hippocampus and cortex tissue have hmC levels of up
to approximately 0.7%/G,[12a] which is about twofold higher
than the hmC values measured in mES cells (0.39%/G). The
chromatogram obtained of a fully digested DNA sample from
mES cells shows the signals for the four canonical bases A, C,
G, and T plus the signal for mC (Figure 3A).[10a,12a] If detection
is performed by mass spectrometry, the correct high-resolu-
tion mass (m/z values) for these five compounds and addi-
tionally the mass signal for hmC can be clearly detected. To
our surprise, we detected in addition to these six signals one
more signal of a compound that eluted with a retention time
very close to T (Figure 1A). This signal was initially only
detectable in the DNA material isolated from mES cells. The
new signal could not be directly detected in DNA isolated
from mEBs, but unknown fragment ions were seen in further
MSn studies. The unknown compound detected in the mES
cell DNA had a high-resolution mass signal (m/zfound=
256.0929) which is in excellent agreement with the calculated
exact mass for fC (m/zcalcd= 256.0928; Figure 1B). To
unequivocally prove that the signal is generated by the
presence of fC we synthesized the fC compound indepen-
dently, as reported previously by us,[10a] and co-injected a
small amount of the synthetic material into the DNA digest
obtained from the mES cell DNA. Indeed, the synthetic
material eluted with the same retention time (see the
Supporting Information). Finally MSn-fragmentation experi-
ments were performed, which are highly compound specific.
In these studies, the fC compound is fragmented directly in
the mass spectrometer to give characteristic fragment ions.
(Figure 1C,D) The MS/MS data obtained from the putative
fC compound isolated from mES cell DNAwere found to be
identical with literature data[13] and with the MS/MS data
obtained from the authentic synthetic fC material (data not
shown). In addition, the obtained MSn data were identical
with the unknown fragment ions detected in the mEB cell
DNA. These data prove that the newly discovered compound
Figure 1. A) HPLC trace of digested mES cell DNA together with the MS signals from T and fC. The UV detection has a general delay of 0.2 min
and was adjusted manually to the ion current. B) High-resolution mass data of fC. C) Fragment mass data from MS/MS and MS3 studies proving
the structure of fC. D) Fragmentation pattern of fC in the MS2 and MS3 experiments.
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in mES cell DNA has the structure of fC. This base is present
at significant levels in mES cells and in traces in mEB cell
DNA.
We next quantified the amount of fC base in the mES
sample (Figure 2A). To this end we co-injected a defined
amount of synthetic fC together with digested mES cell DNA
and integrated the ion currents of the combined fC signal. In
addition, we measured the fC ion current of the added
amount of synthetic fC alone and compared the values to the
fC ion current measured in the mES sample. The integrals
allowed us to estimate the fC level to be around 0.02%/G
(Figure 2B). This is a surprisingly high value compared with
the mC levels (Figure 2C) as well as with the hmC levels,
which we determined by using isotope spiking to be around
0.39% hmC/G (Figure 2D).[10a,12a] Consequently, every 10th
to 20th hmC base in the mES DNA is oxidized to fC, which
shows that this oxidation is a significant process.
We next performed mass spectrometry experiments to
study the presence of the hydrate form of fC (fC-hydrate)
since further oxidation of fC to caC or elimination of a formyl
group would require the addition of water to the formyl group
(Scheme 1A). We indeed detected the hydrate form in DNA
containing synthetic fC at a level of about 0.5% (retention
time of the hydrate= 21.7 and 26.5 min; m/zfound= 274.1037,
m/zcalcd= 274.1034; see the Supporting Information) which is
high enough to enable either direct elimination of a formyl
group (Scheme 1) or further oxidation. To investigate the
presence of the further oxidized compound caC in the DNA
samples from mES and mEB cells, we performed additional
MS studies that were also extended to a search for the hmC-
and fC-derived deamination products hmU and fU. However,
signals corresponding to caC, hmU, and fU were not found. In
additional MSn experiments, fragmentation products charac-
teristic for all these compounds were also not detected, which
shows that if these compounds are present, their levels are
below our detection limit.
We performed two more experiments to correlate the fC
levels with the mC and hmC levels. Firstly we quantified the
hmC levels in various DNA samples and secondly we studied
the levels of mC, hmC, and fC in DNMT3a/3b double knock-
out mES cells. Since the DNMT enzymes are needed to
methylate C to mC, we hoped to learn if the newly discovered
base fC is generated de novo from C (by a formylation
reaction) or whether it is created from mC by stepwise
oxidation via hmC. In agreement with earlier studies, we
observed the highest hmC levels in nerve cell DNA (hmC/
G= 0.65%). The levels of hmC in mES cell DNA are
significantly lower and they decrease with differentiation (in
accordance with the results of Szwagierczak et al.[14]), while
the mC levels increase. A level of hmC/G= 0.39% was
measured in mES cell DNA. Here also, the fC level is the
highest with fC/G= 0.02%. In mEB cells, the hmC levels are
hmC/G= 0.2% after 2 days of differentiation and hmC/G=
0.15% after 3 days of differentiation. The fC compound was
only detected in trace amounts in both sets of mEB cells by
MSn studies. A stronger difference can be seen in the
DNMT3a/3b double knock-out cells. Here, the mC levels
are greatly reduced to mC/G= 0.5%, compared to 5–6%
determined in the mES and mEB cells. The mC level in
cultured C2C12 myoblasts is slightly lower, in agreement with
other cell lines,[12a] but still at around 4%, thus showing that
C methylation is, as expected, strongly hindered in the
DNMT double knock-out mES cells. The same trend can be
observed when studying the hmC levels. The DNMT3a/3b –/–
mES cells contain practically no hmC (0.02%) and also no fC.
These experiments show that fC is likely produced from mC
via hmC through further oxidation. We currently speculate
that the TET enzymes may convert mC into fC by iterative
oxidation, as it is found for related T7H enzymes that catalyze
the stepwise oxidation of thymine to 5-formyluracil.[15]
Since the formyl group of the fC compound was shown to
be reactive (hydrate formation with water), we next inves-
tigated the possibility of reacting the fC base in DNA with a
reagent that would allow isolation[16] of fC-containing DNA
fragments for sequencing[17] and more-sensitive detection of
fC. Since formyl groups react selectively with hydroxylamines
to give stable oxime derivatives,[18] we treated the mES DNA
with the biotin-hydroxylamine reagent (Figure 3A).[19] After
Figure 2. A) Correlation of the mass signal of fC and the UV signal of
G in mES cell DNA, in DNA from nerve tissue, in DNA from mEBs
after 2 and 3 days, in DNA from cultured myoblasts, and in DNA from
mES lacking DNMT3a and -3b. The detection limit of fC was
determined to be 1 pmol. B) Co-injection studies of fC with digested
embryonic stem cell DNA indicated an amount of approx. 2 pmol,
which corresponds to a level of 0.02%/G. C) Quantitative levels of mC
in mES cell DNA, in DNA from nerve tissue, in DNA from mEBs after
2 and 3 days, in DNA from cultured myoblasts, and in DNA from mES
lacking DNMT3a and -3b measured by quantitative mass spectrometry
using an isotopically labeled mC standard.[10a, 12a] D) Quantitative levels
of hmC in mES cell DNA, in DNA from nerve tissue, in DNA from
mEBs after 2 and 3 days, in DNA from cultured myoblasts, and in
DNA from mES lacking DNMT3a and -3b measured by quantitative
mass spectrometry using an isotopically labeled hmC standard.[10a, 12a]
Green: fC, yellow: mC, blue: hmC.
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24 h of incubation (pH 5.5, 25 8C, p-methoxyaniline/NaOAc
buffer),[20] the converted DNAwas isolated and fully digested
(see the Supporting Information). In a parallel experiment,
we also added the biotin reagent to synthetic DNA in which
the fC compound was synthetically incorporated by using a
newly developed phosphoramidite building block (see the
Supporting Information and for alternative synthetic strat-
egies[21]). MS analysis of both digests showed the appearance
of only a single newMS signal derived from the biotin-labeled
fC nucleoside (fC-biotin). To our surprise, we no longer
observed a signal for fC, thus showing that the reaction allows
not only the highly selective but also complete (> 90%)
labeling of the fC nucleobase in genomic mES material
(Figure 3A). Most importantly, the fC-biotin derivative
produced a strongly increased MS signal, which allowed us
to study the presence of fC in the mEB cell DNA in more
detail. Indeed, after derivatization we could detect signals for
the biotinylated fC base in mEB DNA (Figure 3B) directly in
the mass spectrometer.
In summary, we provide here direct evidence for the
presence of 5-formylcytosine (fC) in DNA isolated from mES
und mEB cells. The fC levels were found to dramatically
decrease with ongoing differentiation. Interestingly, we do
not detect the fC compound in DNA isolated from neuronal
cells, which contain the highest amounts of hmC. We explain
this result on the basis of data from a recent study by Song and
co-workers,[9] who showed that active demethylation in adult
brain cells proceeds likely through deamination of hmC to
hmU followed by removal of the hmU base by the base
excision repair pathway. Thus, fC is in this respect a clear
marker nucleoside for the development of mES cells. It has
not escaped our notice that the oxidative demethylation of
methylcytosine via 5-formylcytosine we have postulated,
immediately suggests a possible globally acting epigenetic
control mechanism.
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Introduction: 
As described in chapter I.2.3 several pathways for active demethylation have been proposed. 
A very attractive pathway is the decarboxylation of caC to C which avoids the formation of 
abasic sides that occurs in the BER pathway and is explained in detail in chapter I.2.3.3.5. In 
this manuscript hints for such a decarboxylation were found and chemical properties were 
elucidated using LC-MS. 
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5-Methylcytosine (mC) is an important, well-known nucleo-
base modification that is involved in many biological pro-
cesses, including gene expression, genomic imprinting, X-
chromosome inactivation, and suppression of transposable
elements.[1–3] Recently it was discovered that mC can be
further processed in neurons and in embryonic stem cells by
TET enzymes, which utilize 2-ketoglutarate, to oxidize mC
first to 5-hydroxymethylcytosine (hmC)[4,5] and further to 5-
formylcytosine (fC)[6] and 5-carboxycytosine (caC)[7,8]
(Scheme 1).[9,10] It is
currently believed
that this oxidation
chemistry is involved
in a process of active
demethylation, which
allows cells to
exchange mC with
unmodified 2’-deoxy-
cytidine (dC) to
revert the biological
effects caused by
cytosine methyla-
tion.[11] Two possible
active demethylation
mechanisms are cur-
rently being inten-
sively investigated
(Scheme 1). Mecha-
nism 1 is based on
special glycosylases,[12–15] such as the thymine–DNA glycosy-
lase (TDG), which was shown to also cleave the glycosidic
bonds of fC and caC, as well as of 5-hydroxymethyluridine
(hmU).[15,16] The latter is formed after deamination of hmC.[15]
This base cleavage reaction first generates an abasic site,
which is repaired by the base excision repair system (BER) by
insertion of dC (Scheme 1, lower part). This whole process
leads in summary to an exchange of mC by dC. The second
mechanism is thought to involve retro-Aldol-type chemistry
starting with hmC[17,18] or fC. Alternatively, decarboxylation
of caC (Scheme 1) is a highly attractive alternative, because
this mechanism allows exchange of mC by dC without
formation of intermediate strand breaks, which are DNA
lesions that are known to cause genome instability, and
without formation of potentially harmful side products, such
as formaldehyde. Although decarboxylation of caC has never
been observed, similar transformations are known for orotate
and isoorotate, which are decarboxylated to uracil.[19]
To gain deeper insight into the putative decarboxylation
of caC in stem cells, we developed a sensitive isotope tracing
experiment. A double 15N-labeled caC phosphoramidite
reagent [15N2]-caC was developed, which we incorporated
into the 30 mer oligonucleotide D1 with a sequence from the
Ecat1 promoter[23] that is known to be the subject of active
demethylation. The natural occurrence of the double 15N
isotopologue of dC ([15N2]-dC) is extremely low, which allows
us to monitor the chemistry that operates on the caC
Scheme 1. Active demethylation pathways involving elimination (mechanism 2) of formaldehyde from hmC, formic
acid from fC, or decarboxylation of caC. In contrast, mechanism 1 involves the base excision repair (BER)-based
replacement of fC and caC by dC, or of hmC by dC after prior deamination of hmC to hmU.
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compound by high-resolution mass spectrometry. The syn-
thesis of the [15N2]-caC phosphoramidite is depicted in
Scheme 2 (see also the Supporting Information). The starting
point is [15N2]-uracil 1, which was prepared from [
15N2]-urea
and propiolic acid.[20] Vorbrggen nucleosidation with the
bis(toluoyl)-protected chlororibofuranoside[21] furnished the
b-configured nucleoside 2 in 60% yield. Electrophilic iodi-
nation to 3,[22] conversion of the C4-keto function into the
amine as needed for the cytosine base (4), and protecting-
group exchange gave the key intermediate 5. Pd-catalyzed
CO insertion and quenching of the Pd–CO intermediate with
methanol provided the [15N2]-caC precursor 6 in about 65%
yield. Double benzoyl protection of the C4-amino group (7)
and cleavage of the TBS groups (8) was followed by
protection of the 5’OH group with dimethoxytritylchloride
(DMT-Cl; 9). We subsequently converted the 3’OH group
into the final phosphoramidite 10 using standard procedures.
The phosphoramidite was used to synthesize the 30 mer
oligonucleotides ODN1 and ODN2. The two strands were
finally hybridized to give the DNA duplex D1 with the
sequence of the Ecat1 promoter containing two [15N2]-labeled
caC derivatives.
In one of the DNA strands (ODN1), we also inserted the
base 5-octadienyl-dU (Scheme 2, bottom) and subsequently
used mild click chemistry with the depicted biotin azide
(Scheme 2, bottom; Supporting Information) to attach
a biotin label to 5-octadienyl-dU, giving the biotinylated
uridine Y.[23] All of the DNA strands needed for the experi-
ment were carefully purified by HPLC to obtain the labeled
DNA material in extremely high purity (> 99.9%). After
successful click chemistry, we purified the biotinylated
oligonucleotide again using a second HPLC purification
step. The identity of the oligonucleotides was confirmed in all
cases by MALDI-TOF mass spectrometry (Scheme 2; Sup-
porting Information).
For the isotope tracing experiment depicted in Figure 1a,
we added the DNA duplex D1 (ODN1+ODN2) containing
the two [15N2]-labeled caC bases and the biotin tag to nuclear
extracts of mouse embryonic stem cells (mESC). After 1 h of
incubation at 37 8C (for details see Supporting Information),
we re-isolated the biotinylated oligonucleotide with the help
of streptavidin-bound magnetic beads. The isolated DNAwas
subsequently totally digested (Supporting Information) and
the digest was analyzed by HPLC-MS using a high-resolution
mass spectrometer (Orbitrap XL; for details, see the Sup-
porting Information). The obtained data are depicted in
Figure 1b–e. We first investigated the results of the control
experiments. To this end we treated D1 with non-mESC
nuclear extracts and we incubated D1 with buffer only. The
mass-spectrometric analysis of the control experiments (Fig-
ure 1d,e) provided two distinct signals with m/z= 230.1014
and 230.0976 in the mass range of the dC nucleoside
(Figure 1e). These m/z signals correspond to the naturally
occurring isotopologues [13C2]- and [
18O]-dC, respectively, and
[15N,13C]-dC. The exact mass expected for double 15N-
containing [15N2]-dC was not detected in all of these control
experiments, even when we digested and analyzed higher
amounts of DNA (2.5 nmol dC vs 0.9 nmol dC; Figure 1d,e).
We then analyzed the digests obtained from D1 after
incubation with mESC nuclear extract. Surprisingly we
noted that after 1 h of incubation with mESC nuclear extracts,
the [15N2]-labeled dC species was indeed detected in the total
digest of the re-isolated duplex D1. The compound [15N2]-dC
eluted with a retention time of 7.18 min. The obtained mass
Scheme 2. Synthesis of the [15N2]-labeled caC phosphoramidite and of
the DNA strands ODN1 and ODN2 containing one [15N2]-labeled caC
nucleobases each. The biotin label was inserted using click chemistry.
Reagents and conditions: a) polyphosphoric acid, 95 8C, 19 h; b) 1.
HMDS, TMS-Cl, 120 8C, 1 h; 2. Hoffer’s chlorosugar, CHCl3, RT, 2.5 h;
c) CAN, LiI, MeCN, 80 8C, 2 h; d) 1. 1,2,4-triazole, POCl3, TEA, 30 8C,
overnight; 2. NH4OH, 1,4-dioxane, RT, 10 min; e) 1. K2CO3, MeOH,
RT, 19 h; 2. TBS-Cl, imidazole, DMF, RT, 4 days; f) [Pd(MeCN)2Cl2] ,
CO, MeOH, 60 8C, 17 h; g) BzCl, pyridine, 0 8C to RT, 19 h; h) HF-
pyridine, EtOAc, RT, 14 h; i) DMT-Cl, pyridine, RT, 16.5 h; j) Diisopro-
pylammonium tetrazolide, 2-cyanoethyl-N,N,N’,N’-tetraisopropylphos-
phordiamidite, CH2Cl2, RT, 17 h. HMDS=Hexamethyldisilazane,
TMS= trimethylsilyl, CAN=cerium ammonium nitrate, TEA= triethyl-
amine, TBS= tert-butyldimethylsilyl, DMT=dimethoxytrityl.
Angewandte
Chemie
6517Angew. Chem. Int. Ed. 2012, 51, 6516 –6520  2012 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim www.angewandte.org
spectrometry signal has the exact mass of m/zfound= 230.0913
(Figure 1c). The signal is nicely separated from the signals of
the other naturally occurring isotopologues [15N,13C]-dC
(m/z=230.0976) and [18O/13C2]-dC (m/z= 230.1016) and thus
is clearly detectable. Furthermore, the measured high-reso-
lution data for the compound [15N2]-dC agrees very well with
the calculated exact mass of [15N2]-dC (m/zcalcd= 230.0920).
The data show all together that mESC nuclear extract has the
capability to decarboxylate caC to dC. Whether this activity is
caused by a specific enzyme or by other factors present in the
extract requires further investigation.
To investigate the reactions that would allow stem cells to
decarboxylate caC, we first heated the caC nucleoside and an
oligonucleotide containing a caC base. However, under no
circumstances was decarboxylation observable. Even when
the caC nucleoside was heated to reflux in water for several
hours, the mass spectrometric analysis of the reaction solution
provided no evidence for decarboxylation (data
not shown). This is not surprising because decar-
boxylation would furnish a high-energy cytosine
carbanion. In contrast, saturation of the C5C6
double bond followed by tautomerization of the
C4-amino group would give an imine intermediate
with the substructure of a b-iminocarboxylic acid,
which would allow efficient decarboxylation
(Figure 2).[10,24] To investigate this idea, we re-
duced the 5-carboxy-dC methyl ester 11 with
NaBH4. The reduced compound 12 is stable and
was isolated and fully characterized (Figure 2a;
Supporting Information). However, upon saponi-
fication of the methyl ester, rapid decarboxylation
to compound 13 is observed. Subsequent treat-
ment of the dihydro-dC derivative with DDQ
furnishes the TBS-protected compound dC. This
result shows that saturation of the C5C6 double
bond is critical for efficient decarboxylation, as
suggested recently.[10] As reaction with a H spe-
cies is unlikely to occur naturally, we then treated
TBS-protected caC with a thiol/imidazole mixture,
hoping for a more temporary 1,4-addition fol-
lowed by decarboxylation and elimination. This
chemical cascade is indeed observed (data not
shown). Treatment of the caC nucleoside with
octane thiol in presence of imidazole gave rise to
a new spot on the TLC plate. This spot was not
observed in the absence of imidazole, showing that
some proton catalysis is required for the reaction.
Isolation of the compound and full characteriza-
tion (Supporting Information) showed that the
new compound is indeed the TBS-protected dC.
This compound is generated by decarboxylation
followed by elimination of the added thiol. To
investigate if this chemistry would be compatible
with the decarboxylation of caC embedded in an
oligonucleotide (Figure 2b, c), we again used the
isotope tracing method. For the experiment, we
incubated the [15N2]-caC-containing DNA strand
ODN2 with different amino acids. Indeed, when
we added the amino acid cysteine or combinations
of cysteine with histidine/arginine to an aqueous solution of
ODN2, decarboxylation was detectable (Figure 2b). To con-
firm that decarboxylation is occurring, we re-isolated the
DNA after reaction overnight, digested the oligonucleotide
down to the nucleoside level and analyzed the mixture using
high resolution HPLC-MS. Figure 2b (left) shows the data
obtained for the cysteine/histidine combination. The data
depicted in Figure 2b (right) are the results of the cysteine/
arginine experiment. In both cases, the [15N2]-dC signal with
an
m/z value of 230.0922 was clearly detected. The amount of
decarboxylation increases with an increasing concentration of
thiol in solution and was in total around 5% (half-saturated
solution of amino acids, 50 8C, overnight).
In summary, using isotope tracing with a DNA strand in
which we incorporated double 15N-labeled caC, we could gain
first evidence that stem-cell nuclear extracts have the ability
Figure 1. a) Depiction of the nuclear extract experiment. b,d) HPLC-MS analysis of
D1 treated with mESC nuclear extract (b) and non-mESC extract (d). UV traces of
HPLC runs at the retention time of dC (top), as well as the mass traces for dC
(228.0948–228.1008, middle), and the mass traces for [15N2]-labeled dC (230.0890–
230.0940, bottom). c,e) High-resolution mass spectra (m/z=230.0700–230.1300) of
D1 treated with mESC nuclear extract (c) and non-mESC extract (e).
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to decarboxylate caC. Chemical model studies show that this
decarboxylation is accelerated by saturation of the C5C6
double bond of caC. This saturation is for example achieved
after attack of the electrophilic C6 position of caC by a thiol.
The C6-reacted caC will decarboxylate and re-aromatize.
Notably, the methylation of dC to mC by the different DNMT
(methyltransferase) enzymes proceeds by a quite similar
mechanism. Here the C6 carbon of dC is first attacked by
a thiol nucleophile, followed by reaction of the C5 atom with
the coenzyme S-adenoylmethionine (SAM), which provides
a CH3
+-ion equivalent. These enzymes have already been
associated with demethylation activity. For example, they
were shown to eliminate formaldehyde from hmC, converting
it into dC.[17,25] Another enzymatic reaction on pyrimidine
nucleobases, in which the C5C6 double bound is temporarily
saturated is performed by isoorotate decarboxylase (IDCase),
which activates water with the help of a Zn2+ ion so that an
hydroxide anion is generated that is thought to
react with the C6 position. This reaction is
followed by a decarboxylation that converts
isoorotate to uracil.[26,27] The chemical reactivity
that we suggest is consequently in agreement
with other known enzymatic transformations. We
believe that the decarboxylation of caC by stem
cells is an important mechanism in the frame-
work of active genome demethylation.
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ABSTRACT
The synthesis of the triphosphates of 5-hydroxymethyl-, 5-formyl-, and 5-carboxycytidine and the incorporation of these building blocks into
long DNA fragments using the polymerase chain reaction (PCR) are reported. In this way DNA fragments containing multiple hmC, fC, and caC
nucleobases are readily accessible.
Recently three new nucleobases were discovered in
DNA isolated from mouse embryonic stem cells.14 The
three nucleobases are oxidation products of 5-methylcyto-
sine (mC), which is a base that regulates transcriptional
activity.5 The oxidation reaction of 5-methylcytosine to
5-hydroxymethylcytosine (hmC), 5-formylcytosine (fC),
and finally 5-carboxycytosine (caC) is now understood to
be performed by 10-11-translocon proteins (TET13).6
These enzymes are R-ketoglutarate dependent oxidases,
which directly utilize molecular oxygen for the oxidation
reaction.7 The three newnucleobases are currently thought
to be involved in epigenetic programming of cells,
and they could be intermediates of a long searched for
pathway of active demethylation.810 Recently new se-
quencingmethods that allow the genomewide localization
of hmC11,12 and fC13 in genomic DNA were reported.†These authors contributed equally.
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In the past couple of years phosphoramidite building
blocks of hmC, fC, and caC, which allow the solid phase
synthesis of oligonucleotides containing the new bases
at defined sites, were developed.1418 However, to search
for proteins that interactwith these new epigenetic bases, and
to decipher the biological/biochemical questions associated
with the new nucleobases, longer oligonucleotides contain-
ing multiple hmC, fC, and caC bases are required. In this
direction, we thought that using the corresponding triphos-
phates (Figure 1) in combination with the polymerase chain
reaction (PCR) would solve this chemical problem.1921
In such a PCR, onewould exchange the dCTP either com-
pletely or partially by the corresponding xdCTP (x = hm,
f or ca) so that these DNA fragments contain the new bases
hmC, fC, and caC at the corresponding dC positions.
While the triphosphate of hmC (hmdCTP) is already
commercially available and its incorporation via PCR is
established, the corresponding fdCTP and cadCTP com-
pounds were unknown at the beginning of this study. The
chemical synthesis of both building blocks was achieved
as outlined in Scheme 1. For fdCTP we started the synthesis
with the fC nucleoside 1, which was prepared as described
recently by us.22 This compound was converted into the
50-monophosphate 2, which was obtained afterHPLCpurifi-
cation in 29% yield. We subsequently employed the new
triphosphate method recently described by S. D. Taylor et al.
using sulfonyl imidazolium triflate as the activating reagent
and pyrophosphate.23 The procedure allowed us to access the
triphosphate from the monophosphate in 70% yield. The
triphosphate was best isolated by ion exchange chromatogra-
phy at 4 Cusing aDEAE-cellulose column24with a gradient
from 100% water to 0.5 M TEAB (pH 7.5). The crude
triphosphate product was further purified by FPLC (0.1 M
TEAB, 1 M TEAB; 0100% over 30 min) using a MonoQ
5/50 GL anion exchange column (GE). This two-step proce-
dure allowed us to generate the reactive aldehyde-containing
fC triphosphate in sufficient yield for all further studies.
Figure 1. Depiction of the canonical DNA base dC and of mC
as well as of the new epigenetic bases hmC, fC, and caC as
triphosphates.
Scheme 1. Synthesis of fdCTP and cadCTP
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The cadCTP compound was prepared from the TBS
protected caC methyl ester 3 which was also prepared as
described recently by us.17We first cleaved the TBS groups
to obtain compound 4. The methyl ester was subsequently
saponifiedwhichprovided theunprotected caCnucleoside5.
5 was next introduced into the one-step triphosphate
synthesis reported originally byEckstein et al.25Here the
yield could be improved to 7% if the conditions developed
by Huang et al. were employed.26
We recently reported the synthesis of hmC, fC, and caC
phosphoramidites and the incorporation of these building
blocks intoDNAstrands. Primer extension studies showed
that none of the newbases aremutagenic.17Herewe report
the development of PCR conditions for the incorporation
of fdCTP and cadCTP into long oligonucleotides. We
chose the oct4 promotor sequence (see Supporting Infor-
mation (SI)) as the DNA template. The primers for the
PCRwere designed to yield a 150 bp product containing 77
modified dCs (4 dC are present in the primer; these are not
exchanged). For this purpose the forward and reverse
primers were annealed to the template at 55 C. The
elongation of the primers was best performed at 75 C
(for fdCTP) and 72 C (for cadCTP). Different poly-
merases were screened. We discovered that the DNA
polymerase Vent (exo) (for fdCTP) and KOD XL poly-
merase for (cadCTP) provided the best results (see SI). To
ensure complete extension of the primer the elongation
time was lengthened compared to the time used for in-
corporation of dCTP. The experimental results of the
PCRs are described in Figure 2.
The PCR products obtained with cadCTP can only be
visualized when a 1  TBE buffer system is used for the
analysis. When other buffers such as TAE were used we
noted that the obtained oligonucleotide products did not
give a distinct band in the gel electrophoresis potentially
because of the additional carboxylic acid groupspresent on
caC. Rather a broad smear is detected due to the lower
buffer capacity. The TBE buffer system in contrast pro-
vides sharp bands for the caC containing DNA products.
As depicted in lanes 5 and 6, both triphosphates fdCTP
(lane 5) and cadCTP (lane 6) yielded PCR products with
the correct length (negative control lanes 1 and 2) if our
developed PCR methods are employed. In the shown
experiments we replaced the dCTP completely by the
corresponding xdCTP. Hence full length PCR product
can only be formed when the triphosphate is accepted, as
further shown by the negative control in lane 2. Further
proof for the correct incorporation of fC and caC using
PCR was obtained by LC-MS experiments. The PCR
products were to this end fully digested. For this purpose
the sugar phosphate backbone was first cleaved with
nuclease S1 and snake venom phosphodiesterase, giving
the 50-monophosphates. These were further hydrolyzed to
the nucleoside level by Antarctic phosphatase.3 Using this
procedure even the highly modified DNA prepared here
was fully digested. The resulting nucleoside mixture was
subsequently analyzed by LC-HRMS or LC-MS/MS. The
data obtained for incorporated fdCTP are shown in
Figure 2B (for cadCTP, see SI). Clearly evident is the
presence of dA, dT, and dG in addition to the fC-nucleo-
side. Our results show that both fC and caC can be
inserted as triphosphates into long DNA fragments
using PCR. The observation that formyl group contain-
ing nucleosides can be incorporated into PCR products
despite their high reactivity is in line with a recent report
by Hocek et al. This group reported the PCR based
synthesis of aldehyde containing DNA products.27,28
It is interesting that the polymerase tolerates also the
negative charge associated with the carboxylic acid
present in caC. For future quantification of fC and
caC in natural material we also prepared isotope labeled
fC and caC triphosphates and incorporated them into
DNA strands using basically the same PCR conditions
showing the broad applicability of the here reported
technology (see SI).
We next turned our attention to the hmCbase.Here, the
corresponding triphosphate is generated from the mono-
phosphate, which is directly isolated from natural sources.
A chemical synthesis of the hmC triphosphate was not
Figure 2. (A)Depiction of the results of the PCR analyzed by gel
electrophoresis. Lane 1: without template. Lane 2: without any
dCderivative. Lane 3: dCTP.Lane 4: protectedD2,
15N2-hmdCTP.
Lane 5: fdCTP.Lane 6: cadCTP. (B)UV trace (left) andmass trace
of fC (right) of a fully digested PCR mixture with fdCTP.
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performed so far, which limits our ability to create DNA
fragments with modified hmC, e.g. with isotopically la-
beled compounds as needed for mass spectrometry based
quantification and proteomics studies. The synthetic chal-
lenge associated with the synthesis of hmdCTP is the
benzylic hydroxyl group of the hmC heterocycle which is
more reactive than the primary 50-OH group. This makes
it difficult to access the 50-monophosphate directly from
hmC. To circumvent this problem and to enable the PCR
incorporation of modified hmC building blocks, we in-
vestigated the ability to insert a protected hmC derivative
by PCR followed by deprotection. The synthesis of the
protected hmdCTP building block and the results of the
PCR study are shown in Figure 3.
To exemplify the possibilities associated with the chemi-
cal method, we prepared for this study the unnatural 2 
[15N] and 2Dmodified hmC (SI). The starting point for
the synthesis is theTBSprotected iodouracil 6,29whichwas
carbonylated to 7 and reduced to 8. Compound 8 was
protected as the carbamate 9, and the TBS groups were
cleaved to obtain 10. We utilized the optimized one-pot
triphosphate synthesis described above to obtain the la-
beled hmdCTP 11. Subsequent PCR based incorporation
studies showed that the reaction is best performedwith the
KOD XL polymerase with again slightly prolonged elon-
gation times (30 s instead of 15 s). The PCR product was
subsequently deprotected with 0.1 M NaOH in water/
methanol 1:4 for 1 h at rt. The DNA was finally purified
using a silica membrane (see SI). The agarose gel of the
deprotected and purified DNA fragment is depicted in
Figure 2A, lane 4. Again a clean PCR product is observed.
The results of the total digest performed under the opti-
mized conditions reported above are shown in Figure 3B.
Again next to dA, dG, and dT as well as small amounts of
residual dC from theprimers, an additional signal is observed
with the correct retention timeandexactmolecularweight for
D2,
15N2-hmC.Most importantly we do not observe a signal
forun-deprotectedhmCshowing that full deprotectionof the
carbamate protecting group present on our hmdCTP build-
ing block was achieved. In summary we report here the first
chemical synthesis of the three triphosphates hmdCTP,
fdCTP, and cadCTP of the new epigenetic bases hmC, fC,
and caC and describe PCR conditions which enable the
incorporation of these building blocks into long DNA frag-
ments. The chemical synthesis allows even the synthesis and
incorporationof isotopologuesof thenewbases,whichshould
facilitate mass spectrometry based quantification methods.
We believe that the reported synthetic methodologies
disclosed herewill strongly advance our ability to study the
biology andbiochemistry of the new epigenetic bases hmC,
fC and caC.
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Figure 3. (A) Synthesis of the protected D2,
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digested PCR mixture.
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Targeted Mutagenesis Results in an Activation of DNA
Methyltransferase 1 and Confirms an Autoinhibitory Role
of its RFTS Domain
Pavel Bashtrykov,[a] Arumugam Rajavelu,[a] Benjamin Hackner,[b] Sergey Ragozin,[a]
Thomas Carell,[b] and Albert Jeltsch*[a]
Introduction
DNA methylation is a repressive epigenetic signal involved in
the regulation of gene expression and chromatin structure. In
mammals, DNA methylation takes place at position 5 of cyto-
sines, primarily within CpG dinucleotides.[1–5] Approximately
60–70% of CpG sites are methylated, and form cell-type-specif-
ic DNA methylation patterns. Aberrant DNA methylation is im-
plicated in the pathogenesis of many diseases, for example
those of the immune system, the nervous system and
cancer.[6–7] DNA methylation is durable and heritable: it can be
transmitted through cell generations, because hemimethylated
CpG sites in newly synthesised DNA are recognised and reme-
thylated by Dnmt1. Hence, the preference of Dnmt1 for hemi-
methylated CpG sites over unmethylated sites plays a funda-
mental role in the maintenance of DNA methylation pattern.[5]
Mouse Dnmt1 (1620 residues) consists of a C-terminal catalytic
domain and an N-terminal regulatory multidomain, which in-
cludes the RFTS (replication foci targeting sequence, the sub-
ject of this study; Figure 1A). In vitro experiments have shown
that Dnmt1 has a preference of approximately 10- to 40-fold
for hemimethylated CpG sites.[8–14] However, this preference is
not enough to ensure accurate copying of methylation pat-
terns that encompass millions of CpG sites, thus suggesting
that additional mechanisms exist to increase the specificity for
hemimethylated CpG sites and to provide precise control of its
activity in vivo.
Recently, based on structural and biochemical studies, two
models of allosteric control of Dnmt1 activity by its N-terminal
The N-terminal regulatory part of DNA methyltransferase 1
(Dnmt1) contains a replication foci targeting sequence (RFTS)
domain, which is involved in the recruitment of Dnmt1 to rep-
lication forks. The RFTS domain has been observed in a crystal
structure to bind to the catalytic domain of the enzyme and
block its catalytic centre. Removal of the RFTS domain led to
activation of Dnmt1, thus suggesting an autoinhibitory role of
this domain. Here, we destabilised the interaction of the RFTS
domain with the catalytic domain by site-directed mutagenesis
and purified the corresponding Dnmt1 variants. Our data show
that these mutations resulted in an up to fourfold increase in
Dnmt1 methylation activity in vitro. Activation of Dnmt1 was
not accompanied by a change in its preference for methylation
of hemimethylated CpG sites. We also show that the Dnmt1
E572R/D575R variant has a higher DNA methylation activity in
human cells after transfection into HCT116 cells, which are
hypomorphic for Dnmt1. Our findings strongly support the au-
toinhibitory role of the RFTS domain, and indicate that it con-
tributes to the regulation of Dnmt1 activity in cells.
Figure 1. Structure of Dnmt1. A) Domain architecture of Dnmt1 showing
RFTS domain (light grey) and catalytic domain (dark grey). B) Binding of the
RFTS domain to the DNA-binding pocket of Dnmt1 is stabilised by several
hydrogen bonds and ionic contacts. Parts of the catalytic and CXXC domains
are shown in dark and light grey, respectively; RFTS residues selected for
mutagenesis are labelled; catalytic and CXXC domain residues involved in
the interaction with the RFTS domain are shown as well. (Images prepared
from crystal structure PDB ID: 3AV4.)[15]
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region were proposed. The structure of a truncated form of
Dnmt1 (amino acids 650–1620: CXXC, BAH1, BAH2 and catalyt-
ic domains) bound to unmethylated DNA was solved, and bio-
chemical experiments with this Dnmt1 fragment provided evi-
dence that the CXXC domain has an autoinhibitory role.[11]
However, in a separate investigation, the regulatory role of the
CXXC domain in full-length Dnmt1 could not be shown.[13] In
addition, the structure of a Dnmt1 variant (residues 291–1620)
showed that the RFTS domain binds to the DNA-binding
pocket in the catalytic domain of Dnmt1, and that the CXXC
domain is pushed aside.[15] Based on this, it was proposed that
Dnmt1 has to undergo a structural change to allow DNA bind-
ing and methylation; this includes movement of the RFTS
domain. In a parallel study, Syeda et al. crystallised the isolated
RFTS domain (351–600) and, based on modelling, proposed
that the RFTS domain can bind to the catalytic domain and
can occupy the catalytic site of the enzyme.[16] In support of
their proposal, a human Dnmt1 variant (621–1616) without the
RFTS domain showed stronger binding to DNA than a longer
Dnmt1 fragment (351–1616) that included the domain. They
also compared the DNA methylation activity of these two trun-
cated variants and found that the turnover of Dnmt1 (621–
1616) was approximately 40 times higher than that of Dnmt1
(351–1616), and that addition of the RFTS domain to the meth-
ylation reaction inhibited the activity of Dnmt1 (621–1616).[16]
These data support the model that the RFTS domain is an
endogenous inhibitor of DNA binding and methylation by
Dnmt1. However, as Dnmt1 is a large multidomain protein, the
removal of domains by truncation might have unpredictable
consequences, as illustrated by the different results obtained
with full-length Dnmt1 and with truncated versions in the
studies related to the role of the CXXC domain in the regula-
tion of the specificity of the enzyme.[11,13] In the current, work
we aimed to verify the autoinhibitory role of the RFTS domain
in the context of the full-length Dnmt1, by targeted site-direct-
ed mutagenesis within the RFTS domain to reduce its inter-
action with the catalytic domain, and by measurement of the
catalytic activity of the corresponding full-length Dnmt1 vari-
ants in vitro and in cells.
Results and Discussion
Design and expression of Dnmt1 mutants
According to the crystal structure of Dnmt1 (291–1620) pub-
lished by Takeshita et al. ,[15] the RFTS domain plays an autoinhi-
bitory role in Dnmt1 by occupying the catalytic cleft of the
enzyme and thereby preventing access of the DNA substrate
to the catalytic site. To catalyse a methylation reaction, Dnmt1
has to adopt another conformation: one in which the RFTS
domain is released from the catalytic domain. Binding of the
RFTS domain to the DNA-binding cleft involves several hydro-
gen bonds and ionic contacts, including E531–K1537, D532–
R1576, D554–S1495, A594–H1504 and L593–T1505 (first residue
in the RFTS domain, second in the catalytic domain). In addi-
tion, the RFTS domain forms interactions with the CXXC
domain, including E572–K691, E572–R601 and D575–R693 (first
residue in RFTS, second in CXXC), thus stabilising its binding to
the catalytic domain. We selected residues in the RFTS domain
for charge reversal mutagenesis to destabilise the interaction
of the RFTS domain with the catalytic domain and thereby trig-
ger its release from the catalytic domain. Amino acids E531,
D532, D554, E572 and D575 were selected (Figure 1), and three
Dnmt1 variants (E531R/D532R, D554R and E572R/D575R) were
cloned in a baculovirus expression system. However, we were
unable to express the E531R/D535R variant, so experiments
were performed with just the other two (Figure 2). We did not
mutate residues in the catalytic domain of Dnmt1, because
this could cause direct effects on the catalytic activity; such
effects would not be related to an autoinhibitory role of the
RFTS domain and would confuse the interpretation of results.
DNA methylation activity of Dnmt1 mutants
The DNA methylation activity of the mutants was investigated
by in vitro DNA methylation assays. The methylation reactions
were carried out with a 30-mer DNA substrate containing
a single CpG site in a hemimethylated state and S-adenosyl-l-
methionine (AdoMet) with a radioactively labelled methyl
group. The activities of wild-type Dnmt1 and its variants were
assessed by incorporation of radioactivity into the DNA. We
observed a DNA methylation rate of 1.3 h1 under our condi-
tions (Figure 3A), which was too slow to conduct multiple-
turnover experiments. Therefore, we measured DNA methyla-
tion during the initial reaction phase using excess DNA and
AdoMet, to determine the single-turnover rate. Interestingly,
the mutations resulted in an increase in DNA methylation ac-
tivity in comparison to the wild type: approximately fourfold
and 2.5-fold for E572R/D575R and D554R, respectively
(Figure 3). Thus, removal of contacts involved in stabilising the
autoinhibitory conformation of Dnmt1 resulted in its activa-
tion.
Figure 2. SDS PAGE of wild-type (WT) and mutant Dnmt1 to compare con-
centrations of WT and E572R/D575R and D554R mutants used in the kinetics
experiments. Arrow indicates bands of full-length proteins.
 2014 Wiley-VCH Verlag GmbH&Co. KGaA, Weinheim ChemBioChem 0000, 00, 1 – 7 &2&
These are not the final page numbers! 
CHEMBIOCHEM
FULL PAPERS www.chembiochem.org
Substrate specificity of Dnmt1 mutants
Next, we analysed the substrate specificity of the Dnmt1 mu-
tants. For this we used an otherwise identical 30-mer DNA sub-
strate, but with an unmethylated CpG site. Methylation reac-
tions with hemimethylated and unmethylated substrates were
carried out in parallel for wild-
type Dnmt1 and the variants.
Wild-type Dnmt1 showed a 16-
fold preference for the hemime-
thylated substrate over unme-
thylated under the tested condi-
tions (Figure 4), similarly to pre-
vious results.[13,14] The specifici-
ties of the Dnmt1 E572R/D575R
and D554R variants were very
similar and within the error
range of the data obtained for
wild-type Dnmt1. We conclude
that autoinhibition of Dnmt1 by
the RFTS domain plays a role in
the control of the catalytic activi-
ty of Dnmt1, but that it is not
involved in a regulation of the
specificity of Dnmt1.
Dnmt1 E572R/D575R has
increased activity in cells
To study the DNA methylation
activity of Dnmt1 in human cells
we used HCT116 Dnmt1 hypo-
morphic cells, which contain
a truncated Dnmt1 with reduced
activity. Because of the impaired
maintenance DNA methylation
activity, these cells have an
about 20% reduced DNA meth-
ylation and show increased
levels of hemimethylation.[17,18]
The cells were transfected with
plasmids encoding YFP-fused
Dnmt1 and Dnmt1 E572R/
D575R. A YFP-expressing plasmid
was used as a control. Transfec-
tion yields were assessed by
FACS and found to be almost
identical in all three experiments
(Figure 5A). Genomic DNA was
isolated, and 5-methylcytosine
was quantified by LC-MS/MS
(Figure 5B). Transfection with
wild-type Dnmt1 led to a strong
increase in DNA methylation of
the hypomorphic cells (from
2.59 to 2.82%), thus indicating
that the assay was working.
Transfection with the E572R/D575R variant led to an even
higher increase in DNA methylation (to 2.95%) that was 60%
larger than for wild-type Dnmt1. This shows that the E572R/
D575R variant has higher activity in human cells, thus indicat-
ing that the binding of the RFTS domain to the catalytic
pocket also reduces the activity of Dnmt1 in vivo.
Figure 3. Targeted mutagenesis in the Dnmt1 RFTS domain results in activation of DNA methylation activity. A) Ex-
amples of DNA methylation kinetics with Dnmt1 variants and hemimethylated substrates. B) Catalytic activities of
Dnmt1 variants for methylation of a hemimethylated oligonucleotide substrate, relative to wild-type Dnmt1. Activ-
ities are averages of three to six independent experiments (error bars : SEM).
Figure 4. Substrate specificities of Dnmt1 variants. A) Example kinetics of wild-type Dnmt1 and mutants for meth-
ylation of unmethylated (um) and hemimethylated (hm) substrates. B) Dnmt1 specificity of variants is expressed
as the ratio of the rate of methylation of hemimethylated substrate to that of unmethylated substrate. Mutagene-
sis in the RFTS domain did not change specificity of the mutants. Specificities are averages of three to six inde-
pendent experiments (error bars : SEM).
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Conclusions
Autoinhibition is a common mechanism for regulation of
enzyme activity. Protein kinase A is a well-investigated exam-
ple. The enzyme consists of regulatory and catalytic subunits
and forms a heterotetrameric complex in the absence of cAMP.
This complex is catalytically inactive because the regulatory
subunits contain pseudosubstrate sites, which mimic the sub-
strate and tightly bind to the active site of the catalytic sub-
unit, thereby blocking its activity. After binding of cAMP to the
regulatory subunits, they undergo a conformational change
and dissociate from the catalytic subunit ; catalytic activity is
switched on by this event.[19,20]
Here we provide evidence that the RFTS domain plays a simi-
lar autoinhibitory role in Dnmt1 by binding to its catalytic
domain and blocking the DNA binding cleft of the enzyme
(Figure 6). We were able to show that charge-reversal muta-
tions of residues that mediate binding of the RFTS domain to
the catalytic domain weaken this interaction and lead to acti-
vation of Dnmt1. As it is rare that such a drastic exchange of
residues of an enzyme leads to increased activity, our finding
provides strong support for the autoinhibition model pro-
posed previously by Syeda et al.[16] and Takeshita et al.[15] A sim-
ilar increase in activity by the mutants was observed with sub-
strates containing unmethylated or hemimethylated CpG sites,
thus indicating that the RFTS domain represses activity of
Dnmt1 but does not change its specificity. We interpret this
finding as indicating that the weaker binding of the RFTS
domain to the catalytic domain changes the ratio of Dnmt1
conformations with blocked and open DNA binding cleft, and
that this results in higher overall activity. As specificity is deter-
mined mainly by specific interactions of the DNA substrate
with the catalytic domain,[12–14] the change in the conformation
of the RFTS domain did not affect the preference of the
enzyme for hemimethylated DNA.
The elevated activity of Dnmt1 E572R/D575R in cells shows
that the binding of the RFTS domain to the catalytic pocket
also reduces the activity of Dnmt1 in vivo. This indicates that
modulation of this interaction could be a regulatory mecha-
nism in Dnmt1. However, the endogenous signal to trigger
release of the RFTS domain from the DNA-binding pocket re-
mains to be determined. One may speculate that interaction
with other proteins plays a role in this. The protein Uhrf1 has
been shown to recruit Dnmt1 to hemimethylated DNA and re-
pressed DNA.[21–23] Syeda et al. proposed that Uhrf1 interacts
with the RFTS domain of Dnmt1 and helps to release it from
the catalytic site, and thereby activates DNA methylation by
Dnmt1.[16] In agreement with this, we recently showed that
binding of Uhrf1 stimulates Dnmt1, and that this effect is
mediated by the RFTS domain.[28] Other factors involved in this
regulation remain to be elucidated.
Experimental Section
Protein expression and purification: Wild-type mouse Dnmt1 (ac-
cession: NP_034196.5) and Dnmt1 mutants E531R/D535R, D554R
and E575R/D575R were expressed by using the Bac-to-Bac baculo-
virus expression system (Invitrogen/Life Technologies) according to
the manufacturer’s instructions, basically as previously de-
Figure 5. Mutant E572R/D575R is more active than wild-type Dnmt1 in
HCT116 Dnmt1 hypomorphic cells. A) HCT116 Dnmt1 hypomorphic cells
were transfected with YFP (control) or expression plasmids for YFP-fused
Dnmt1 and Dnmt1 E572R/D575R. Transfection yields were determined by
FACS, and found to be similar in all three experiments. The percentage of
YFP-positive cells is indicated in the corresponding images. B) Genomic DNA
was isolated from transfected cells, and the amount of methylated cytosine
was quantified by LC-MS/MS (average of three measurements, SEM). Cyto-
sine methylation is given here as the ratio of 5-methylcytosine and guanine
as a measure of total cytosine (mC/G) in %.
Figure 6. Allosteric regulation of Dnmt1. The RFTS domain (dark grey) has
an autoinhibition function, because it binds to the catalytic domain of the
enzyme (light grey). This blocks access by the DNA to the DNA-binding cleft
and catalytic centre (star). Mutations in the RFTS domain weakened its bind-
ing to the catalytic domain, thereby causing activation of the enzyme both
in vitro and in cells.
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scribed.[13,24] All genes were cloned into pFastBacHTa as N-terminal
His6 and EYFP fusions and purified with Ni-NTA Agarose (Genaxxon,
Ulm, Germany) by following standard procedures. Dnmt1 mutants
were generated by site-directed mutagenesis[25] using the following
primers: E531R/D532R (forward primer 5’-CTG TAT ATC GGC GCT
TGA TCA ATA-3’, reverse primer 5’-TCA TCG TCG TCT GCC TCC
TTCA-3’), D554R (forward primer 5’-TTC ACA GAG AGA TCT CTC
TTA CGC CA-3’, reverse primer 5’-TCA TCG TCG TCT GCC TCC TTCA-
3’), E572R/D575R (forward primer 5’-TAC GAC AGG GCC AAG AGA
GAT GAT GA-3’, reverse primer 5’-TCA TCG TCG TCT GCC TCC
TTCA-3’).
In vitro DNA methylation assay: DNA methylation assays were
performed as described previously.[24] Briefly, methylation reactions
were carried out with DNA substrate (2 mm), [methyl-3H]AdoMet
(1.125 mm; PerkinElmer) and recombinant Dnmt1 (0.2 mm) at 37 8C
in methylation buffer (HEPES (20 mm, pH 7.5), EDTA (1 mm), KCl
(50 mm)). DNA substrates for the assay were prepared by anneal-
ing a 30-mer oligonucleotide (TTG CAC TCT CCT CCCG GAA GTC
CCA GCT TC) containing one unmethylated CpG site (bold) with
a complementary oligonucleotide (either unmethylated or methy-
lated), to form unmethylated and hemimethylated substrates. All
methylation experiments were carried out at least in triplicate. Ini-
tial rates were determined by linear regression. Methylation assays
were calibrated by complete methylation of the substrates with
M.SssI (CpG methyltransferase; NEB).
Cell culture and transfection: To study the activity of Dnmt1 and
the Dnmt1 E572R/D575R mutant in cells, we used HCT116 Dnmt1
hypomorph cells, kindly provided by Prof. Bert Vogelstein (Johns
Hopkins University, Baltimore).[17] The cells were cultivated in
McCoy’s 5A medium (#16600; Gibco) supplemented with FBS
(10%), penicillin (100 UmL1) and streptomycin (0.1 mgmL1) at
37 8C. EYFP fusions of Dnmt1 wild type and E572R/D575R mutant
were cloned into pcDNA3 for expression in mammalian cells yield-
ing the pEYFP-Dnmt1 and pEYFP-Dnmt1 E572R/D575R constructs.
The plasmids were transfected into HCT116 cells, and DNA methyl-
ation was analysed by LC-MS/MS. The pEYFP plasmid (encoding
only EYFP) was used as a control. The HCT116 cells were seeded in
a T25 flask, grown to 60–70% confluence, then transfected with
Lipofectamine (Invitrogen/Life Technologies) by following the man-
ufacturer’s instructions. Briefly, plasmid (12 mg) was incubated with
Lipofectamine (12 mL) at room temperature for 20 min, then trans-
ferred to the T25 flask containing the cells and incubated at 37 8C.
Fresh medium was supplemented the next day; cells were incubat-
ed over four to five days with daily supplementing of the medium.
Transfected cells were quantified by FACS analysis (Calibur system;
BD Bioscience) equipped with 488 nm laser and CellQuest Pro soft-
ware, as previously described.[26] Fluorescence intensity was mea-
sured in the FL1 channel (log scale, 1 to 104; 10000 cells per
sample). Non-transfected HCT116 Dnmt1 hyphomorph cells were
used as a control. Cells with a fluorescence intensity above 7 were
considered YFP-positive. Genomic DNA was prepared by using the
Blood and Cell Culture DNA Midi Kit (Qiagen). DNA extraction was
performed by following the manufacturer’s instructions for genom-
ic DNA isolation from cell culture. DNA amounts were quantified
spectroscopically at OD260.
Sample preparation of genomic DNA for LC-MS/MS analysis: Ge-
nomic DNA (0.5–1 mg) in H2O (25 mL) was digested by addition of
ZnSO4 (480 mm, 7.5 mL) containing Aspergillus oryzae nuclease S1
(42 U; Sigma–Aldrich), antarctic phosphatase (5 U, NEB) and specif-
ic amounts of HPLC-purified, labelled, internal standards (VWR), as
previously described.[27] The mixture was incubated at 37 8C for 3 h
in a Thermomixer comfort (Eppendorf). After addition of EDTA-Na2
(7.5 mL, 520 mm) containing snake venom phosphodiesterase I
(0.2 U; USB Corporation/Affymetrix, Santa Clara, CA), the sample
was incubated for another 3 h at 37 8C (total volume 40 mL). The
sample was stored at 20 8C until analysis. Samples were filtered
through an AcroPrep Advance 96 filter plate (0.2 mm Supor; Pall
Life Sciences, Port Washington, NY) and then analysed by LC-MS/
MS as described below.
LC-ESI-MS/MS: Acetonitrile (LC-MS grade) was purchased from Carl
Roth; formic acid (p.a. grade for MS) was purchased from Fluka;
water was purified by a Milli-Q Plus system (Merck Millipore) ; gen-
eral HPLC and source settings for LC-ESI-MS/MS settings were as
previously described.[27] Compound-dependent LC-MS/MS parame-
ters for analysis of genomic DNA were as follows: time segment
1.5–4.0 min; precursor ion (m/z) 245.13 for [D3]-mC and 242.11 for
mC. MS1 resolution: enhanced, product ion (m/z) 129.09 for [D3]-
mC and 126.07 for mC, MS2 resolution: enhanced, dwell time
30 ms; collision energy 60 V; collision cell accelerator voltage 1 V;
positive polarity.
Note added in revision: Recently, an independent study showed
that mutations of residues at the interface of the RFTS and catalyt-
ic domains stimulate a Dnmt1 (291–1620) fragment as well.[29]
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Introduction: 
Many pathways for active demethylation have been suggested as stated in chapter I.2.3. The 
C-C bond cleavage of the oxidized cytidine derivatives has been previously described in 
chapter VI and supports the idea of a decarboxylation pathway. In this manuscript the 
chemical requirements for decarboxylation are clarified and the efficiency determined. 
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ABSTRACT: Three new cytosine derived DNA modiﬁca-
tions, 5-hydroxymethyl-2′-deoxycytidine (hmdC), 5-formyl-2′-
deoxycytidine (fdC) and 5-carboxy-2′-deoxycytidine (cadC)
were recently discovered in mammalian DNA, particularly in
stem cell DNA. Their function is currently not clear, but it is
assumed that in stem cells they might be intermediates of an
active demethylation process. This process may involve base
excision repair, C−C bond cleaving reactions or deamination
of hmdC to 5-hydroxymethyl-2′-deoxyuridine (hmdU). Here
we report chemical studies that enlighten the chemical reactivity of the new cytosine nucleobases. We investigated their
sensitivity toward oxidation and deamination and we studied the C−C bond cleaving reactivity of hmdC, fdC, and cadC in the
absence and presence of thiols as biologically relevant (organo)catalysts. We show that hmdC is in comparison to mdC rapidly
oxidized to fdC already in the presence of air. In contrast, deamination reactions were found to occur only to a minor extent. The
C−C bond cleavage reactions require the presence of high concentration of thiols and are acid catalyzed. While hmdC
dehydroxymethylates very slowly, fdC and especially cadC react considerably faster to dC. Thiols are active site residues in many
DNA modiﬁying enzymes indicating that such enzymes could play a role in an alternative active DNA demethylation mechanism
via deformylation of fdC or decarboxylation of cadC. Quantum-chemical calculations support the catalytic inﬂuence of a thiol on
the C−C bond cleavage.
■ INTRODUCTION
In addition to the canonical nucleosides dA, dC, dG, and dT,
mammalian DNA contains 5-methyl-2′-deoxycytidine (mdC)
and further dC derivatives that are generated from mdC by
oxidation of the methyl group. The oxidizing enzymes are TET
(ten eleven translocation) enzymes. These are α-ketoglutarate
dependent oxygenases, which oxidize 5-methyl-2′-deoxycyti-
dine to 5-hydroxymethyl-2′-deoxycytidine (hmdC) and further
to 5-formyl-2′-deoxycytidine (fdC) and 5-carboxy-2′-deoxycy-
tidine (cadC).1−5 The fate of these nucleosides and their
function are currently controversially discussed. For hmdC for
example it was postulated that the nucleoside may be
deaminated in vivo to give 5-hydroxymethyl-2′-deoxyuridine
(hmdU) by the action of special deaminases such as the AID
(activation-induced deaminase)/APOBEC (apolipoprotein B
mRNA-editing enzyme complex) protein family.6,7 However,
newer in vitro data suggest that deamination of hmdC is
unlikely to occur enzymatically,8 raising the question of
whether the occurrence of hmdU may result from non-
enzymatic spontaneous deamination of hmdC. Furthermore,
since hmdC and fdC are known oxidative lesions of mdC9−11
and because the levels of fdC and in particular cadC3−5,12 are in
the range of those reported for 8-oxo-dG,13 which is a well-
known oxidative damage, one has to consider the possibility
that they are formed by nonenzymatic oxidation processes
during DNA isolation and analysis.13,14 Finally, while there is a
possibility that enzymatic dehydroxymethylation of hmdC,
deformylation of fdC, and decarboxylation of cadC might
occur,15−19 it cannot be ruled out that these processes occur
Received: April 11, 2013
Published: August 27, 2013
Scheme 1. The dC Derivatives hmdC, fdC, and cadC Could
Either Deaminate to dU Derivatives (Left), Undergo C−C
bond Cleavage to dC (Right), or Oxidize
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already to a signiﬁcant extent without the help of an
enzyme.18,20
To diﬀerentiate between potential nonenzymatic background
reactivities and enzyme-catalyzed processes, it is therefore
essential to understand the intrinsic reactivity proﬁle of the new
nucleosides hmdC, fdC and cadC (Scheme 1).
■ RESULTS AND DISCUSSION
Recently, others and us reported the synthesis of phosphor-
amidite and triphosphate building blocks for hmdC, fdC, and
cadC and their incorporation into oligonucleotides using either
solid phase phosphoramidite chemistry or by polymerase chain
reaction (PCR).21−25 For this study we synthesized hmdC, fdC,
and cadC nucleosides and phosphoramidites and incorporated
the latter into 20mer hairpin-oligodeoxynucleotides (ODN)
with either hmdC (ODN1 and ODN4), fdC (ODN2 and
ODN5), or cadC (ODN3 and ODN6) in a double-stranded
xCpG or xCpNpG context using solid phase phosphoramidite
chemistry (Scheme 2).
To investigate deamination-, oxidation-, and C−C bond
cleavage reactions, the reactivities of the new epigenetic
modiﬁcations were studied on the nucleoside level and in
hairpin ODNs in buﬀer and in the presence of thiols. We
investigated the reactivity with thiols in order to simulate
potential enzymatic reactions, which often start by initial
nucleophilic attack of the thiol at the C6 position of the
pyrimidine. This then activates the corresponding C5 position
(numbering see Scheme 1).18 Examples are the DNA
methyltransferases (DNMT), which convert dC to mdC.19
We ﬁrst studied the reactivity of the diﬀerent xdC-
nucleosides at pH 7.4 in buﬀer at diﬀerent temperatures. We
simultaneously quantiﬁed the various oxidation, deamination,
and C−C bond cleavage reactions. Moreover, to elucidate how
thiol-mediated C5 activation would inﬂuence the reactions, we
performed studies with a systematic increase of β-mercapto-
ethanol (β-ME, 0 to 12 M). High thiol concentrations (12 M)
were chosen to simulate the high eﬀective molarity of, for
example, the reactive cysteine moiety in the active sites of
enzymes.17,18 In all cases we performed product analysis using a
UHPLC-MS/MS method with a triple quadrupole mass
spectrometer (Scheme 2; for method development see
Supporting Information [SI]). The developed method allows
sensitive and accurate quantiﬁcation of the whole product
spectrum in one single analysis (12 min total run time). The
exact quantiﬁcation of the reaction products was conducted
using the stable isotope dilution technique as described by
others and us.12,13,26,27 For the synthesis of the used
isotopologues [15N2]-dC, [D2,
15N2]-hmdC, [
15N2]-fdC,
[15N2]-cadC, [D3]-dT, [
15N2]-dU, [D2]-hmdU, and [
15N2]-
fdU see SI.
Oxidation Processes. Our ﬁrst question was how quickly
air would oxidize mdC to hmdC, hmdC to fdC, and fdC to
cadC. We dissolved the respective nucleosides in a phosphate
buﬀer at pH = 7.4 and incubated the solution exposed to air for
up to 60 h at 60.0, 67.5, 75.0, and 80.0 °C (Figure 1 and SI).
For data analysis we assumed a pseudo-ﬁrst order kinetic proﬁle
in which the oxygen concentration is a not rate limiting factor.
Under these conditions we observed that mdC is oxidized only
to a small extent to hmdC. In contrast, hmdC reacts eﬃciently
to form fdC (Figure 1, blue line). Oxidation of fdC to cadC
(Figure 1, green dots) is slow.
After 60 h at 60 °C, the yield of cadC was only 0.03%. Table
1 summarizes the determined pseudo-ﬁrst-order rate constants.
The data show that the formation of fdC by oxidation of hmdC
is more than 2 orders of magnitude faster than the oxidation of
mdC to hmdC. For the fdC to cadC oxidation, a rate constant
Scheme 2. Depiction of the Hairpins Used in This Study and
of the Experimental Workﬂowa
aAfter incubation of the xdC-containing hairpins in β-mercaptoethanol
(β-ME)/imidazole, the DNA was isolated. The corresponding
isotopologues were added (omitted for clarity in the chromatogram),
and the DNA was digested. Quantiﬁcation of the reaction products
was performed by UHPLC-MS/MS. Im = imidazole.
Figure 1. Oxidation kinetics of mdC to hmdC (cyan), hmdC to fdC
(blue), and fdC to cadC (green) at 60.0 °C at pH 7.4. While hmdC is
eﬃciently oxidized to fdC, fdC gives only a little cadC. Depicted are
the means of triplicate experiments; error bars reﬂect the standard
deviations. For details of the kinetic measurements at 67.5, 75.0, and
80.0 °C and linear regression analyses see SI.
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could not be calculated, since the data deviated substantially
from linearity (see Figure 1 and SI, Figure S2, Figure S11).
We next studied the oxidation reactions of hmdC and fdC in
the hairpin-ODNs (Scheme 2). The reactions were performed
without and with increasing amounts of β-ME (and imidazole
at pH 5.0) in solution for 48 h at 50 °C (melting temperatures
of hairpins: ≥70 °C; see SI, Table S1). The samples were
desalted with a 0.025 μm ﬁlter, spiked with the labeled internal
standards, then fully digested with nuclease S1, snake venom
phosphodiesterase, and antarctic phosphatase and analyzed by
LC−MS/MS (Scheme 2). The amounts of the nucleoside
products were normalized to the amount of dT [%]. Despite
the shielding eﬀect of the duplex environment, which could
limit the reaction of the thiol at the C6 position, we measured
increasing amounts of fdC with increasing concentrations of β-
ME in ODN1 (hmdC). The fdC compound reached
surprisingly high levels of up to 20% at 12 M β-ME (80% v/
v β-ME; Figure 2, blue curve), showing that the C5−C6
saturation by the thiol has a dramatic inﬂuence on the event of
oxidation. In the absence of thiols we detected fdC at about
0.2% in ODN1 (48 h, 37 °C, pH 5.0). Other typical pyrimidine
oxidation products were not detected regardless of the reaction
conditions. We also monitored the levels of the well-established
dG oxidation product 8-oxo-dG and noted here no signiﬁcant
level change (Figure 2, black curve), arguing for a thiol-
catalyzed oxidation of hmdC to fdC.
Analyzing the mixture by mass spectrometry in more detail
revealed the presence of 5-((2″-hydroxyethyl)thio)methyl-dC
(Figure 2, yellow curve; top structure in Scheme 3), which
shows that a 5-methylene intermediate may be formed during
the reaction, which was ﬁrst described by the Klimasauskas
group.28
Treatment of ODN2 (fdC) at 80% v/v β-ME gave rise to the
formation of the oxidized product cadC, but the reaction is
comparatively slow (Figure 2, green curve). The formation of a
dithioacetal of fdC was not detected (see SI). It should be
noted that concomitant deformylation of fdC or decarbox-
ylation of the oxidation product cadC to form dC in the
presensce of β-ME (see last section) may cause a slight
underestimation of the oxidation rate.
In summary, experiments on the nucleoside and duplex level
reveal that the oxidation of hmdC to fdC is a relatively fast
process that is furthermore catalyzed by thiols. This result has
to be taken into account when biological samples are
investigated regarding the fdC levels.
Deamination Reactions. We next incubated the diﬀerent
nucleosides at pH 7.4 in water to investigate the deamination of
dC, mdC, hmdC, and fdC to dU, dT, hmdU, and fdU (5-
formyl-2′-deoxyuridine), respectively. The data are depicted in
Figure 3. Clearly evident is that dC, mdC, hmdC, and fdC are
deaminated under these conditions by about the same extent.
Deamination of cadC was not detected. To obtain kinetic data
at 37 °C, we determined the deamination rate constants at four
Table 1. Rate Constants k for the Oxidation of mdC to
hmdC and hmdC to fdC at pH 7.4. For the Rate Constants
at Higher Temperatures see SIa
k37 °C [s
−1] k60 °C [s
−1] Ea [kJ mol
−1]
mdC→hmdC n.d. 4.7 ± 0.6 × 10−11 n.d.
hmdC→fdC 1.3 ± 0.1 × 10−8 2.2 ± 0.2 × 10−8 20.8 ± 2.2
an.d. = not determined.
Figure 2. Investigation of the oxidation reactions of either hmdC or
fdC in a hairpin-oligonucleotide (CpG-ODN 1, 2) with increasing
concentration of β-mercaptoethanol/imidazole (pH 5.0, 50 °C, 48 h).
Reaction yields (normalized to dT [%]) are plotted against the
concentration of β-mercaptoethanol [% v/v]. The yellow data points
show the intensity of the mass signal of the thiol adduct 5-((2″-
hydroxyethyl)thio)methyl-dC (see top structure of Scheme 3), which
was scaled to the right ordinate.
Scheme 3. Depiction of the Thiol-Catalyzed Oxidation of
hmdC to fdC and the Proposed Mechanism of the C−C
Bond Cleavage of hmdC to dC. R-SH = β-Mercaptoethanol
R = CH2CH2OH
Figure 3. Deamination kinetics of dC to dU (black), mdC to dT
(cyan), hmdC to hmdU (blue), and fdC to fdU (green) at 60.0 °C, pH
7.4. Depicted are the means of triplicate experiments; error bars reﬂect
the standard deviations. For details of the kinetic measurements at
67.5, 75.0, and 82.5 °C and linear regression analyses see SI.
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diﬀerent temperatures (see SI) and extrapolated the pseudo-
ﬁrst-order deamination rates to 37 °C. The data are compiled
in Table 2.
At 37 °C, the deamination rates of dC, mdC, hmdC, and fdC
to form their corresponding 2′-deoxyuridine derivatives are
approximately the same with (6−12) × 10−10 s−1 on the
nucleoside level. The determined rate constant and activation
energy for the deamination of dC are in good agreement with
those reported for single-stranded DNA.29 Bearing in mind that
the rates are more than 2 orders of magnitude lower in double-
stranded DNA,29,30 our data argue that spontaneous deam-
ination of hmdC, fdC, and cadC should be a negligible
background reaction in comparison to the oxidation of hmdC
to form fdC (k37 °C = 1.3 ± 0.1 × 10
−8 s −1; Ea = 20.8 ± 2.2 kJ
mol−1). If, consequently, signiﬁcant amounts of deaminated
compounds are detected, we conclude that these are likely
derived from an enzymatic process.
C−C bond Cleaving Reactions. To investigate the
reaction of hmdC, fdC, and cadC to form dC we heated the
nucleosides for 60 h in water at pH 7.4 at 60 and 80 °C. At
60 °C we detected only traces of dC and the obtained reaction
rates at 80 °C were slow (SI, Figure S9 and Table 3), showing
that uncatalyzed C−C bond cleavage reactions can be
neglected.
This picture changes in the presence of thiols, which we
recently reported to catalyze the decarboxylation of cadC.18 To
investigate the conditions of the thiol-mediated decarboxylation
reaction in more detail, we treated the cadC-containing ODN3
with increasing concentrations of β-ME for 48 h at diﬀerent
pH-values and diﬀerent temperatures in the presence of
imidazole.18 The oligonucleotides were isolated and analyzed
by LC−MS/MS as outlined in Scheme 2. The results of the
experiments are depicted in Figure 4. Clearly evident is that
under the investigated conditions (pH 5.0 and 50 °C)
decarboxylation of cadC is a relatively eﬃcient reaction. The
yield of dC increased along with the concentration of β-ME up
to 28%. A lower temperature of 37 °C and a higher pH-value of
7.4 resulted in a strong reduction of the dC yield, which shows
that the decarboxylation reaction is an activated proton
catalyzed reaction. We next performed analogous experiments
with hmdC and fdC (pH 5.0, 50 °C, 48 h). Figure 5 compares
the C−C bond cleaving yields of all three nucleosides
embedded in the hairpin duplex structures.
We noticed that hmdC dehydroxymethylates to give dC.
However, the obtained yield of dC was very small (0.5%). Far
higher yields were reported by the Klimasauskas group, who
applied a mutated DNA methyltransferase and by the Sowers
group, who used photohydration conditions.16,17,20 For fdC, in
contrast, we observed considerable deformylation and obtained
yields of up to 2.5%. Decarboxylation of cadC is most eﬃcient
with an obtained yield of up to 28%.
We next studied how diﬀerent sequences would aﬀect the
C−C bond cleaving and deamination reactions and repeated
the experiments with ODNs 4−6 which feature the xdC-
derivatives in a non-CpG context (Figure 6). We observed only
a small reactivity diﬀerence in these sequences compared to the
CpG-ODNs. The yields of deamination products were found to
be lower than 0.4% under these conditions.
The data show that both fdC and cadC can undergo C−C
bond cleavage reactions mediated by thiols. Dehydroxymethy-
lation of hmdC is in contrast a considerably slower process.
To gain deeper insights into the thiol catalysis of the C−C
bond cleavage reactions, we ﬁnally computed the reaction
energies using quantum-chemical methods. Computational
details are described in the SI. Carboxylated nucleobases
(caC and caU) were capped at the N1 position with a methyl
Table 2. Rate Constants k and Activation Energies Ea for the
Deamination of dC, mdC, hmdC, and fdC at pH 7.4
k37 °C [s
−1] Ea [kJ mol
−1]
dC→dU 9.4 ± 0.5 × 10−10 108.7 ± 1.9
mdC→dT 7.8 ± 0.3 × 10−10 105.0 ± 2.5
hmdC→hmdU 5.8 ± 0.8 × 10−10 104.8 ± 3.9
fdC→fdU 1.2 ± 0.2 × 10−9 102.2 ± 2.4
Table 3. Rate Constants for the Non-Thiol-Mediated C−C Bond Cleavage of hmdC, fdC, and cadC to dC at pH 7.4 at 80 °C
hmdC→dC fdC→dC cadC→dC
k80 °C [s
−1] 1.3 ± 0.2 × 10−9 7.3 ± 1.1 × 10−9 6.9 ± 0.7 × 10−9
Figure 4. Investigation of the C−C bond cleavage reaction of cadC to
dC in a hairpin-oligonucleotide (CpG-ODN 3) in a β-mercapto-
ethanol/imidazole mixture. Depicted are the reaction yields
(normalized to dT [%]) depending on the concentration of β-
mercaptoethanol [% v/v] at pH = 5.0 or 7.4 and at 37 or 50 °C after
48 h. The gray area reﬂects the limit of quantiﬁcation.
Figure 5. Investigation of the C−C bond cleavage reactions of either
hmdC, fdC, or cadC in a hairpin-oligonucleotide (CpG-ODN 1, 2, 3)
in a β-mercaptoethanol/imidazole mixture (pH 5.0, 50 °C, 48 h).
Depicted are the reaction yields (normalized to dT [%]) of hmdC
(blue), fdC (green), and cadC (red) to dC depending on the
concentration of β-mercaptoethanol [% v/v]. The gray area in the
inset shows the limit of quantiﬁcation.
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group. To describe the explicit solvent−solute hydrogen bonds,
ﬁve water molecules were included in the study. Ideally, one
would like to describe more of the long-range electrostatic
solute−solvent interactions by including more water molecules
in the calculations. This would, however, mean a computational
eﬀort which is beyond the scope of this work. A crude way to
approximate the inﬂuence of the continuum is to use an
implicit solvent model. Here, we have performed calculations
with an implicit solvent cavity using the COSMO-model31
(data shown in SI). Although the energetics are clearly aﬀected,
the overall trend remains the same. Triple-zeta basis sets32 were
used throughout the calculations. RI-MP232,33 reaction
energies, obtained using the DFT/B3LYP-D334−36 energy
optimized structures, are depicted in Figure 7. No transition
state search was carried out as the reaction rates are already
obtained from the experimental data presented above.
We ﬁrst computed the direct decarboxylation of isoorotate
(caU), a reaction that is catalyzed by the enzyme isoorotate
decarboxylase (IDCase).37,38 We assumed in our study a direct
decarboxylation via formation of a vinyl anion type
intermediate. Similar mechanistic ideas were the basis of a
recent detailed mechanistic and structural study of the
IDCase.39 We obtained by our calculations a rather high
energy of +34 kcal mol−1 for the vinyl anion of U (gray
intermediate in Figure 7). In agreement with our results from
the thiol-free reaction conditions, our data show that a direct
decarboxylation mechanism for caC is unlikely. In comparison
to the vinyl anion of U, the energy of the vinyl anion of C is
with +47 kcal mol−1 signiﬁcantly higher. This may in part
explain the observed weak activity39 of IDCase to decarboxylate
5caC to C. In contrast, the energetics of the thiol addition at
the C6 position of caC and the subsequent decarboxylation are
much more favorable: Calculations predict an only slightly
endothermic reaction energy of +6 kcal mol−1 for the
decarboxylation of the thiol-reacted anionic intermediate.
Overall, the reaction of the C6 position with the thiol reduces
the energy of the corresponding anionic intermediate by more
than 40 kcal mol−1 (Figure 7, intermediates shown in red). This
explains why the reaction of cadC with a thiol leads to fast
decarboxylation. We also noted during the computational study
that simultaneous decarboxylation and thiol elimination is an
even more favorable process. This reaction pathway is
symbolized with dotted lines in Figure 7 and illustrated in
Scheme 4. In summary, the calculations support the inﬂuence
of the thiol catalysis.
■ CONCLUSIONS
We show that the new nucleosides hmdC, fdC, and cadC
possess an increased reactivity compared to mdC and dC. First,
the intrinsic deamination rates of hmdC and fdC are
comparable to those of mdC and dC. Second, hmdC is more
susceptible to oxidation. It reacts surprisingly quickly to fdC if
exposed to atmospheric oxygen, which is a problem that needs
to be considered when DNA is isolated from biological material
for the determination of fdC. In addition, the reaction of hmdC
to fdC is accelerated in the presence of thiols. If fdC is exposed
to atmospheric oxygen further oxidation to cadC is a rather
ineﬃcient process.
Third and importantly, fdC and cadC can undergo thiol-
mediated and acid-catalyzed C−C bond cleavage reactions to
form dC under release of formic acid and CO2, respectively
(see Scheme 4). Here decarboxylation is by a factor of 11 more
eﬃcient than the deformylation of fdC. If we consider that
DNA demethylation requires stepwise oxidation of hmdC to
fdC and cadC, both deformylation of fdC and decarboxylation
of cadC could take place via alternative active demethylation
mechanisms.
Figure 6. The C−C-bond cleavage of hmdC, fdC, and cadC to dC is
almost independent of the sequence context. Investigation of the C−C
bond cleavage and deamination reactions of either hmdC, fdC, or
cadC in a hairpin-oligonucleotide (CpG-ODN 1, 2, 3; CpNpG-ODN
4, 5, 6) in a 80% (v/v) β-mercaptoethanol/imidazole mixture (pH 5.0,
50 °C, 48 h). Depicted are the reaction yields (normalized to dT [%])
of hmdC (blue), fdC (green), and cadC (red) to dC as well as the
corresponding deamination products hmdU and fdU. Depicted are the
means of triplicate experiments; error bars reﬂect the standard
deviations.
Figure 7. Schematic representation of diﬀerent decarboxylation
pathways. Depicted are the reaction energies obtained from quantum
chemical calculations.
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Introduction: 
Methylation of cytidine to mC plays a role in several biological processes including tumor 
biology. The TET enzymes oxidize mC to hmC utilizing FeII and 2-oxogluterate. This process 
is suggested to play a role in active DNA demethylation and other biological processes as 
described in chapter I.2.3.3.2. Aberrant levels of mC are associated with cancer and other 
severe diseases. In this manuscript the levels of hmC in tumor and healthy tissue are analyzed 
to determine whether or not they are associated with the disease. 
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5-Methylcytosine (5mC) in genomic DNA has important epigenetic functions in embryonic development and tumor biology.
5-Hydroxymethylcytosine (5hmC) is generated from 5mC by the action of the TET (Ten-Eleven-Translocation) enzymes and may
be an intermediate to further oxidation and finally demethylation of 5mC. We have used immunohistochemistry (IHC) and
isotope-based liquid chromatography mass spectrometry (LC-MS) to investigate the presence and distribution of 5hmC in
human brain and brain tumors. In the normal adult brain, IHC identified 61.5% 5hmC positive cells in the cortex and 32.4%
5hmC in white matter (WM) areas. In tumors, positive staining of cells ranged from 1.1% in glioblastomas (GBMs) (WHO
Grade IV) to 8.9% in Grade I gliomas (pilocytic astrocytomas). In the normal adult human brain, LC-MS also showed highest
values in cortical areas (1.17% 5hmC/dG [deoxyguanosine]), in the cerebral WM we measured around 0.70% 5hmC/dG. 5hmC
levels were related to tumor differentiation, ranging from lowest values of 0.078% 5hmC/dG in GBMs (WHO Grade IV) to
0.24% 5hmC/dG in WHO Grade II diffuse astrocytomas. 5hmC measurements were unrelated to 5mC values. We find that the
number of 5hmC positive cells and the amount of 5hmC/dG in the genome that has been proposed to be related to
pluripotency and lineage commitment in embryonic stem cells is also associated with brain tumor differentiation and
anaplasia.
Epigenetics, the study of mechanisms that control gene expres-
sion (in a potentially heritable way), may be the most rapidly
expanding ﬁeld in tumor biology. On a molecular level, (i)
DNA methylation, i.e., covalent modiﬁcation of cytosine bases
resulting in 5-methylcytosine (5mC), (ii) histone modiﬁcations
and (iii) nucleosome positioning are regarded as the driving
epigenetic mechanisms. They are fundamental to the regula-
tion of many cellular processes, including gene and micro
RNA expression, DNA-protein interactions, suppression of
transposable element mobility, cellular differentiation, embryo-
genesis, X-chromosome inactivation and genomic imprinting.
In tumor biology, DNA methylation is the best-studied epi-
genetic change. Epigenetic silencing of O6-methylguanine
DNA-methyltransferase (MGMT)1 has been described as a
strong predictive factor of treatment response to chemotherapy
with alkylating agents of glioblastoma (GBM) and anaplastic
astrocytoma (AA).2 Methylation of CpG islands in the MGMT
promoter with ensuing repression of MGMT transcriptional
activity is generally viewed as the cause for this correlation.3
Oxidation of 5mC leading to 5-hydroxymethylcytosine
(5hmC) has been identiﬁed as a new epigenetic phenomenon
in mouse Purkinje cells.4 Three possible modes of action of
5hmC were discussed. (i) It might inﬂuence chromatin struc-
ture and local transcriptional activity by recruiting selective
5hmC-binding proteins or excluding 5mC-binding proteins.
(ii) Conversion of 5mC to 5hmC might facilitate passive
DNA demethylation by excluding the maintenance DNMT1,
which recognizes 5hmC poorly. (iii) 5hmC may be an inter-
mediate in a pathway of active DNA demethylation either by
conversion to cytosine under certain conditions or by
replacement of 5hmC by speciﬁc DNA repair mechanisms.
Most recent ﬁndings support the hypothesis that 5hmC is an
intermediate in a pathway for active DNA demethylation.5–7
The TET proteins, identiﬁed as a new family of enzymes that
Key words: epigenetics, brain tumors, 5-hydroxymethylcytosine,
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alter the methylation status of DNA, are 2-oxoglutarate (2OG)-
and Fe(II)-dependent enzymes that catalyze the conversion of
5mC to 5hmC,8 5-formylcytosine and 5-carboxylcytosine.5–7
TET proteins and 5hmC have been reported in various tissues
and both are tightly regulated during embryonic stem cells
(ESC) differentiation.9 5hmC content has been described as sig-
niﬁcantly reduced in stem cell/progenitor cell compartments
and in human cancers (prostate, breast and colon).10
To obtain a ﬁrst insight into a possible role of 5hmC in the
human brain, we used isotope-based liquid chromatography
mass spectrometry (LC-MS) to measure 5hmC concentrations
in various cortical and white matter regions of the adult human
brain to elucidate whether hydroxymethylation may be present
in human brain tumors, we measured 5hmC content in slowly
growing frequent brain tumors, i.e., astrocytomas WHO Grades
I, II and rapidly growing AAs WHO Grade III and GBMs
(WHO Grade IV)11 and other brain tumors. In addition, we
used immunohistochemistry (IHC) to investigate the distribu-
tion of 5hmC in the brain and in brain tumor cells.
Material and Methods
Sample selection normal brain regions
To evaluate the amount of 5hmC in human brain, we
selected tissue of nine donors that had provided their brains
for research purposes after death. The samples were obtained
from the Brain Bank Munich. As target regions we selected
frontal cortex, occipital cortex, frontal white matter and occi-
pital white matter. The tissue samples had either been forma-
lin-ﬁxed and parafﬁn-embedded (FFPE) or stored at 80C.
For this study, we chose 22 human control samples, well
characterized by age and gender (Table 1). The age of the
patients varied from 26 to 87 with a mean age of 59 years.
Sample selection tumors
To evaluate 5hmC in human brain tumors, we used FFPE
and frozen material that had been stored at 80C. The sam-
ples were obtained from the Brain Tumor Bank, Center for
Neuropathology, LMU Munich, as well as from the Brain Tu-
mor Bank of the Institute for Neuropathology, University
Hospital Homburg. For this study, we selected areas consist-
ing of more than 75% of tumor cells as estimated from
freshly made and H&E stained sections. In each case we sep-
arated clearly visible tumor areas. One hundred seventeen
human tumor samples derived from 117 different tumors
were selected, including 80 astrocytomas and GBMs, 23 epen-
dymomas and 14 meningiomas (Table 2). The age of the
patients ranged from 3 to 81 years with a mean of 46 years
and the male to female ratio was 67:43. In the astrocytoma
Table 1. Twenty-two tissue samples were selected from nine control cases from the BrainBank Munich
Case Sample Age Gender
Postmortem
time (h) Region Cause of death
5hmC
positive
cells (%)
5mC/dG
(%)
5hmC/dG
(%)
1 a 85 F 20 Occipital cortex Cardiac arrest 55.05 5.16 1.17
1 b 85 F 20 Occipital white matter Cardiac arrest 19.07 4.26 0.76
1 c 85 F 20 Frontal cortex Cardiac arrest 70.29 – –
1 d 85 F 20 Frontal white matter Cardiac arrest 23.27 – –
2 a 61 M 24 Frontal cortex Cardiac arrest 55.46 5.05 1.06
2 b 61 M 24 Frontal white matter Cardiac arrest 16.45 – –
3 a 87 M 48 Frontal cortex Cardiac arrest 54.32 5.94 1.13
3 b 87 M 48 Frontal white matter Cardiac arrest 22.85 – –
3 c 87 M 48 Occipital cortex Cardiac arrest 54.70 5.64 1.14
3 d 87 M 48 Occipital white matter Cardiac arrest 23.08 4.23 0.64
4 a 46 M n.a. Occipital cortex Cardiac arrest 64.29 5.74 1.12
4 b 46 M n.a. Occipital white matter Cardiac arrest 36.34 4.36 0.54
5 a 84 M 19 Frontal white matter Cardiac arrest 28.57 3.82 0.78
5 b 84 M 19 Frontal cortex Cardiac arrest 59.92 4.55 1.19
6 a 61 M n.a. Frontal white matter Cardiac arrest 61.61 4.14 0.76
6 b 61 M n.a. Frontal cortex Cardiac arrest 70.33 5.35 1.35
7 a 26 F n.a. Frontal cortex Hemorrhagic pericard effusion 80.17 – –
7 b 26 F n.a. Frontal white matter Hemorrhagic pericard effusion 58.06 – –
8 a 41 M n.a. Frontal cortex Multiple organ failure 65.02 – –
8 b 41 M n.a. Frontal white matter Multiple organ failure 38.70 – –
9 a 39 M n.a. Frontal cortex Haematothorax 46.75 – –
9 b 39 M n.a. Frontal white matter Haematothorax 30.00 – –
C
an
ce
r
G
en
et
ic
s
1578 5hmC in human brain tumors
Int. J. Cancer: 131, 1577–1590 (2012) VC 2012 UICC
Table 2. One hundred seventeen tumor samples were selected from the Brain Tumour Bank, Center for Neuropathology, LMU Munich and the
Brain Tumour Bank of the Institute for Neuropathology, University Hospital Homburg
Case Age Gender Tumor Grade Region
5hmC
positive
cells (%)
5mC/dG
(%)
5hmC/dG
(%)
IDH
status
1 15 M Pilocytic astrocytoma (WHO Grade I) I Temporal 13.66 4.75 0.18 No mutation
2 23 F Pilocytic astrocytoma (WHO Grade I) I Thoracic spine 10.83 4.10 0.24 No mutation
3 23 M Pilocytic astrocytoma (WHO Grade I) I n.a. 7.69 4.58 0.24 No mutation
4 12 F Pilocytic astrocytoma (WHO Grade I) I Rhombencephalon 10.03 4.99 0.17 No mutation
5 9 M Pilocytic astrocytoma (WHO Grade I) I Cerebellum 1.66 4.98 0.12 No mutation
6 21 M Pilocytic astrocytoma (WHO Grade I) I Temporal 9.57 – – No mutation
7 34 M Diffuse astrocytoma (WHO Grade II) II Fronto-temporal 3.75 4.66 0.17 Mutation
8 35 M Diffuse astrocytoma (WHO Grade II) II Insula 1.47 – – Mutation
9 36 F Diffuse astrocytoma (WHO Grade II) II Occipital 0.72 – – Mutation
10 15 M Diffuse astrocytoma (WHO Grade II) II Thalamus 3.35 – – No mutation
11 28 F Diffuse astrocytoma (WHO Grade II) II Precentral 1.55 – – Mutation
12 n.a. n.a. Diffuse astrocytoma (WHO Grade II) II n.a. – 4.50 0.09 Mutation
13 n.a. n.a. Diffuse astrocytoma (WHO Grade II) II n.a. – 4.57 0.24 Mutation
14 44 M Diffuse astrocytoma (WHO Grade II) II Insula 7.04 – – No mutation
15 66 F Diffuse astrocytoma (WHO Grade II) II Insula 5.19 – – No mutation
16 35 M Diffuse astrocytoma (WHO Grade II) II Pons 9.06 – – No mutation
17 41 F Diffuse astrocytoma (WHO Grade II) II Tectum 11.89 – – No mutation
18 30 M Diffuse astrocytoma (WHO Grade II) II Temporal 0.00 – – Mutation
19 3 M Diffuse astrocytoma (WHO Grade II) II Basal Ganglia – 5.53 0.46 No mutation
20 74 M Anaplastic astrocytoma (WHO Grade III) III Fronto-temporal 0.59 4.40 0.08 Mutation
21 43 M Anaplastic astrocytoma (WHO Grade III) III Frontal – 4.34 0.08 Mutation
22 41 F Anaplastic astrocytoma (WHO Grade III) III Parietal – 4.51 0.10 Mutation
23 59 M Anaplastic astrocytoma (WHO Grade III) III n.a. 7.27 – – No mutation
24 62 M Anaplastic astrocytoma (WHO Grade III) III Central 3.72 – – Mutation
25 41 M Anaplastic astrocytoma (WHO Grade III) III Frontal 2.40 – – Mutation
26 37 F Anaplastic astrocytoma (WHO Grade III) III Frontal 2.29 – – Mutation
27 37 F Anaplastic astrocytoma (WHO Grade III) III Temporal 2.68 – – No mutation
28 31 M Anaplastic astrocytoma (WHO Grade III) III Temporal 0.80 – – Mutation
29 32 M Anaplastic astrocytoma (WHO Grade III) III Temporal 2.69 – – Mutation
30 42 M Anaplastic astrocytoma (WHO Grade III) III Temporal 0.13 – – Mutation
31 44 F Anaplastic astrocytoma (WHO Grade III) III n.a. 6.85 – – No mutation
32 44 F Anaplastic astrocytoma (WHO Grade III) III Frontal 4.86 – – No mutation
33 81 F Anaplastic astrocytoma (WHO Grade III) III Cerebellum 1.11 – – No mutation
34 70 M Anaplastic astrocytoma (WHO Grade III) III Temporal 5.35 – – No mutation
35 61 M Anaplastic astrocytoma (WHO Grade III) III Thalamus 6.00 – – No mutation
36 53 M Anaplastic astrocytoma (WHO Grade III) III Temporo-mesial – 4.76 0.30 No mutation
37 50 M Anaplastic astrocytoma (WHO Grade III) III Temporal – 3.79 0.10 No mutation
38 72 M Glioblastoma multiforme (WHO Grade IV) IV Temporp-parietal 0.37 4.35 0.16 No mutation
39 47 M Glioblastoma multiforme (WHO Grade IV) IV Frontal – 4.33 0.13 No mutation
40 61 M Glioblastoma multiforme (WHO Grade IV) IV Parietal 2.26 4.06 0.10 No mutation
41 69 F Glioblastoma multiforme (WHO Grade IV) IV Occipital 0.25 3.77 0.09 No mutation
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Table 2. One hundred seventeen tumor samples were selected from the Brain Tumour Bank, Center for Neuropathology, LMU Munich and the
Brain Tumour Bank of the Institute for Neuropathology, University Hospital Homburg (Continued)
Case Age Gender Tumor Grade Region
5hmC
positive
cells (%)
5mC/dG
(%)
5hmC/dG
(%)
IDH
status
42 55 M Glioblastoma multiforme (WHO Grade IV) IV Parietal 0.08 5.58 0.03 No mutation
43 44 F Glioblastoma multiforme (WHO Grade IV) IV Frontal 0.28 4.70 0.09 No mutation
44 64 M Glioblastoma multiforme (WHO Grade IV) IV Parietal 0.97 4.32 0.07 No mutation
45 25 F Glioblastoma multiforme (WHO Grade IV) IV Frontal 1.37 4.70 0.03 Mutation
46 66 M Glioblastoma multiforme (WHO Grade IV) IV Temporal 3.48 4.27 0.05 No mutation
47 64 M Glioblastoma multiforme (WHO Grade IV) IV Temporal 0.49 4.06 0.11 No mutation
48 67 F Glioblastoma multiforme (WHO Grade IV) IV Temporal 0.00 – – No mutation
49 67 M Glioblastoma multiforme (WHO Grade IV) IV Occipital 0.55 – – No mutation
50 41 M Glioblastoma multiforme (WHO Grade IV) IV Temporal 0.67 – – No mutation
51 66 M Glioblastoma multiforme (WHO Grade IV) IV Temporal 1.82 – – No mutation
52 58 M Glioblastoma multiforme (WHO Grade IV) IV Parietal 1.82 – – No mutation
53 30 M Glioblastoma multiforme (WHO Grade IV) IV Temporal 1.22 – – Mutation
54 69 F Glioblastoma multiforme (WHO Grade IV) IV Temporal 1.45 – – No mutation
55 53 f Glioblastoma multiforme (WHO Grade IV) IV Frontal 1.60 – – No mutation
56 43 M Glioblastoma multiforme (WHO Grade IV) IV Temporo-parieto-
occipital
2.21 – – No mutation
57 59 M Glioblastoma multiforme (WHO Grade IV) IV Temporal 1.14 – – No mutation
58 7 M Glioblastoma multiforme (WHO Grade IV) IV Thalamus 2.28 – – No mutation
59 67 M Glioblastoma multiforme (WHO Grade IV) IV Temporal 0.78 – – No mutation
60 64 F Glioblastoma multiforme (WHO Grade IV) IV Temporo-mesial 1.61 – – No mutation
61 43 F Glioblastoma multiforme (WHO Grade IV) IV Frontal 1.19 – – Mutation
62 72 M Glioblastoma multiforme (WHO Grade IV) IV Temporal 1.49 – – No mutation
63 32 M Glioblastoma multiforme (WHO Grade IV) IV Temporal 0.53 – – Mutation
64 33 M Glioblastoma multiforme (WHO Grade IV) IV Temporal 1.20 – – Mutation
65 46 M Glioblastoma multiforme (WHO Grade IV) IV Temporal 1.92 – – Mutation
66 40 F Glioblastoma multiforme (WHO Grade IV) IV Parieto-occipital 0.96 – – Mutation
67 38 M Glioblastoma multiforme (WHO Grade IV) IV Temporal 0.60 – – Mutation
68 61 M Glioblastoma multiforme (WHO Grade IV) IV Temporal 0.31 – – No mutation
69 47 M Glioblastoma multiforme (WHO Grade IV) IV Temporal 0.62 – – No mutation
70 78 M Glioblastoma multiforme (WHO Grade IV) IV Temporal 0.38 – – No mutation
71 71 F Glioblastoma multiforme (WHO Grade IV) IV Frontal 1.23 – – No mutation
72 62 F Glioblastoma multiforme (WHO Grade IV) IV Temporal 0.43 – – No mutation
73 64 F Glioblastoma multiforme (WHO Grade IV) IV Frontal 1.89 – – No mutation
74 70 M Glioblastoma multiforme (WHO Grade IV) IV Parietal 0.87 – – No mutation
75 41 F Glioblastoma multiforme (WHO Grade IV) IV Parietal 0.40 – – No mutation
76 74 M Glioblastoma multiforme (WHO Grade IV) IV Postcentral 0.53 – – No mutation
77 55 M Glioblastoma multiforme (WHO Grade IV) IV Thalamus 0.60 – – No mutation
78 37 F Glioblastoma multiforme (WHO Grade IV) IV Frontal – 4.36 0.08 Mutation
79 34 M Glioblastoma multiforme (WHO Grade IV) IV Frontal – 4.03 0.04 Mutation
80 34 F Glioblastoma multiforme (WHO Grade IV) IV Temporal – 3.68 0.04 Mutation
81 30 F Myxopapillary ependymoma (WHO Grade I) I Lumbal spine 44.14 5.19 0.09 n.a.
82 68 M Subependymoma (WHO Grade I) I Rhombencephalon 36.50 4.57 0.42 n.a.
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and GBM group, the mean age was 47 years, in ependymo-
mas 40 years and in meningiomas 54 years.
Immunohistochemistry and cell counting
FFPE tissue samples were used for IHC. Standard protocols
were followed, in brief 4-lm FFPE sections were deparafﬁ-
nized by subsequent incubation in xylene (30 min), 100%
ethanol (10 min), 96% ethanol (5 min) and 70% ethanol
(5 min). The sections were then treated with 2N HCl (35C,
20 min), pre-incubated with blocking solution (3% I-Block
Protein-Based Blocking Reagent (Applied Biosystems, Darm-
stadt, Germany)) and incubated with the diluted primary
Table 2. One hundred seventeen tumor samples were selected from the Brain Tumour Bank, Center for Neuropathology, LMU Munich and the
Brain Tumour Bank of the Institute for Neuropathology, University Hospital Homburg (Continued)
Case Age Gender Tumor Grade Region
5hmC
positive
cells (%)
5mC/dG
(%)
5hmC/dG
(%)
IDH
status
83 20 M Subependymoma (WHO Grade I) I Lateral ventricle 13.54 – – n.a.
84 59 M Subependymoma (WHO Grade I) I Lateral ventricle 28.95 – – n.a.
85 54 M Subependymoma (WHO Grade I) I Rhombencephalon 16.49 4.55 0.35 n.a.
86 46 F Subependymoma (WHO Grade I) I Thoracic spine 1.28 – – n.a.
87 46 F Subependymoma (WHO Grade I) I Lateral ventricle 16.81 – – n.a.
88 46 M Subependymoma (WHO Grade I) I Rhombencephalon 15.22 – – n.a.
89 n.a. n.a. Subependymoma (WHO Grade I) I n.a. – 4.63 0.20 n.a.
90 n.a. n.a. Subependymoma (WHO Grade I) I n.a. – 4.58 0.37 n.a.
91 30 F Ependymoma (WHO Grade II) II Filum 20.09 5.04 0.09 n.a.
92 41 M Ependymoma (WHO Grade II) II Cervical spine 5.15 4.74 0.17 n.a.
93 39 M Ependymoma (WHO Grade II) II Cervical spine 6.26 3.38 0.25 n.a.
94 70 F Ependymoma (WHO Grade II) II Cervical spine 15.85 3.70 0.41 n.a.
95 23 M Ependymoma (WHO Grade II) II Thoracic spine 14.43 6.16 0.21 n.a.
96 54 M Ependymoma (WHO Grade II) II Cervical spine 10.86 5.01 0.12 n.a.
97 42 M Ependymoma (WHO Grade II) II n.a. 12.02 – – n.a.
98 76 F Ependymoma (WHO Grade II) II Lumbal spine 15.04 – – n.a.
99 21 M Cellular ependymoma (WHO Grade II) II Lateral ventricle 12.49 5.05 0.13 n.a.
100 4 M Anaplastic ependymoma (WHO Grade III) III Rhombencephalon 24.16 4.95 0.23 n.a.
101 5 F Anaplastic ependymoma (WHO Grade III) III Posterior cranial
fossa
10.47 4.22 0.03 n.a.
102 59 F Anaplastic ependymoma (WHO Grade III) III Thoracic spine 16.59 4.78 0.32 n.a.
103 6 F Anaplastic ependymoma (WHO Grade III) III Lateral ventricle 1.25 – – n.a.
104 72 F Transitional meningioma (WHO Grade I) I Fronto-basal 32.12 4.48 0.12 n.a.
105 22 F Meningotheliomatous meningiom
(WHO Grade I)
I Frontal 29.06 4.04 0.17 n.a.
106 60 F Transitional meningioma (WHO Grade I) I Cerebellum 9.52 4.08 0.20 n.a.
107 59 M Fibrious meningioma (WHO Grade I) I Occipital 6.82 – – n.a.
108 28 M Meningothelial meningioma (WHO Grade I) I Precentral 18.30 – – n.a.
109 79 F Meningothelial meningioma (WHO Grade I) I Temporal 12.46 – – n.a.
110 61 M Atypical meningioma (WHO Grade II) II Frontal 1.11 4.65 0.08 n.a.
111 33 F Chordoid meningioma (WHO Grade II) II Frontal 5.24 – – n.a.
112 72 F Atypical meningioma (WHO Grade II) II Frontal 14.34 – – n.a.
113 79 F Atypical meningioma (WHO Grade II) II Frontal 2.93 4.44 0.11 n.a.
114 26 M Atypical meningioma (WHO Grade II) II Skullbase 8.94 – – n.a.
115 n.a. n.a. Atypical meningioma (WHO Grade II) II n.a. – 4.24 0.27 n.a.
116 n.a. n.a. Atypical meningioma (WHO Grade II) II n.a. – 4.29 0.08 n.a.
117 n.a. n.a. Atypical meningioma (WHO Grade II) II n.a. – 3.98 0.16 n.a.
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antibody for 18 hr at 4C. As primary antibody, we used pol-
yclonal rabbit anti-5hmC diluted 1:1,000 (Active Motif, Rix-
ensart, Belgium). Subsequently, the sections were treated with
Super Sensitive Polymer-Horseradish peroxidase (HRP)
Detection System (BioGenix, San Ramon, CA), followed by
incubation in 3,30-diaminobenzidine (DAB) for 5 min and
staining in hemalum. For immunoﬂuorescence staining, we
followed standard protocols. As primary antibody, we used
polyclonal rabbit anti-5hmC diluted 1:1,000 (Active Motif,
Rixensart, Belgium) and monoclonal mouse anti-Ki-67
diluted 1:500 (Dako, Hamburg, Germany). As secondary anti-
bodies, we used Alexa Fluor 488 goat-anti-rabbit IgG diluted
1:300 (Invitrogen, Darmstadt, Germany) and Alexa Fluor 546
goat-anti-mouse IgG diluted 1:300 (Roth, Karlsruhe, Ger-
many). For nuclear staining, we used 40,6-diamidin-2-phenyl-
indol (Roth, Karlsruhe, Germany). Finally, we used Dako ﬂu-
orescence mounting medium (Dako, Hamburg, Germany).
For cell counting, randomly selected sections were photo-
graphed at 10 and 20 magniﬁcation depending on tissue
type and size. Following that at least 200 cells were counted
in each case.
To identify IDH1 mutations in astrocytoma and GBM,
FFPE samples were stained using the monoclonal mouse
IDH1R132H antibody (Dianova, Hamburg, Germany), diluted
1:20, according to the manufacturer’s protocol on a Ventana
BenchMark system (Roche, Basel, Switzerland).
DNA extraction
For LC-MS, DNA isolation was performed on the basis of
the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany)
according to the manufacturer’s protocol with slight modiﬁ-
cations. The RNA digestion was executed twice and instead
of column puriﬁcation phenol extraction was performed, i.e.,
after addition of buffer AL, the sample was mixed and incu-
bated. The sample was distributed equally to two 2 mL reac-
tion tubes, if necessary. A 1/1 mixture of RotiVR Phenol/chlo-
roform (1 vol) was added and the tube was shaken
vigorously at RT for 5 min. The tube was centrifuged
(12,100g, 15 min) and the aqueous layer was collected. This
procedure was repeated once. To the obtained aqueous layer
chloroform (1 vol) was added and the tube was shaken at RT
for 1 min. After centrifugation (12,100g, 5 min) the aqueous
layer was collected. During collection of the aqueous layer,
special care was taken to include the interphase. The sample
was distributed equally to two 2 mL reaction tubes, if neces-
sary. Ethanol (3 vol) was added. The sample was left to stand
at RT for approximately 2 h. After precipitation of the DNA
the tube was centrifuged (12,100g, 30 min). The supernatant
was discarded and the pellet was dried. Subsequently, it was
dissolved in water (100–400 lL). The solution was centri-
fuged (12,100g, 30 min) and the supernatant was collected.
Additionally, we isolated DNA from FFPE samples for
IDH mutation analysis using a Maxwell 16 system (Promega,
Madison, WI) and Maxwell 16 FEV FFPE kit (Promega,
Madison, WI) according to the manufacturer’s protocols.
Enzymatic digestion
For the enzymatic digestion DNA mixtures (4–10 lg in a
ﬁnal volume of 100 lL H2O) were heated to 100C for 5
min to denature the DNA and rapidly cooled on ice. After
addition of standard solutions, buffer A (10 lL, 300 mM am-
monium acetate, 100 mM CaCl2, 1 mM ZnSO4, pH 5.7) and
nuclease S1 (80 units, Aspergillus oryzae) the mixture was
incubated for 3 hr at 37C. Addition of buffer B (12 lL, 500
mM Tris-HCl, 1 mM EDTA), antarctic phosphatase (10
units), snake venom phosphodiesterase I (0.2 units, Crotalus
adamanteus venom) and incubation for further 3 hr at 37C
completed the digestion. Labeled nucleosides d2-5hmC and
d3-5mC were added, followed by centrifugation of the sample
(12,100g, 15 min). Each sample was performed at least in
duplicate with independent concentrations of the two labeled
nucleosides. The concentrations of standard solutions were
chosen to be in the expected range of the sample nucleoside
concentration.
LC-MS
The samples (100 lL injection volume) were analyzed by
LC-MS on a Thermo Finnigan LTQ Orbitrap XL and were
chromatographed by a Dionex Ultimate 3000 HPLC system
with a ﬂow of 0.15 mL/min over an Uptisphere120-3HDO
column from Interchim. The column temperature was main-
tained at 30C. Eluting buffers were buffer C (2 mM
HCOONH4 in H2O (pH 5.5)) and buffer D (2 mM
HCOONH4 in H2O/MeCN 20/80 (pH 5.5)). The gradient
was 0 –> 12 min; 0% –> 3% buffer D; 12 –> 60 min; 3% –>
60% buffer D; 60 –> 62 min; 60% –> 100% buffer D; 62 –>
70 min; 100% buffer D; 70 –> 85 min; 100 –> 0% buffer D;
85 –> 95 min; 0 % buffer D. The elution was monitored at
260 nm (Dionex Ultimate 3000 Diode Array Detector). The
chromatographic eluent was directly injected into the ion
source without prior splitting. Ions were scanned by the use
of a positive polarity mode over a full-scan range of m/z
200–1,000 with a resolution of 30,000. Parameters of the
mass spectrometer were tuned with a freshly mixed solution
of adenosine (5 lM) in buffer C. The parameters used in
this section were sheath gas ﬂow rate, 16 arb; auxiliary gas
ﬂow rate, 11 arb; sweep gas ﬂow rate, 4 arb; spray voltage,
5.0 kV; capillary temperature, 200C; capillary voltage, 12 V,
tube lens 86 V.
Pyrosequencing of DNA
To conﬁrm IDH1 mutations detected by IHC staining, we
sequenced a 88 bp long fragment of the IDH1 gene including
codon 132. The IDH1 primers were designed using PSQ
Assay design software (Qiagen, Hilden, Germany). As for-
ward primer, we used 50-biotin-AAAAATATCCCCCG
GCTTG-30 and as reverse primer 50-TGCCAACATGACTTA
CTTGATCC-30. PCR reactions were performed using the
HotStarTaq DNA polymerase master mix (Qiagen, Hilden,
Germany) according to the manufacturer’s protocol and a
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standard PCR protocol. The PCR product was then
sequenced using a PyroMark Q24 System (Qiagen, Hilden,
Germany) and the Pyro Gold reagent kit (Qiagen, Hilden,
Germany). We used 50-TGATCCCCATAAGCAT-30 as
sequencing primer. The subsequent processing was per-
formed according to the manufacturer’s protocols. Data anal-
ysis was performed using PyroMark Q24 software (Qiagen,
Hilden, Germany).
Statistical analysis
Statistical calculations were performed using ANOVA single
factor analysis and Tukey–Kramer post hoc test as well as
unpaired t-test. Analysis was performed using GraphPad
Prism 5.
Results
Not all cells express 5hmC in normal human brain and
brain tumors at detectable levels
IHC with an antibody against 5hmC in general showed ei-
ther strong staining or no staining with only a small num-
ber of faintly stained nuclei (Fig. 1). In normal human
frontal brain, the majority of neurons of the cortex showed
strong reactivity for 5hmC (Fig. 1a, upper right corner). In
contrast, there was weaker immunohistochemical staining
for 5hmC in the frontal subcortical white matter (Fig. 1a,
lower left corner). About 70% of WM cells showed negative
staining; these cells had mostly round, small nuclei and
appeared to be oligodendrocytes. In the occipital cortex
(Fig. 1b) and subcortical white matter (Fig. 1c), we found
comparable results. In human brain tumors, we found sig-
niﬁcantly lower numbers of 5hmC positive cells. In astrocy-
tomas and GBMs (Figs. 1d–1g), the number of 5hmC posi-
tive cells decreased from pilocytic astrocytomas (Fig. 1d) to
diffuse astrocytomas (Fig. 1e), AAs (Fig. 1f) and GBMs with
mean of 1.43% positive cells (Fig. 1g). Whilst there were
about 10% of positive cells in pilocytic astrocytomas, GBMs
showed only very few positive cells. In ependymomas (Figs.
1h–1j), we found that most of the cells were not stained.
Grade I ependymomas (Fig. 1h) showed more 5hmC posi-
tive cells than Grade II (Fig. 1i) and Grade III tumors (Fig.
1j). Grades II and III ependymomas showed more or less
equal staining but anaplastic ependymomas showed a
weaker staining for 5hmC. Furthermore, there were strong
regional variations. In meningiomas (Figs. 1k–1l), we found
similar results to ependymomas. Grade I meningiomas (Fig.
1k) showed more 5hmC positive cells than Grade II tumors
(Fig. 1l) and Grade II meningiomas showed a weaker stain-
ing for 5hmC with regional variations. We found that stain-
ing for 5hmC and the proliferation-associated Ki-67 was
mutually exclusive; an example of this general ﬁnding is
shown in Figures 1m–1o. We often observed a rhythmic
variation of areas with higher proliferative activity (Ki-67)
and sparse 5hmC staining and vice versa.
There are significantly more 5hmC positive stained cells in
the cortex compared to white matter areas. 5hmC/dG in
human brain is significantly higher in cortex than white
matter
When we counted the 5hmC positive and negative cells the
values for various cortical areas did not show signiﬁcant dif-
ferences (Fig. 2a, p > 0.05, ANOVA and Tukey–Kramer post
hoc test). Furthermore, we did not ﬁnd any signiﬁcant differ-
ence in the ration of 5hmC positive cells in various white
matter areas (Fig. 2a, p > 0.05, ANOVA and Tukey–Kramer
post hoc test). However, we found signiﬁcant differences com-
paring frontal cortex and frontal white matter areas (Fig. 2a,
p < 0.01, ANOVA and Tukey–Kramer post hoc test) as well
as occipital cortex and occipital white matter areas (Fig. 2a, p
< 0.05, ANOVA and Tukey–Kramer post hoc test).
Additionally, we performed LC-MS measurements. 5hmC
was found in measurable amounts in all brain regions but
there was no signiﬁcant difference between various cortical
(Fig. 2b, p > 0.05, ANOVA and Tukey–Kramer post hoc test)
and various white matter areas (Fig. 2b, p > 0.05, ANOVA
and Tukey–Kramer post hoc test). But the values measured in
the frontal cortex were signiﬁcantly higher than in the frontal
white matter (Fig. 2b, p < 0.01, ANOVA and Tukey–Kramer
post hoc test) and the values measured in the occipital cortex
were signiﬁcantly higher than in the occipital white matter
(Fig. 2b, p < 0.001, ANOVA and Tukey–Kramer post hoc
test).
The 5mC values measured by LC-MS did not show signif-
icant differences between different cortical areas (p > 0.05
using ANOVA and Tukey–Kramer post hoc test, Fig. 2c) nor
between different white matter areas (p > 0.05 using
ANOVA and Tukey–Kramer post hoc test, Fig. 2c) but we
found signiﬁcant differences between cortical and white mat-
ter areas (p < 0.05, ANOVA and Tukey–Kramer post hoc
test, Fig. 2c).
The number of 5hmC positive cells and 5hmC/dG levels in
human brain tumors are related to WHO grade
One hundred seventeen human tumors were selected for
analysis including 6 pilocytic astrocytomas (Grade I), 13 dif-
fuse astrocytomas (Grade II), 18 AAs (Grade III) and 43
GBMs (Grade IV), 10 ependymomas Grade I, 9 ependymo-
mas (Grade II) and 4 anaplastic ependymomas (Grade III), 6
WHO Grade I meningiomas and 8 atypical meningiomas
(Grade II).
In WHO Grade I tumors, the mean of 5hmC positive cells
was 16.73%, in Grade II 7.87%, in Grade III 5.51% and in
Grade IV 1.07% (Fig. 2d) with a highly signiﬁcant difference
between Grades I and II (p < 0.001, ANOVA and Tukey–
Kramer post hoc test), Grades I and III (p < 0.001, ANOVA
and Tukey–Kramer post hoc test), Grades I and IV (p <
0.001, ANOVA and Tukey–Kramer post hoc test) as well as
Grades II and IV (p < 0.001, ANOVA and Tukey–Kramer
post hoc test).
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Figure 1. IHC with an antibody against 5hmC. (a) In the normal frontal lobe we see differences in staining of the cortex and subcortical
white matter. In the cortex (upper right corner) there are numerous clearly visible positively stained neurons. In the subcortical white matter
(lower left corner) there is diminished staining for 5hmC, but distinct positively stained cells are seen surrounded by negative ones. (b) In
the normal occipital cortex, there is a clear staining of the majority (about 60%) of cells. (c) In normal occipital white matter, there are
fewer 5hmC positive cells (about 30%) compared to the occipital cortex. (d) In human pilocytic astrocytomas (WHO Grade I) the majority of
tumor cells are negative, only about 10% of tumor cells stain positive. (e) In diffuse astrocytomas less than 5% of cells stain positive for
5hmC. (f) AAs show lower values of 5hmC positive cells compared to low-grade gliomas. (g) GBMs show only very low positive staining for
5hmC. (h) In Grade I ependymomas most cells stain negative for 5hmC. (i) Ependymomas Grade II show lower numbers of 5hmC positive
cells than Grade I tumors with a large intratumoral variation. (j) Anaplastic ependymomas show almost the same number of 5hmC positive
cells compared to Grade II ependymomas but the cells stain much weaker. Furthermore there is a large intratumoral variation. (k) In Grade I
meningiomas we see only a minority of positively stained cells with a large intratumoral variation. (l) Meningiomas Grade II show fewer
5hmC positive cells than Grade I tumors and the cells seem to stain more weakly than in Grade I tumors with large intratumoral variations.
(m–o) Immunofluorescence staining of a GBM with antibodies against 5hmC (m), the proliferation marker Ki-67 (n) and DAPI. Scale bar is
100 lm. Cells stained positive for Ki-67 show no detectable signal for 5hmC in the merge picture (o).
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Figure 2. Percentage of 5hmC positive cells and LC-MS values of 5hmC and 5mC in normal human brain and in brain tumors. Indicated are
the mean and SD. (a) There was no significant differences of 5hmC positive cells in various white matter areas as well as in various cortex
regions of the human brain (p > 0.05, ANOVA and Tukey–Kramer post hoc test) but there were highly significant differences in the cortex
compared to the white matter (p < 0.01 in case of frontal cortex and frontal white matter and p < 0.05 in case of occipital cortex and
occipital white matter, ANOVA and Tukey–Kramer post hoc test). (b) LC-MS values showed no significant difference between various white
matter regions and between various cortex regions (p > 0.05, ANOVA and Tukey–Kramer post hoc test) but highly significant differences
between cortex and white matter regions (p < 0.01 in case of fontal cortex and frontal white matter and p < 0.001 in case of occipital
cortex and occipital white matter, ANOVA and Tukey–Kramer post hoc test). (c) The distribution of 5mC in different brain regions showed no
significant difference between different cortical regions as well as in different white matter regions (p > 0.05, ANOVA and Tukey–Kramer
post hoc test) but there were significant difference between cortical and white matter regions (p < 0.05, ANOVA and Tukey–Kramer post
hoc test). (d) A comparison of 5hmC positive cells in human brain tumors showed highly significant differences between Grade I and Grade
II tumors (p < 0.001, ANOVA and Tukey–Kramer post hoc test), Grade I and Grade III tumors (p < 0.001, ANOVA and Tukey–Kramer post
hoc test), Grade I and Grade IV tumors (p < 0.001, ANOVA and Tukey–Kramer post hoc test) as well as Grade II and Grade IV tumors (p <
0.001, ANOVA and Tukey–Kramer post hoc test). (e) In LC-MS we found significant lower amounts of 5hmC in Grade I compared to Grade IV
tumors (p < 0.01, ANOVA and Tukey–Kramer post hoc test). (f) The 5mC values did not show a correlation with tumor grade (p > 0.05,
ANOVA and Tukey–Kramer post hoc test). (g) A comparison of tumors with normal brain showed highly significantly lower numbers of 5hmC
positive cells in tumors compared to normal brain (p < 0.0001, unpaired t-test). (h) In LC-MS we found that tumors show significant higher
amount of 5hmC compared to normal brain (p < 0.0001, unpaired t-test). (i) There was no significant difference between tumor and normal
brain in regard to 5mC (p > 0.05, unpaired t-test). [Color figure can be viewed in the online issue, which is available at
wileyonlinelibrary.com.]
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By mass spectrometry we see that in Grade I tumors the
5hmC values were 0.22% 5hmC/dG, in Grade II 0.19%
5hmC/dG, in Grade III 0.16% 5hmC/dG and in Grade IV
0.078% 5hmC/dG with a signiﬁcant difference between
Grades I and IV tumors (p < 0.01, ANOVA and Tukey–
Kramer post hoc test) as well as Grades II and IV tumors (p
< 0.05, ANOVA and Tukey–Kramer post hoc test) (Fig. 2e).
No such relation was found in LC-MS measurements of
5mC in WHO tumor grades (Fig. 2f). Grade I tumors showed
mean values of 4.58% 5mC/dG, Grade II 4.62% 5mC/dG,
Grade III 4.47% 5mC/dG and Grade IV 4.32% 5mC/dG with
no signiﬁcant difference between different tumor grades (p >
0.05, ANOVA and Tukey–Kramer post hoc test).
The number of 5hmC positive cells identiﬁed in brain
tumors was signiﬁcantly lower compared to normal cortex
and white matter (Fig. 2g). While in normal human brain
mean number of 5hmC positive cells was 61.48% in the cor-
tex and 32.39% in the white matter, the mean in tumor tissue
was 6.58% (p < 0.0001, unpaired t-test).
These data were paralleled by LC-MS (Fig. 2h). In normal
cortex, we measured 1.17% 5hmC/dG, in the white matter
0.70% 5hmC/dG and in tumor tissue the average value was
0.16% 5hmC/dG (p < 0.0001, unpaired t-test).
As regards 5mC no signiﬁcant difference was observed
between normal brain tissue and tumor (Fig. 2i) with a mean
of 4.85% 5mC/dG in the normal human brain and 4.50%
5mC/dG in tumors (p > 0.05, unpaired t-test).
When tumors were grouped according to their cellular lin-
eages, we obtained similar differences of 5hmC related to the
tumor grade.
In astrocytomas, the mean of 5hmC positive stained cells
was 8.91% in Grade I pilocytic astrocytomas, 4.40% in Grade
II diffuse astrocytomas, 3.34% in Grade III AAs and 1.07% in
Grade IV GBMs (Fig. 3a) with highly signiﬁcant differences
between Grade I and Grade III tumors (p < 0.001, ANOVA
and Tukey–Kramer post hoc test), Grade I and Grade IV
tumors (p < 0.001, ANOVA and Tukey–Kramer post hoc test)
and Grade II and Grade IV tumors (p < 0.001, ANOVA and
Tukey–Kramer post hoc test) as well as signiﬁcant differences
between Grade I and Grade II tumors (p < 0.01, ANOVA and
Tukey–Kramer post hoc test) and Grade III and Grade IV
tumors (p < 0.01, ANOVA and Tukey–Kramer post hoc test)
(Fig. 3a).
Using LC-MS, we found mean values of 0.19% 5hmC/dG
in Grade I astrocytomas, 0.24% 5hmC/dG in Grade II, 0.13%
5hmC/dG in Grade III and 0.078% 5hmC/dG in Grade IV
tumors (Fig. 3b) with signiﬁcant differences between Grade II
and Grade IV tumors (p < 0.01, ANOVA and Tukey–
Kramer post hoc test) (Fig. 3b).
In regard to 5mC, there were no signiﬁcant differences
related to WHO grades of astrocytic gliomas using LC-MS
(Fig. 3c). The mean value of Grade I astrocytomas was 4.68%
5mC/dG, of Grade II 4.82% 5mC/dG, of Grade III 4.36%
5mC/dG and of Grade IV 4.32% 5mC/dG (p > 0.05,
ANOVA and Tukey–Kramer post hoc test) (Fig. 3c).
In ependymal tumors, we found a tendency of 5hmC pos-
itive cells between Grade I as well as Grade II and Grade III
tumors by IHC staining but we did not ﬁnd signiﬁcant differ-
ences (p > 0.05, ANOVA and Tukey–Kramer post hoc test)
(Fig. 3d). Grade I ependymomas showed mean values of
21.62% positive stained cells, Grade II and Grade III tumors
show almost equal values of 5hmC positively stained cells
(12.47% and 13.12%).
LC-MS measurements showed that WHO Grade I epen-
dymomas have mean values of 0.286% 5hmC/dG, Grade II
ependymomas 0.197% 5hmC/dG and anaplastic ependymo-
mas (WHO Grade III) 0.193% 5hmC/dG and thus paralleled
the same tendency as the immunohistochemical stainings (p
> 0.05, ANOVA and Tukey–Kramer post hoc test) (Fig. 3e).
With regard to 5mC no signiﬁcant differences were found using
LC-MS; in Grade I ependymomas the mean was 4.70% 5mC/dG,
in Grade II 4.73% 5mC/dG and in Grade III 4.65% 5mC/dG (p >
0.05, ANOVA and Tukey–Kramer post hoc test) (Fig. 3f).
A comparison of WHO Grades I and II meningiomas in
IHC showed lower numbers of 5hmC positive cells in Grade
II meningiomas compared to Grade I meningiomas (mean of
18.05% positive cells in Grade I and 6.51% positive cells in
Grade II) but the difference did not reach statistical signiﬁ-
cance (p > 0.05, unpaired t-test) (Fig. 3g).
By mass spectrometry, we found a mean value of 0.163%
5hmC/dG in Grade I and 0.140% 5hmC/dG in one Grade II
atypical meningioma, which again paralleled the same tend-
ency as in IHC but this did not reach statistical signiﬁcance
(p > 0.05, unpaired t-test) (Fig. 3h).
Again, 5mC/dG levels did not show signiﬁcant differences
between Grade I and Grade II meningiomas (4.20% 5mC/dG
in Grade I meningiomas and 4.32% 5mC/dG in Grade II me-
ningiomas, p > 0.05, unpaired t-test) (Fig. 3i).
The number of 5hmC positive cells is significantly related
to IDH1 mutations in diffuse and anaplastic astrocytomas
but not in glioblastomas
Additionally, we analyzed the IDH1 status of all astroglial
tumors by IHC using an IDH1R132H antibody and pyrosequenc-
ing of the IDH1 gene. As expected we did not ﬁnd IDH1 muta-
tions in pilocytic astrocytomas (0% mutated IDH1), but we
found 7 IDH1 mutations in diffuse astrocytomas (54% mutated
IDH1), 9 IDH1 mutations in AAs (50% mutated IDH1) and 11
IDH1 mutations in GBMs (26% mutated IDH1).
Comparing 5hmC positive cells of diffuse and AAs as well
as in GBMs (Fig. 4a) we found highly signiﬁcant differences
between diffuse astrocytomas with and without IDH1 mutation
(1.50% 5hmC positive cells in tumors with IDH1 mutation
compared to 7.31% 5hmC positive cells in tumors without
IDH1 mutation, p < 0.001, ANOVA and Tukey–Kramer post
hoc test) and signiﬁcant differences in AAs with and without
IDH1 mutation (1.80% 5hmC positive cells in tumors with
IDH1 mutation and 4.87% 5hmC positive cells in tumors with-
out IDH1 mutation, p < 0.01, ANOVA and Tukey–Kramer
post hoc test). In GBM, we did not ﬁnd signiﬁcant differences
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Figure 3. Percentage of 5hmC positive cells and LC-MS values of 5hmC and 5mC in various tumor entities. Indicated are the mean and SD.
(a) In astrocytomas and GBMs a good correlation between the number of 5hmC positive cells and tumor grade was seen. Pilocytic Grade I
astrocytomas showed highly significantly higher numbers of 5hmC positive cells compared to Grade III tumors (p < 0.001, ANOVA and
Tukey–Kramer post hoc test) and Grade IV tumors (p < 0.001, ANOVA and Tukey–Kramer post hoc test), and Grade II tumors showed highly
significant higher numbers of 5hmC positive cells compared to Grade IV GBM (p < 0.001, ANOVA and Tukey–Kramer post hoc test).
Furthermore Grade I astrocytomas showed significantly lower numbers of 5hmC positive cells compared to Grade II tumors (p < 0.01, ANOVA
and Tukey–Kramer post hoc test) as well as Grade III tumors showed significantly lower numbers of 5hmC positive cells compared to Grade IV
GBM (p < 0.01, ANOVA and Tukey-Kramer post–hoc test). (b) LC-MS showed similar results. Diffuse Grade II astrocytomas showed
significantly higher amounts of 5hmC compared to undifferentiated Grade IV GBMs (p < 0.01, ANOVA and Tukey–Kramer post hoc test). (c)
5mC showed no significant differences between different tumor grades (p > 0.05, ANOVA and Tukey–Kramer post hoc test). (d) Using IHC, in
ependymomas Grade I there were more 5hmC positive cells than in ependymomas Grades II and III, but there was no significant decrease (p
> 0.05, ANOVA and Tukey–Kramer post hoc test). (e) Using LC-MS we found higher amounts of 5hmC in Grade I ependymomas compared to
Grades II and III tumors without statistical significance (p > 0.05, ANOVA and Tukey–Kramer post hoc test). (f) 5mC showed no significant
differences in ependymomas of different WHO grades (p > 0.05, ANOVA and Tukey–Kramer post hoc test). (g) Meningiomas showed a
decrease of 5hmC positive cells in Grade II tumors compared to Grade I tumors but the difference did not reach statistical significance (p >
0.05, unpaired t-test). (h) LC-MS showed higher amounts of 5hmC in Grade I tumors compared to Grade II tumors without statistical
significance (p > 0.05, unpaired t-test). (i) The amount of 5mC did not show any significant differences in regard to tumor grade (p > 0.05,
unpaired t-test) [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.].
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between tumors with or without IDH1 mutation (p > 0.05,
ANOVA and Tukey–Kramer post hoc test) (Fig. 4a).
By mass spectrometry, we found a mean value of 0.287%
5hmC/dG in Grade II and Grade III tumors without IDH1
mutation and 0.127% 5hmC/dG in tumors with IDH1 muta-
tion with a signiﬁcant difference (p < 0.05, ANOVA and
Tukey–Kramer post hoc test) (Fig. 4b). In GBM, we did not
ﬁnd signiﬁcant differences between tumors with or without
IDH1 mutation (p > 0.05, ANOVA and Tukey–Kramer post
hoc test) (Fig. 4b).
We did not ﬁnd signiﬁcant differences in the amount of
5mC/dG between Grades II and III astrocytomas with and
without IDH1 mutation as well as GBMs (4.69% 5mC/dG in
Grades II and III tumors without IDH1 mutation and 4.50%
5hmC/dG in tumors with IDH1 mutation, p > 0.05, ANOVA
and Tukey–Kramer post hoc test, and 4.38% 5hmC/dG in
GBMs without IDH1 mutation and 4.19% 5hmC/dG with
IDH1 mutation, p > 0.05, ANOVA and Tukey–Kramer post
hoc test) (Fig. 4c).
Discussion
The profoundly distorted epigenetic landscape of tumor cells
is only beginning to emerge.12–14 DNA methylation, a major
epigenetic mechanism of gene silencing, seems to play a
major role in tumor pathogenesis. Transcriptional inactiva-
tion caused by promoter hypermethylation affects genes
involved in the main cellular pathways, DNA repair, vitamin
response, Ras signaling, cell-cycle control, p53 network and
apoptosis.15 Hypermethylation patterns are tumor-type spe-
ciﬁc and it is still unclear why certain regions become hyper-
methylated, whereas others remain unmethylated. Hypome-
thylation at speciﬁc promoters can activate the aberrant
expression of oncogenes and induce loss of imprinting.14
DNA methylation is mediated by the DNMT family of
enzymes that catalyze the transfer of a methyl group from S-
adenosyl methionine to DNA. However, it seems that the
DNA methylome is reprogrammed during development and
we hypothesized that this might also be the case in gliomas.
The discovery that 5mC can be oxidized to 5hmC by the
action of the TET enzymes has engendered ideas of a role of
TET and 5hmC in genetic reprogramming, i.e., that 5hmC
could be an intermediate leading to demethylation of 5mC
and consequently a reversal of gene silencing by methylation.
Indeed, very recent research has shown that TET proteins
can convert 5mC to 5-formylcytosine and 5-carboxylcytosine
and that the latter can be excised by thymine-DNA glycosy-
lase (TDG), which has been interpreted as a pathway for
active DNA demethylation.5–7
The results presented here show that hydroxymethylation
of genomic DNA cytidine residues is a feature found in the
human central nervous system (CNS). The highest values
were found in cortical areas (mean 1.17% 5hmC/dG) while
Figure 4. Number of 5hmC positive cells and LC-MS values of 5hmC/dG and 5mC/dG in astrocytomas and GBMs with regard to IDH1
status. Indicated are the mean and SD. (a) Comparing the number of 5hmC positive cells in diffuse and AAs as well as in GBMs with and
without IDH1 mutations we found that diffuse astrocytomas without IDH1 mutation had significantly more 5hmC positive cells (p < 0.001,
ANOVA and Tukey–Kramer post hoc test). Similar and highly significant differences were noted between AAs with and without IDH1
mutation (p < 0.01, ANOVA and Tukey–Kramer post hoc test). GBMs with and without IDH1 mutation did not show significant differences
in the number of 5hmC positive cells (p > 0.05, ANOVA and Tukey–Kramer post hoc test). Remarkably, Grade II diffuse and Grade III AAs
that had a IDH1 mutation and GBMs with and without mutation had very low 5hmC counts, which were not significantly different between
these groups (p > 0.05). (b) Using MS-LC we could parallel these results with significant differences between Grades II and III
astrocytomas with and without mutant IDH1 (p < 0.05, ANOVA and Tukey–Kramer post hoc test). There was no significant difference in
GBMs with and without IDH1 mutation (p > 0.05, ANOVA and Tukey–Kramer post hoc test). (c) The amount of 5mC did not show any
significant differences in regard to IDH1 mutations (p > 0.05, ANOVA and Tukey–Kramer post hoc test). [Color figure can be viewed in the
online issue, which is available at wileyonlinelibrary.com.]
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the white matter showed much lower values of 0.696% 5hmC/
dG (ratio 1.68:1). Since neurons in the cortex are outnum-
bered by glia cells by a factor of 2–10 and IHC did not show
a difference in the percentage of glial nuclei in the cortex and
WM, we have to assume that the values of 5hmC/dG in neu-
rons must be even higher. Percentage values of 5hmC/dG in
the human adult cortex are the highest values published to
date. The values of 5mC were around 5.3% of dG in the cere-
bral cortex and 4.2% in the cerebral white matter (ratio
1.26:1). Thus, overall it seems that a higher percentage of
DNA is hydroxymethylated in neurons in absolute terms but
also in relation to 5mC.
By comparison in the adult mouse, 5hmC/dG levels were
highest in the CNS16; the adult murine cerebral cortex and
hippocampus showed values around 0.6% 5hmC/dG while in
other organs such as the kidney, heart and lung values were
around 0.15%–0.2% and even lower in the liver, spleen and
testis. Remarkably, 5mC/dG percentages were around 4.5% in
most organs16 and various areas of the brain.17 Using an
immunoprecipitation technique Jin et al. reported that 5hmC
in DNA from human frontal lobe was more selectively tar-
geted to genes than was 5mC and was particularly enriched
at promoters and in intragenic regions. The presence of
5hmC was more positively correlated with gene expression
than was the presence of 5mC.18
Surprisingly, our immunohistochemical results demon-
strate that 5hmC is quite unevenly distributed in cells of neu-
ronal and glial lineage. We would not conclude from our
data that DNA in some cells is free of 5hmC, but our results
unequivocally show that there is a wide variation in cellular
5hmC concentration.
In our investigation, 5hmC values in gliomas range from
0.086% to 0.24% 5hmC/dG and thus are surprisingly low when
compared to measurements in the white matter. 5mC/dG val-
ues in tumors were around 4.5% and thus were slightly higher
than in normal white matter. Since tumor inﬁltration areas
could be a possible confounding factor that is difﬁcult to
exclude in investigating gliomas, we took great care to sample
pure tumor areas excluding inﬁltration zones of the white mat-
ter or cortex as far as that is possible on light-microscopic
inspection. However, tumor inﬁltration may still not be a totally
negligible factor. When all tumor entities including astrocyto-
mas, ependymomas and meningiomas were grouped by WHO
grade, signiﬁcantly lower 5hmC/dG values were noted in high-
grade anaplastic tumors than in low-grade tumors while no sig-
niﬁcant differences were found in 5mC/dG values. When con-
sidering 5hmC/dG values of the individual tumor lineages, sig-
niﬁcant differences were found for low-grade astrocytomas
versus GBMs, whereas only a tendency could be shown regard-
ing ependymomas and meningiomas. Again, as in the normal
brain, IHC demonstrated uneven cellular distribution in vari-
ous tumor cell populations. We found that staining for 5hmC
and the proliferation-associated Ki-67 was mutually exclusive
and often observed a rhythmic variation of areas with higher
proliferative activity (Ki-67) and sparse 5hmC staining and vice
versa. Again, 5mC/dG measurements showed no signiﬁcant dif-
ferences between WHO low- and high-grade tumors.
Thus by using LC-MS we have shown that 5hmC values
related to the number of dG in the human brain are highest in
gray matter areas, considerably lower in the white matter and
even lower in brain tumors. Comparable values of 5hmC in the
prefrontal cortex and a similar reduction in astrocytomas have
recently been published by Jin et al.19; data on the white matter,
GBMs and other brain tumors are not available at present. In
the tumor group, lower 5hmC values were associated with ana-
plasia (WHO Grade IV), i.e., a low degree of cellular differen-
tiation and high mitotic activity. IHC with an antibody against
5hmC, more precisely the ratio of positively stained nuclei
related to unstained nuclei, showed the same tendency as LC-
MS; higher values were measured in the gray matter vs. white
matter and highly differentiated tumors vs. anaplastic tumors.
Additional factors such as the different cells of origin of these
tumors may inﬂuence the 5hmC values. Pilocytic astrocytomas
may be a particular case in point since they are known to be ge-
netically different from higher-grade astrocytomas.
Acute myeloid leukemia (AML)-associated mutations of
IDH1 and IDH2 that display a neomorphic enzyme activity
resulting in the production of 2-hydroxyglutarate (2HG) have
been shown to impair the catalytic function of TET2, an a-ke-
toglutarate (2-oxoglutarate or 2OG)-dependent enzyme.20 Xu
et al. reported decreased 5hmC values in a mixture of Grade
III astrocytomas and GBMs harboring mutant IDH1.21 Simi-
larly our data show in greater depth a signiﬁcant difference in
the percentage of 5hmC positive cells in diffuse and AAs with
and without IDH1 mutation but not in GBMs (Fig. 4a). LC-
MS measurements showed the same relationship between dif-
fuse and AAs with and without IDH1 mutation and in GBMs.
Jin et al. found 5hmC levels were independent of IDH1
mutations in their sample of gliomas19; their data showed the
same tendency as ours but did not reach statistical signiﬁcance.
In a cohort of patients with AML, IDH1/2 mutations and
TET2 loss-of-function mutations were mutually exclusive and
elicited similar epigenetic defects.20 Kim et al. found no TET2
mutation in 29 low-grade diffuse gliomas,22 neither have we
identiﬁed TET2 loss-of function mutations in seven investi-
gated cases of astrocytomas and GBMs (data not shown).
Thus, concluding from what we know from myeloid leukemia,
in human gliomas the observed very low 5hmC values may be
related to functional impairment of the TET enzymes by 2HG.
Remarkably, Grade II diffuse and Grade III AAs and GBMs
that had IDH1 mutations had almost identical low 5hmC val-
ues. GBMs with no IDH1 mutation, which by and large are
primary GBMs, had equally low values; therefore other,
unknown factors may impair 5mC oxidation in these tumors.
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Introduction: 
TET enzymes are involved in the oxidation of mC as described in chapter I.2.3.3.1. In this 
manuscript it is shown, that not only mC is oxidized but also dT. The product hmU was 
earlier only associated with deamination in mES cells as explained in I.2.3.3.3. 
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mC is an epigenetically important nucleobase associated with the control of transcriptional activity, genomic imprinting, X-chromosome inactivation and suppression of transpos-
able elements1. Controlled formation and removal of mC at spe-
cific genomic loci is critical for correct genome programming or 
reprogramming during cellular differentiation2. Recently, it was 
discovered that Tet proteins (Tet1–3) oxidize mC to give the oxi-
dized C-derived nucleobases hmC3, 5-formylcytosine (fC)4,5 and 
5-carboxycytosine (caC)5,6, whose biological functions are still yet 
unclear (Fig. 1a)7. As fC and caC are both removed by thymine 
DNA glycosylase (Tdg)6,8, it is currently assumed that they serve 
as intermediates of an active DNA demethylation process involv-
ing base excision repair. In addition to these oxidized C deriva-
tives, cells also contain oxidized T nucleobases such as hmU and 
fU. These compounds are currently known as oxidative lesions that 
are thought to form upon the reaction of T with reactive oxygen 
species (ROS)9,10. It was recently suggested that hmU might also be 
produced by deamination of hmC, a hypothesis that remains con-
troversial11–14. Deamination of hmC, situated in a base pair with G 
(hmC:G), would give rise to hmU:G mismatches, which are known 
substrates for the DNA glycosylases Tdg, Smug1, Mbd4, Ung2 
(ref. 15), Neil1 and Nthl1 (ref. 16). Deamination of hmC:G to 
hmU:G followed by mismatch repair would therefore establish an 
alternative pathway to active demethylation (Fig. 1a).
To unravel the origin of oxidized nucleobases, and of hmU 
in particular, in DNA from mESCs, we performed isotope trac-
ing and quantitative MS studies using the chemically synthesized 
isotopologs of mC, hmC, fC, caC, hmU and fU as internal standards 
(Fig. 1b and Supplementary Results, Supplementary Fig. 1). For 
the assessment of oxidation products that are formed by the action 
of ROS, we additionally quantified 8-oxo-G because 8-oxo-G is a 
well-established ROS reaction product formed from G17,18. We show 
here that hmU is generated enzymatically from thymidine during 
stem cell differentiation by the action of the Tet enzymes. A pro-
teomic analysis provides new insight into how genomic hmU can 
influence the binding of chromatin remodeling proteins and tran-
scription factors.
RESULTS
hmU is present at elevated levels in mESCs
We first created an inventory of the named nucleosides 
(Supplementary Fig. 1) in mESCs (Fig. 1c) and adult cortex tissue 
(Fig. 1d). In mESCs, we observed that hmC is, as expected, the most 
abundant oxidized pyrimidine (10% relative to mC), followed by fC 
(~1–2% of hmC). The ROS marker 8-oxo-G was detected at simi-
lar levels (~45% of fC), showing that nonenzymatic, ROS-induced 
oxidations of nucleobases are important processes, as expected. We 
also found relatively high levels of fU (22% of fC). Clearly detect-
able were also caC and hmU. hmU, which is at the center of this 
study, was unequivocally detected, as shown by its retention time 
and its specific fragmentation pattern, which were found to be iden-
tical with that of the internal standard [D2]hmU (Fig. 1e). Notably, 
both caC and hmU were present in comparable amounts (5% 
of fC). In adult mouse cortex DNA (Fig. 1d; for other tissues see 
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Supplementary Fig. 2), the hmC levels are very high (13% rela-
tive to mC), as previously reported19–21. In contrast, fC was detected 
only in very small amounts (0.03% relative to hmC), and caC was 
not observed at all22. The detected amounts of 8-oxo-G and fU are 
comparable. Notably, the detected levels of hmU in the cortex were 
significantly lower compared to that in mESCs (27%; P = 2.2 × 10−4 
by Student’s t-test). Because the detected levels of 8-oxo-G were 
similar in the cortex (Fig. 1d) and in mESCs (Fig. 1c), the elevated 
hmU levels in mESCs cannot be explained by greater ROS-induced 
damage in mESCs and must have a different origin.
We next investigated this in more detail and quantified the levels 
of hmU in three different mESC lines (WT01, J1 and R1) and in 
a variety of tissues (Fig. 2a). Clearly, the hmU levels were higher 
in mESCs than in somatic tissues by factors of 2–15. The detected 
hmU levels correspond roughly to 500–1,700 hmU bases per 
genome in tissue and 2,900–7,800 in mESCs (Fig. 2a) depending on 
the cell type and growth conditions. We cannot explain these differ-
ences by elevated oxidative stress levels in mESCs (Supplementary 
Fig. 3). We next analyzed the levels of C, mC and the oxidized 
pyrimidines hmC, fC, hmU and fU as well as 8-oxo-G in somatic 
tissues (Supplementary Fig. 2) and performed a correlation and 
cluster analysis to reveal relationships of the modification levels 
(Fig. 2b). The data analysis confirmed that the low levels of hmU 
in somatic tissues correlate strongly (significant on a level < 0.001) 
with the levels of fU and 8-oxo-G within a separated cluster. 
This result showed that in somatic cells, hmU and fU are ROS-
induced reaction products. If we assume that in somatic tissues 
hmU is exclusively formed by ROS, the data showed that in mESCs, 
70–80% of the detected hmU is produced by ROS-independent 
processes (Supplementary Fig. 3).
hmU formation by oxidation of T
To analyze the origin of the oxidized nucleobases in mESCs, we per-
formed isotope tracing experiments (Fig. 3a–c and Supplementary 
Fig. 4). Substitution of L-methionine with [methyl-13CD3]L-methi-
onine ([13CD3]L-Met) in the growth medium is known to give the 
labeled S-adenosylmethionine cofactor, which is needed for the 
conversion of C to mC. Replacement of L-Met by [13CD3]L-Met for 
5 d (2 passages) in the medium at a concentration of 0.2 mM fur-
nished 89% labeled [13CD3]mC, 88% labeled [hydroxymethyl-13CD2]
hmC and 93% labeled [formyl-13CD]fC (Fig. 3b and Supplementary 
Fig. 4). Within the detection limit (7 and 50 molecules per 108  
nucleosides, respectively), no incorporation of the isotopes 13C and 
D into hmU and fU was observed, showing that hmC is not the 
precursor of hmU. We next added isotope-labeled [13C,15N2]thy-
midine to the growth medium and observed ~76% of label incor-
poration into T, hmU and fU (Fig. 3a, Supplementary Fig. 4 and 
Supplementary Table 1). The combined data showed that hmU is not 
generated by deamination of hmC but by oxidation of T (T → hmU; 
Fig. 3c). Consequently, all of the detected hmU (and also fU) resides 
b
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Figure 1 | Metabolism of cytosine derivatives, their detection by LC-UV ESI-MS/MS and levels in mESCs and mouse cortex. (a) potential active 
demethylation pathways. (b) overlaid lc-uv and lc/MS/MS chromatograms of a representative dnA sample from meScs. the dotted lc-uv 
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hmu. Shown are the overlaid chromatograms for the two characteristic fragment ions of hmu (top trace) and the [d2]hmu internal standard (bottom 
trace) derived from a meSc dnA sample. the insets show the MS/MS full-scan spectra of synthetic hmu and [d2]hmu matching the proposed 
fragmentation pathway.
nature CHeMICaL BIOLOGY | AdvAnce online publicAtion | www.nature.com/naturechemicalbiology 3
articleNATURE ChEMICAL bIoLogy dOI: 10.1038/nCHeMBIO.1532
in an A base pair context (hmU:A). In this base pair, hmU is repaired 
by Smug1 but not Tdg12. This was confirmed by siRNA-mediated 
knockdown of Smug1 in mESC cells and HEK-293T cells. Indeed, 
the hmU level increased in these cells (Supplementary Fig. 5).
The fact that we were unable to detect hmU derived from 
hmC deamination, which would be situated in a base pair with G 
(hmU:G), could also be explained by very fast repair. If repair of the 
hmU:G base pair is extremely efficient, for example, because deami-
nation and glycosylase-based repair occurs in a tight complex of the 
involved enzymes, we would be unable to detect this type of hmU 
because of low steady state levels. Indeed, it was proposed that hmC 
deamination and hmU excision requires a complex of the cytidine 
deaminase Aid and the glycosylase Tdg12. To assess this possibility, 
we performed isotope tracing experiments using [13CD3]L-Met in 
Tdg−/− mESCs stably complemented with either empty vector (con-
trol) or a minigene expressing a catalytically incompetent Tdg at 
near-endogenous levels. These cells are able to form the Aid–Tdg 
complex, but the Tdg is inactive, which should give elevated hmU 
levels if deamination occurs. In both cell lines, we detected high 
levels of labeled hmC. In the control cells, [hydroxymethyl-13CD2]
hmU was not detected. However, in the cell line complemented 
with inactive Tdg, some labeled [hydroxymethyl-13CD2]hmU was 
indeed observed, albeit only in small amounts (~7% of total hmU 
and ~0.06% of total hmC; Supplementary Fig. 6). Thus, the Tdg 
protein is required for deamination of hmC to hmU. In wild-type 
(WT) mESCs, the hmU:G mismatches are obviously repaired so 
quickly that they do not contribute to steady state levels of hmU. 
All of the detected hmU was derived from T oxidation and resided 
in hmU:A base pairs.
Tet enzymes form hmU in correlation with mC oxidation
We next investigated whether enzymatic oxidation or ROS-
dependent processes are responsible for the observed oxidation of 
T to hmU. To this end, we studied mESCs with genetic or func-
tional depletions of Tet or DNA methyltransferase (Dnmt) 
enzymes (Fig. 4). Although hmU levels were maintained at nor-
mal levels in the severely hypomethylated, Dnmt-depleted cell 
lines, they were substantially reduced upon knockdown of Tet1 
and Tet2. As the levels of fU and 8-oxo-G remained unaffected, 
the data establish that, though both hmU and fU are generated by 
T oxidation, their formation must occur by two independent pro-
cesses in mESCs. The data supported the idea that fU is a ROS-
created lesion similar to 8-oxo-G9,10,17,18, whereas most hmU is 
generated by Tet-induced oxidation of T.
In support of enzymatic T oxidation by Tet proteins, ectopic 
expression of the catalytic domain of Tet1 (Tet1cd) in HEK-293T 
cells led to a 65-fold increase for both hmC and hmU levels. This 
was not observed when a catalytic mutant of Tet1 (Tet1cm) was 
expressed (Supplementary Fig. 7a). To determine whether under 
these conditions hmU is generated by deamination, as previously 
suggested11,12, we again replaced natural L-Met with [13CD3]L-Met 
in the medium, but we did not detect incorporation of heavy iso-
topes into hmU, providing evidence that the elevated hmU levels 
do not originate from hmC deamination (Supplementary Table 1). 
Finally, we confirmed enzymatic generation of hmU in vitro by 
incubating recombinant Tet1cd with a plasmid that was premethy-
lated by bacterial methyltransferase M.SssI. In addition to oxidation 
of mC to hmC, fC and caC, we detected hmU at a prominent level 
of 9% relative to hmC (Supplementary Fig. 7b), showing that the 
catalytic center of the Tet enzymes clearly has the capacity to oxidize 
T to hmU.
To further confirm that hmU is formed in mESCs in the process 
of epigenetic reprogramming, we analyzed the dynamic changes of 
mC and all of the oxidized pyrimidines plus 8-oxo-G during dif-
ferentiation. It was recently shown that mC and hmC levels sharply 
increase when mESCs maintained in the naive state are shifted to a 
primed state in serum-containing medium23–25. To investigate global 
kinetics of all of the Tet-generated oxidation products under more 
physiologically relevant priming conditions, we used established 
protocols based on serum-free N2B27 medium for differentiation 
of naive mESCs into states resembling that of post-implantation 
epiblasts26,27. mESCs were first grown for several passages in the 
presence of MEK and GSK3 inhibitors (dual inhibition or 2i condi-
tions) and LIF to induce a hypomethylated state resembling that of 
the naive epiblast23–25. The data in Figure 5a are averaged from three 
independent differentiation experiments, each performed with two 
cell lines in the absence of growth factors. First, we observed that 
the fU and 8-oxo-G levels stayed constant (Fig. 5a), in line with the 
idea that both are ROS-derived products. In contrast, fC and caC 
levels peaked at about 8 h. Both hmU and hmC also peak between 
8 h and 16 h. Isotope tracing with [13CD3]L-Met under these condi-
tions provided no evidence for switched-on deamination of hmC to 
hmU (Supplementary Table 1). At these peak levels, we estimated 
that mESCs contain roughly 110,000 fC bases, 4,400 caC bases and 
Figure 2 | hmU is present at elevated levels in mESCs compared to tissue. 
(a) hmu levels per genome in meScs (nWt01 = 7 replicates, nJ1 = 2, nR1 = 3) 
and mouse tissue (3-month-old individuals, n = 3). levels per genome 
were obtained considering a mouse genome size of 2.7 × 109 base pairs. 
depicted are mean values ± s.d. the differences between meScs and 
mouse tissues are significant (*P = 2.9 × 10−5 to 3.6 × 10−2; unpaired  
two-tailed t-test) except for Wt01 and hippocampus (P = 0.292) or 
heart (P = 0.069). these exceptions are due to higher hmu levels in the 
hippocampus and heart caused by higher background oxidation (higher 
8-oxo-G levels). hmu levels normalized to oxidative background (8-oxo-G) 
levels are in Supplementary Figure 3. (b) unsupervised clustering 
analysis of pearson correlation coefficients of 24 data sets of selected 
mouse organs at a defined time point (3-month-old individuals: cortex, 
hippocampus, cerebellum, heart, liver and kidney). discussed correlations 
are strong to very strong (pearson coefficient >0.7) and significant on a 
level <0.001.
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14,000 hmU bases per genome, showing that, at its peak level, hmU 
is three times more abundant than caC. The dynamic peaking data 
allowed us to estimate half-life times for fC (7 h), caC (5 h) and hmU 
(4 h) during the differentiation process (Supplementary Fig. 8). 
Using the dynamic quantitative data, we performed a correlation 
and cluster analysis of the DNA modification levels (Fig. 5b). Three 
independent clusters were obtained. One cluster involves members 
of cytosine methylation (and demethylation) dynamics, including 
C, mC, fC and caC, but, to our surprise, not hmC. Instead, hmC 
groups with hmU. We therefore concluded that the formation 
of these modifications is tightly coupled by the action of the Tet 
enzymes. The ROS-induced lesions fU and 8-oxo-G form the third, 
well-separated cluster. Notably, hmU does not correlate with the 
ROS lesions.
Recently, it was shown that exposure of naive mESCs to fibro-
blast growth factor 2 (FGF-2) and activin A (ActA) for 48 h under 
similar conditions as those described above gives a homogeneous 
cell population whose transcriptome closely resembles that of the 
post-implantation epiblast26. Under these conditions, mC levels 
increased more rapidly, approaching somatic levels within a time 
frame closely reflecting that observed during embryonic develop-
ment (Supplementary Fig. 9a). Levels of hmC rose steadily 
throughout the 48-h time course. Whereas fC peaked at 36 h, hmU 
reached its maximum at 24 h (Supplementary Fig. 9b). qPCR data 
showed a robust induction of Dnmt3b that is 
most likely responsible for the increasing mC 
levels (Supplementary Fig. 9a). A transient 
peak of Tet1 expression at 24 h went in hand 
with rising hmU and fC levels, whereas Tet3 
expression started rising slowly from the same 
time point and may drive further accumulation 
of hmC and fC (Supplementary Fig. 9b). Tdg 
was progressively upregulated together with the 
onset of methylation activity, whereas Smug1 
showed little, if any, change (Supplementary 
Fig. 10). These data supported our view that 
hmU peaking is not caused by downregulation 
of the repair pathway.
Thus, the kinetic data showed a com-
plex interplay between methylation and two 
oxidation reactions during differentiation, 
which depends on the exact conditions. Most 
important is the fact that hmU showed a time-
 dependent occurrence similar to the other oxi-
dized bases hmC, fC and caC independently 
of the conditions investigated, confirming its 
formation during epigenetic reprogramming.
hmU attracts specific readers
To obtain initial insight into a potential biologi-
cal function of hmU in comparison to hmC, we 
screened for specific readers associating with 
hmU:A as well as with hmC:G and hmU:G 
using protein pulldown and relative quantifica-
tion by LC/MS/MS. In previous stable isotope 
labeling by amino acids in cell culture (SILAC)-
based proteomics studies with hmC, fC and 
caC containing oligonucleotides, we and oth-
ers observed a high number of specific protein 
readers, arguing that the new bases influence a 
variety of different processes28,29. For this hmU 
study, we further developed this approach for 
the detection of only those proteins, which 
directly interact with the modified bases hmU 
(as well as hmC for comparison) to get a more 
direct insight into their function (Fig. 6a). For 
the study, we not only included into the biotinylated DNA duplexes 
(24mers) an hmU (hmC) base but also equipped the counter 
strand with a polyethylene glycol–based linker carrying a reactive 
N-hydroxysuccinimide (NHS) ester moiety and a reductively cleav-
able disulfide bond in the middle. This reactive linker cannot be 
inserted into the DNA strand using solid phase synthesis. In addition, 
the NHS ester does not survive hybridization conditions. We there-
fore attached the linker as its azide derivative, using Cu(I)-catalyzed 
click chemistry, to an alkyne-bearing base present in the DNA 
duplex30,31. These DNA duplexes were subsequently incubated with 
nuclear extracts from mESCs. The DNA-bound protein complexes 
were isolated using streptavidin-coated magnetic beads (Fig. 6a)32. 
DNA duplexes with the canonical base pairs A:T and C:G at the 
respective positions served as reference strands. The NHS linker has 
two functions in the experiment: First, it will covalently trap the 
reader proteins specifically at the ε-amino groups of lysines, which 
allows the identification of transiently binding proteins as well. 
Second, because the linker is cleavable, it will tag the trapped lysine 
residues, leaving a defined label on those proteins that bind in close 
proximity to the modified bases hmC and hmU. This allowed us to 
distinguish protein readers that bound close to hmC and hmU from 
proteins that are secondary members of the complexes. The cova-
lently trapped proteins were next tryptically digested and labeled 
with tandem mass tagging (TMT) isobaric tags to allow protein 
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identification and quantification by MS32,33. Only proteins that were 
enriched in both the forward and the reverse TMT experiment were 
considered to be specific hmU (hmC) readers (Fig. 6). All of the 
readers were subsequently divided into two groups. Proteins that 
were enriched relative to the control strands are termed specific 
readers (sRs). Of those, the proteins that were identified with a pep-
tide containing the tag are termed direct-specific readers (dsRs).
The scatter plot (Fig. 6b and Supplementary Fig. 11a) revealed 
over 250 sRs recognizing the hmU:A base pair (relative to T:A). 
Of those proteins, 99 were identified with tagged peptides. These 
proteins were therefore designated dsRs. A gene ontology analysis 
showed that 64 proteins of the 250 sRs are nucleotide bind-
ers, and 25 proteins are involved in chromatin organization 
(Supplementary Fig. 11b).
Among the dsRs we identified were the regulatory proteins Uhrf2, 
transcription factor HIVEP3 or the poly [ADP-ribose]  polymerase 
14 (Parp14), which showed that these proteins interacted directly 
with hmU. We also detected several H2A and H2B histone proteins 
among the dsRs and the sRs. Notably, in the group of the sRs, we 
observed also Dnmt3a and Dnmt3b, which are involved in gene 
expression regulation. Methyl CpG-binding protein 2 (MeCP2) 
was identified as well, but it showed only low enrichment. We also 
detected several transcriptional regulators, such as bromodomain 
0
2 × 10–3
4 × 10–3
6 × 10–3
8 × 10–3
10 × 10–3
m
C
 /
 N
WT01 J1
W
T
W
T
Dn
mt
1–
/–
Dn
mt
3a
b
–/
–
Te
t1 
KD
Te
t2 
KD
2.5 × 10–6
2.0 × 10–6
1.5 × 10–6
1.0 × 10–6
0.5 × 10–6
0
hm
U
 /
 N
WT01 J1
W
T
Dn
mt
1–
/–
Dn
mt
3a
b
–/
–
W
T
Te
t1 
KD
Te
t2 
KD
5 × 10–6
4 × 10–6
3 × 10–6
2 × 10–6
1 × 10–6
0
fU
 /
 N
WT01 J1
W
T
Dn
mt
1–
/–
Dn
mt
3a
b
–/
–
W
T
Te
t1 
KD
Te
t2 
KD
8 × 10–6
6 × 10–6
4 × 10–6
2 × 10–6
0
8-
ox
o-
G
 /
 N
WT01 J1
W
T
Dn
mt
1–
/–
Dn
mt
3a
b
–/
–
W
T
Te
t1 
KD
Te
t2 
KD
0
hm
C
 /
 N
WT01 J1
8 × 10–4
6 × 10–4
4 × 10–4
2 × 10–4
W
T
Dn
mt
1–
/–
Dn
mt
3a
b
–/
–
W
T
Te
t1 
KD
Te
t2 
KD
0
fC
 /
 N
WT01 J1
12 × 10–6
9 × 10–6
6 × 10–6
3 × 10–6
W
T
Dn
mt
1–
/–
Dn
mt
3a
b
–/
–
W
T
Te
t1 
KD
Te
t2 
KD
0
ca
C
 /
 N
WT01 J1
10 × 10–7
8 × 10–7
6 × 10–7
4 × 10–7
2 × 10–7
W
T
Dn
mt
1–
/–
Dn
mt
3a
b
–/
–
W
T
Te
t1 
KD
Te
t2 
KD
Figure 4 | Tet1 and Tet2 generate hmU in mESCs. effect of tet and dnmt 
depletion on dnA modification levels in meScs. J1 cell lines bearing 
homozygous Dnmt-null mutations and Wt01 meScs expressing tet1 
or tet2 shRnAs (knockdown (Kd)) were analyzed. depicted are mean 
values per nucleoside (N) ±s.d. of biological replicates as follows: wild type 
(Wt01, n = 7), tet1 Kd (Wt01, n = 3) and tet2 Kd (Wt01, n = 3); Wt (J1, 
n = 2), Dnmt1−/− (J1, n = 2) and Dnmt3a/b−/− (J1, n = 6).
C mC fC caC hmC hmU fU 8-oxo-G
C
mC
fC
caC
hmC
hmU
fU
8-oxo-
G
–1.0 –0.8 –0.6 –0.4 –0.2 0 0.2 0.4 0.6 0.8 1.0
Correlation coecient
b
0.2
0.4
0.6
0.8
1.0
Re
l. 
Eu
cl
id
ea
n
di
st
an
ce
0
hmU
fU
8-oxo-G
hmC
0 8 16
Time (h)
Time (h) Time (h)
Time (h)
24 40
0
0.5
1.0
1.5
Re
l. 
ch
an
ge
*** **
fC
0 h 8 16 24 40
0
0.5
1.0
1.5
2.0
****
caC
0 8 16 24 40
0
0.5
1.0
1.5
2.0 * ***
hmU
0 8 16 24 40
0
1
2
3
** *
mC
0 10 20 30 40
0.8
1.0
1.2
1.4
Dierentiation time (h)
Re
l. 
ch
an
ge
0 10 20 30 40
0
1
2
3
Dierentiation time (h)
Re
l. 
ch
an
ge
a
Figure 5 | hmU is produced during mESC differentiation. (a) time course 
of dnA modification levels during early differentiation (0−40 h) of naive 
meScs in the absence of growth factors. box plot of relative modification 
changes for hmc, fc, cac and hmu averaged from six independent 
experiments using two different meSc lines. in the four upper plots, colored 
diamonds reflect mean values of technical triplicate measurements, open 
squares reflect mean values of biological replicates, boxes represent the 
s.e.m., and whiskers represent the the s.d. of the biological replicates; *P < 
0.05, **P < 0.01 and ***P < 0.005 by unpaired two-tailed t-test. in the two 
lower plots, the relative modification changes of mc, hmu, fu and 8-oxo-G 
are depicted as biological mean values ± s.e.m. (b) unsupervised clustering 
analysis of pearson correlation coefficients of 22 data sets obtained from 
the differentiation experiments depicted in a. discussed correlations are 
strong to very strong (pearson coefficient >0.7)  
and significant on a level <0.001.
6  nature CHeMICaL BIOLOGY | AdvAnce online publicAtion | www.nature.com/naturechemicalbiology
article NATURE ChEMICAL bIoLogy dOI: 10.1038/nCHeMBIO.1532
PHD finger transcription factor (Bptf), transcription factor E2F6 
and mediator of RNA polymerase II transcription subunit 12 
(Med12). Moreover, we identified hmU-binding E3 ubiquitin-
protein ligases such as Uhrf1, Trim37 and Huwe1 and finally the 
chromodomain helicase DNA-binding proteins 1 and 9 (Chd1 and 
Chd9) among the hmU readers, which are chromatin remodeling 
factors and regulate polymerase I and II transcription. To exclude 
bias by sequence-specific binding, we repeated the experiment with 
hmU in a different sequence context. Indeed, 78% of the identi-
fied protein readers are also observed in this control experiment, 
and included among them were all of the proteins discussed above, 
with the notable exception of Uhrf1, which was not observed in 
this experiment (Supplementary Data Set 1). The data show that 
hmU:A recruits specific proteins that are involved in chromatin 
biochemistry in a broad sense.
As a first validation of the MS-identified readers, we focused on 
Uhrf1 and Uhrf2. Uhrf1 is a known mC and hmC binder34, whereas 
we recently identified the homolog Uhrf2 as a specific binder of 
hmC29. The MS data for hmU obtained in this study showed an 
enrichment of Uhrf1 and Uhrf2. In addition, Uhrf2 was identified 
as a direct binder. To validate the MS findings, we overexpressed 
Uhrf1 or Uhrf2 together with Tet1cd in 
HEK-293T29 and measured the levels of mC, 
hmC, fC, caC and also hmU. Indeed, we 
observed increased levels of hmU, proving a 
functional relation between hmU levels and 
Uhrf1 and Uhrf2 (Supplementary Fig. 12). 
As Uhrf2 is known to interact with Dnmt3a 
and Dnmt3b35 and these two proteins are 
also identified as sRs of hmU, our initial data 
provide a consistent picture.
Analysis of the specific hmU readers 
showed that 49 of the identified proteins were 
also enriched with an hmC-modified strand. 
Among these proteins were, for instance, 
 bromodomain PHD finger transcription factor 
(Bptf), MeCP2 and 19 other nucleotide- binding 
proteins. The obtained list of specifically bind-
ing proteins is in good agreement with our 
recently published data set29, which further 
supports the validity of the covalent trapping 
method. Finally, we compared the results 
of the hmU:A pulldown with a pulldown of 
hmU:G, which would be the product of hmC 
deamination. We found 69 of 280 sRs in both 
experiments. We identified transcription regu-
lators as sRs as well in the hmU:G pulldown. 
However, we also found several DNA repair 
proteins, such as DNA repair protein comple-
menting XP-C cells homolog (XPC), DNA 
repair protein Rad50 and five helicases, among 
others (Supplementary Data Set 1).
DISCUSSIoN
This work aimed to analyze the origin of hmU 
in mESCs. Although hmU as well as fU are 
both well-characterized oxidation products of 
thymidine9,10, hmU in particular was recently 
discussed as an intermediate in active demethy-
lation by deamination of hmC11,12. We used sta-
ble isotopologs of the main oxidation products 
hmC, fC, caC, hmU, fU and 8-oxo-G in com-
bination with quantitative MS to show that 
the levels of hmU are strongly elevated in 
stem cells in comparison to somatic tissue. 
Notably, we did not observe equally elevated 
levels of fU and 8-oxo-G, both of which are formed by the reac-
tion of DNA with ROS. This analysis suggests that hmU in stem 
cells is not only formed by ROS. The quantitative data allowed 
us to estimate that in WT stem cells, about 70–80% of the found 
hmU is not formed by ROS but is derived from a different process. 
Isotope tracing studies with labeled [13CD3]L-Met and [13C,15N2] 
thymidine showed that the detected hmU originates exclusively 
from T. Previous studies already proposed a connection between 
Tet activity and hmU levels, but these studies did not address the 
origin of hmU, which led to the hypothesis that hmU could form 
by deamination of hmC11,22. To investigate the involvement of 
deamination11–14, we studied TDG−/− stem cells reconstituted with a 
catalytically inactive TDG. In these cells, the putative deamination– 
repair complex12 of TDG and Aid could form, and we expected to 
see elevated hmU. Indeed, in this experiment, we were able to detect 
labeled hmU, showing that deamination of hmC does occur, but the 
levels were low. Most notably, special conditions were required to 
detect this deamination. In WT cells, all of the detected hmU is clearly 
derived from T oxidation. As such, the detected hmU is situated in 
a base pair with A (hmU:A). In conclusion, the majority of hmU in 
mESCs is produced independently of both ROS and deamination. 
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Using a combination of functional knockdown in mESCs, ecto-
pic expression of Tet1 catalytic domain in HEK-293T cells and 
in vitro studies with recombinant Tet protein, we showed that the 
Tet enzymes, known to oxidize mC to hmC, are also responsible 
for oxidation from T to hmU. A kinetic study in which the tempo-
ral changes of all of the oxidized pyrimidines were observed under 
two different differentiation kinetics showed finally that hmU is 
formed in processes that also generate hmC and fC. Together with 
the observed peak levels of hmU of about 14,000 bases per genome, 
this suggests that hmU could have an epigenetic function similar 
to hmC. It is conceivable that the Tet enzymes introduce a small 
amount of hmU during the hmC manufacturing process to trigger 
faster demethylation by induction of DNA repair. It is known that 
hmC is not a substrate for repair8,12, whereas hmU is efficiently rec-
ognized and repaired36, for example, by the repair glycosylase Smug1 
(refs. 37,38). Sporadic introduction of hmU could therefore allow 
recruitment of repair factors, for example, for long patch repair, as 
recently suggested39. Alternatively, hmU might influence transcrip-
tion factor binding, which is known to be a hallmark of epigenetic 
reprogramming40. To study the proteins that closely interact with 
hmU, a new pulldown experiment was devised in which we inserted 
a trapping linker into the oligonucleotide. This linker is able to react 
covalently with proteins that assemble on the DNA duplex close to 
the hmU base. Because the linker is reductively cleavable, it leaves 
a tag on the respective lysine residues, which is detected in subse-
quent MS-based proteomics measurements. Using this technology, 
we observed that hmU:A recruits transcription factors and proteins 
that are involved in chromatin biochemistry, including Uhrf1 and 
Uhrf2. This result is in line with the recent observation that oxida-
tive lesions in DNA can change the binding affinity of the transcrip-
tion factor CREB when they are present in the respective cognate 
sequence41. A further analysis in HEK-293T revealed that the hmU 
readers Uhrf1 and Uhrf2 are able to modulate the levels of all of 
the oxidized mC bases and of hmU. It is interesting to note that the 
observed level increases of hmC were small, whereas they were sub-
stantial for hmU and also for the further oxidized bases fC and caC. 
As Uhrf1 and Uhrf2 are proteins known to be involved in numer-
ous epigenetic processes, our data supported the hypothesis that 
Tet-induced oxidation of T to hmU may have an epigenetic func-
tion. Even in the case that hmU is formed just as a side product 
of Tet-induced hmC formation, it is now clear that the oxidation 
chemistry performed by the Tet enzymes has to go in hand with 
effective DNA repair. 
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oNLINE METhoDS
General materials and methods. Chemicals were purchased from Sigma-
Aldrich, Fluka, ABCR or Acros organics and used without further purifica-
tion. Acetonitrile of LC/MS grade was purchased from Carl Roth GmbH + Co., 
KG. Formic acid, p.a. for MS, was purchased from Fluka, and water was puri-
fied with a Milli-Q Plus system from Merck Millipore.
The MS standards 5-methyl-2′-deoxycytidine (mC), 5-trideuteromethyl-
2′-deoxycytidine ([D3]mC), 5-hydroxymethyl-2′-deoxycytidine (hmC), 
5-dideuterohydroxymethyl-2′-deoxy-(N1,N3–15N)-cytidine ([15N2,D2]
hmC), 5-formyl-2′-deoxycytidine (fC), 5-formyl-2′-deoxy-(N1,N3–15N)-
cytidine ([15N2]fC), 5-carboxy-2′-deoxycytidine (caC), 5-carboxy-2′-deoxy-
(N1,N3–15N)-cytidine ([15N2]caC), 5-hydroxymethyl-2′-deoxyuridine (hmU), 
5-(dideuterohydroxymethyl)-2′-deoxyuridine ([D2]hmU), 5-formyl-2′-
deoxyuridine (fU) and 5-formyl-2′-deoxy-(N1,N3–15N)-uridine ([15N2]fU) were 
synthesized according to earlier published work19,21,42. All of the synthesized 
compounds were characterized and purity confirmed by 1H-NMR, 13C-NMR 
and ESI-MS, and some were additionally validated by 15N-NMR. 8-hydroxy-2′-
deoxy-(15N5)-guanosine ([15N5]8-oxo-G) (99 atom% 15N) was purchased from 
Cambridge Isotope Laboratories; 8-hydroxy-2′-deoxyguanosine (8-oxo-G) was 
from BIOLOG; 2′-deoxyguanosine (G) and 2′-deoxycytidine (C) were from 
ChemGenes. (methyl-13C,D3)-L-Met (99 atom% D and 13C) was purchased from 
Sigma-Aldrich, and 2′-deoxy-(C2–13C, N1,N3–15N)-thymidine (99 atom% 13C 
and 15N) from Hartmann Analytic. Aqueous stock solutions of these com-
pounds were stored at −20 °C and warmed up to RT before usage.
Oligonucleotide synthesis. Oligonucleotide synthesis was performed on an 
ABI 394 DNA/RNA synthesizer (Applied Biosystems) using standard DNA 
synthesis conditions (DMT off) and acetyl-protected dC. Phosphoramidites 
(including the 5-hydroxymethyl-dU-CE phosphoramidite and the 5′-biotin 
phosphoramidite) and polystyrene carriers were obtained from Glen Research. 
5-octadienyl-dU (Z) phosphoramidite was synthesized according to litera-
ture and characterized by 1H-NMR, 13C-NMR, 31P-NMR and ESI-MS43. The 
crude oligonucleotide was cleaved from the resin and deprotected in 30% (v/v) 
ammonium hydroxide and 40% (v/v) methylamine (1:1) at 65 °C for 10 min 
and purified by preparative and analytical HPLC (Waters Breeze and Alliance, 
respectively). Separation was performed by applying a VP 250/10 Nucleosil 
100-7 C18 column (flow: 5 ml/min) from Macherey-Nagel with a gradient 
of buffer A (0.1 M NHEt3OAc in water) and buffer B (0.1 M NHEt3OAc in 
80% MeCN). DNA-containing fractions were characterized by MALDI-TOF 
(Bruker Autoflex II) and analytical HPLC, combined, and desalted by C18-
Sep-Pak cartridges (Waters). For analytical HPLC, separation was performed 
by applying a CC 250/4 Nucleosil 120-3 C18 column from Macherey-Nagel 
(flow: 0.5 ml/min) with the aforementioned buffer system.
For the protein pulldown studies, an hmU-containing oligonucleotide was 
hybridized with a DNA strand modified with a 5′-biotin and a 5-octadienyl- 
dU. The sequences of the DNA strands are summarized in Supplementary 
Table 3. To 10 nmol of the dsDNA, 0.5 μl of a 200 mM solution of the cross- 
linking azide-PEG3-S-S-NHS ester (C18H29N5O8S2, Jena Bioscience, 
Jena, Germany) in DMSO was added. In a separate tube, CuBr was dis-
solved in a TBTA solution (DMSO/tBuOH 3:1, 100 mM) resulting in a 1:1 
Cu(I):TBTA ratio. This solution was immediately added to the DNA/azide 
mixture. Furthermore, 45 μl of DMSO/tBuOH (3:1) were added, the mixture 
was shaken at 37 °C for 3 h, and the resulting product was purified by 
ethanol-precipitation.
LC/MS analysis of DNA samples. Quantitative LC-UV-ESI-MS/MS analysis of 
digested DNA samples was performed using an Agilent 1290 UHPLC system 
equipped with an UV detector and an Agilent 6490 triple quadrupole mass 
spectrometer coupled with the stable isotope dilution technique. An improved 
method, based on earlier published work29,42,44,45, was developed, which allowed 
the concurrent analysis of all nucleosides in one single analytical run. The 
source-dependent parameters were as follows: gas temperature 50 °C, gas 
flow 15 l/min (N2), nebulizer 30 psi, sheath gas heater 275 °C, sheath gas flow 
11 l/min (N2), capillary voltage 2,500 V in the positive ion mode, capillary volt-
age −2,250 V in the negative ion mode and nozzle voltage 500 V. The fragmentor 
voltage was 380 V. Delta EMV was set to 500 (positive mode) and 800 (negative 
mode). Compound-dependent parameters are summarized in Supplementary 
Tables 4 and 5. Chromatography was performed by a Poroshell 120 SB-C8 
column (Agilent, 2.7 μm, 2.1 mm × 150 mm) at 30 °C using a gradient of water 
and MeCN, each containing 0.0085% (v/v) formic acid, at a flow rate of 
0.35 ml/min: 0 → 5 min; 0 → 3.5% (v/v) MeCN; 5 → 6.9 min; 3.5 → 5% MeCN; 
6.9 → 7.2 min; 5 → 80% MeCN; 7.2 → 10.5 min; 80% MeCN; 10.5 → 11.3 min; 
80 → 0% MeCN; 11.3 → 13 min; 0% MeCN. The effluent up to 1.5 min and after 
9 min was diverted to waste by a Valco valve. The autosampler was cooled to 
10 °C. The injection volume was amounted to 29 μl. Calibration curves, method 
validation and data processing are in Supplementary Note 2. A complete 
compilation of LC/MS quantifications results see Supplementary Note 3.
DNA digestion. 5–25 μg of genomic DNA in 25 μl H2O were digested as follows: 
An aqueous solution (7.5 μl) of 480 μM ZnSO4, containing 42 U nuclease S1 
(Aspergillus oryzae, Sigma-Aldrich), 5 U Antarctic phosphatase (New England 
BioLabs) and specific amounts of labeled internal standards (Supplementary 
Note 2) were added, and the mixture was incubated at 37 °C for 3 h. After 
addition of 7.5 μl of a 520 μM [Na]2-EDTA solution, containing 0.2 U snake 
venom phosphodiesterase I (Crotalus adamanteus, USB corporation), the sam-
ple was incubated for another 3 h at 37 °C and then stored at −20 °C. Prior to 
LC/MS/MS analysis, samples with up to 15 μg DNA, for which the quantifica-
tion of low amounts of caC was aspired, were filtered by using an AcroPrep 
Advance 96 filter plate 0.2 μm Supor (Pall Life Sciences). In contrast, samples 
with 15–25 μg DNA (isotope-tracing experiments) were filtered by using an 
AcroPrep Advance 96 filter plate 10K Omega (Pall Life Sciences).
Genomic DNA isolation. Tissues of female WT mice (C57-BL6/N) were 
dissected at postnatal day 90 and prepared as earlier described19,21. Genomic 
DNA was extracted using the Qiagen Blood and Cell Culture DNA Midi Kit 
except for mESC samples differentiated in the presence of growth factors 
(see below). Extraction was performed following the manufacturer’s instruc-
tions for genomic DNA isolation from cell culture samples or tissue samples, 
respectively. All buffers until loading of the sample on Genomic-tip 100/G 
were additionally supplemented with antioxidants 2,6-di-tert-butyl-4-methyl-
hydroxytoluene (BHT, 200 μM) and deferoxamine mesylate salt (desferal, 
200 μM) as well as the deaminase inhibitor tetrahydrouridine (THU, 200 μM), 
according to published standards, to reduce background oxidation or deami-
nation18. Elution buffer QF was supplemented with 200 μM BHT. Following 
elution, all steps were performed on ice. DNA was then precipitated with 
NaOAc (0.3 M final) and 0.7 volumes iPrOH. DNA pellets from cultured cells 
were washed twice with ice-cold 70% EtOH and resuspended in H2O contain-
ing 20 μM BHT using a Qiagen TissueLyser (30 Hz, 2 min). DNA pellets from 
mouse tissues were resuspended in PBS buffer and additionally extracted with 
phenol/CHCl3, precipitated, washed and resuspended as described above.
R1 mESC samples differentiated in the presence of growth factors or trans-
fected with Smug1 esiRNAs were lysed directly in the plates with RLT buffer 
(Qiagen) supplemented with BHT and desferal as described above. DNA was 
isolated using the Zymo Quick gDNA Midi Kit according to the manufacturer’s 
instruction, except that elution was repeated four times with 100 μl of elu-
tion buffer supplemented with BHT (200 μM). Eluted DNA was precipitated 
with 2 M ammonium acetate and two volumes of absolute ethanol and finally 
resuspended in H2O containing 20 μM BHT. The flow-through from the spin 
columns was used to isolate RNA (see real-time PCR analysis).
mESC cell culture. Feeder independent WT01 mESCs (C57BL/6 strain)46 were 
cultured in the presence of serum and LIF as previously described4. Tdg+/− and 
Tdg−/− mESCs were described previously47. Tdg−/− mESCs were complemented 
by random integration of either empty vector (hereafter referred to as Tdg−/− 
mESCs) or a minigene expressing catalytically inactive Tdg (N151A)47. Clonal 
mESC lines with targeted Tdg alleles, R1 cells (strain 129/Sv)48, J1 cell lines 
(strain 129S4/SvJae)49 and a mESC line derived from C57Bl/6/129 mixed 
background50 were routinely maintained on gelatinized plates in DMEM 
(PAA or Sigma) supplemented with 10% FBS, 1× MEM-nonessential amino 
acids (NEAA), 0.2 mM L-alanyl-L-glutamine, 100 U/ml penicillin, 100 μg/ml 
strepto mycin (all from PAA), 0.1 mM β-mercaptoethanol, 20 ng/ml 
(≥1 ×103 U/ml) mouse recombinant LIF (ORF Genetics), 1 μM PD 0325901 and 
3 μM CHIR 99021 (2i; both from Axon Medchem). In these conditions, the glo-
bal levels of genomic mC were very low (and, as a consequence, the levels of its 
oxidized derivatives were even lower; data not shown). Before DNA isolation, 
2i cultures were passaged twice (over 5 d) in DMEM supplemented with FBS 
and LIF as above but lacking 2i. With this strategy, primed mESC cultures were 
obtained with no sign of overt differentiation and modified genomic cytosines 
reached reproducibly higher and stable levels. For isotope tracing with heavy 
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thymidine in serum-primed mESCs 2i cultures of R1, cells were passaged 
twice (5 d) in the same serum-containing medium lacking 2i and simultane-
ously supplemented with 100 μM [13C,15N2]T. For isotope tracing with heavy 
methionine in serum-primed mESCs, 2i cultures of R1 cells and mESC lines 
with targeted Tdg alleles were passaged twice (over 5 d) without 2i in L-Met-
free DMEM (Life Technology) supplemented as above and with 0.2 mM of 
either [methyl-13C,D3]L-Met or natural L-Met. For mESC differentiation with-
out growth factors, R1 cells and the C57Bl/6/129 mixed background cell line 
were first plated at 1 × 105 cells/cm2 on gelatin-coated plates in N2B27 medium 
containing 1,000 U/ml LIF to favor attachment and initial survival51. After 12 h, 
the medium was replaced without addition of LIF (defined as time point 0 h). 
The medium was replaced once more at 24 h. For isotope tracing with [methyl-
13C,D3]L-Met during mESC differentiation, R1 cells were cultured for two pas-
sages in L-Met-free N2B27 medium supplemented with LIF, 2i and 0.2 mM 
of either [methyl-13C,D3]L-Met or natural L-Met. Differentiation of R1 cells 
in the presence of FGF-2 and ActA was as described26, with minor modifica-
tions. Briefly, mESCs were cultured in N2B27 medium containing 2i and 1,000 
U/ml LIF for several passages and then seeded at 2.2 × 105 cells/cm2 in N2B27 
medium containing 1% KnockOut Serum Replacement (Life Technologies), 
12 ng/ml FGF-2 (PeproTech) and 20 ng/ml ActA (ORF Genetics) on 
plates coated with a thin layer of Geltrex extracellular matrix preparation 
(Life Technologies). The medium was exchanged after 24 h.
Knockdown experiments in mESCs. shRNA expression vectors targeting 
Tet1 and Tet2 were generated by cloning synthetic oligonucleotides in pLKO.1 
(ref. 52). Recombinant lentiviruses were produced by cotransfecting pLKO.1 
shRNA expression vectors and packaging plasmids in HEK-293 cells. 48 h after 
transduction in the presence of 8 μg/ml polybrene, shRNA-expressing mESCs 
were selected with 4 μg/ml puromycin. Cell pools were continuously cultured 
in the presence of puromycin. shRNA target sequences were as follows: SCR 
(control), 5′-CCT AAG GTT AAG TCG CCC TCG-3′ (ref. 52); Tet1, 5′-TGT 
AGA CCA TCA CTG TTC GAC-3′ (see ref. 52), Tet2: 5′-TTC GGA GGA 
GAA GGG TCA TAA-3′. esiRNAs for Smug1 knockdown were generated as 
described53. The cDNA template for in vitro transcription was generated by 
PCR using following primers: forward, 5′- CGT AAT ACG ACT CAC TAT 
AGG GAG CCC GTG GGT G-3′, and reverse, 5′-CGT AAT ACG ACT CAC 
TAT AGG GGT TTC GTC CAC TGG G-3′. R1 mESCs were weaned from 
2i for two passages in FBS- and LIF-containing medium as described above. 
Upon plating the second passage, the cells were transfected in a p60 plate with 
6 μg of Smug1 esiRNAs (34.5 nM) and 20 μl of Lipofectamine RNAi MAX 
(Life Technologies) according to the manufacturer’s instructions and were 
lysed 72 h after transfection.
Culture and transfection procedures for HEK-293T cells. All transfections 
were performed using jetPRIME transfection reagent (PEQLAB Biotechnologie 
GmbH) according to the manufacturer’s instructions. HEK-293T cells were 
seeded 24 h before transfection at a density of 2.5 × 106 cells per 75 cm2 flask and 
incubated in 10 ml of medium. The transfection solution (500 μl of jetPRIME 
buffer, a specific amount of plasmid DNA (Supplementary Note 4) and 20 μl 
of jetPRIME reagent) was added to the medium, and the cells were incub-
ated for 48 h, with an additional medium exchange 24 h after transfection. 
When cotransfection of esiRNA was performed, a second transfection step 
(500 μl of jetPRIME buffer, 5 μg of esiRNA and 20 μl of jetPRIME reagent) was 
carried out 4 h after transfection of plasmid DNA. esiRNAs were purchased 
from Sigma (human TDG esiRNA EHU038971; human SMUG1 esiRNA 
EHU098861; human CDK5RAP1 esiRNAEHU079221). Supplementary 
Note 4 summarizes the overexpression and knockdown procedures.
Isotope tracing with [13C,15N2]thymidine or [13C,D3]L-Met in HEK-293T cells 
transfected with Tet1cd. 24 h before transfection, 2.5 × 106 cells were seeded 
in a 75-cm2 flask containing 10 ml either of (for [13C,15N2]thymidine) DMEM 
medium supplemented with 50 μM [13C,15N2]T or (for [13C,D3]L-Met) DMEM 
medium lacking L-Met, L-cystine and pyruvate, which was supplemented with 
10% dialyzed FBS, 2 mM [13C,D3]L-Met and 0.2 mM L-cystine. Transfection 
was performed as described above using labeled medium.
Real-time PCR analysis of mRNA expression. For analysis of Tet1 and Tet2 
knockdown in mESC total RNA was prepared with Trizol (Invitrogen), cDNA 
synthesis was performed with Quantitect reverse transcription kit from 
Qiagen, and real-time PCR was performed with the Power Sybr Green PCR 
master mix from Applied Biosystems on an Applied Biosystems 75oo Fast sys-
tem. Knockdown efficiencies relative to control samples transfected with SCR 
esiRNAs were 79% and 70% for Tet1 and Tet2, respectively. The primers used 
to estimate them are listed in Supplementary Note 4. For analysis of Smug1 
knockdown in mESCs and EpiLC differentiation samples, total RNA was pre-
pared with RNeasy spin columns (Qiagen), followed by DNase treatment using 
TURBO DNA-free (Ambion, Life Technologies); cDNA synthesis was carried 
out using iScript cDNA Synthesis kit (Biorad); real-time PCR was performed 
with SsoFast EvaGreen Supermix (Biorad). Smug1 knockdown efficiency rela-
tive to control samples transfected with esiRNAs targeting GFP was estimated 
to be 60%. Quantification of Tet, Dnmt, Tdg and Smug1 transcripts during 
EpiLC differentiation and Smug1 knockdown samples was performed using 
the primers listed in Supplementary Note 4. Expression levels were quanti-
fied with respect to the housekeeping gene Gapdh and normalized to time 
point 0 h.
Tet in vitro assay. A plasmid was prepared from dam−/dcm− competent E. coli 
strain (New England BioLabs) and methylated with M.SssI (New England 
BioLabs). 1.5 μg of plasmid DNA were then treated with recombinant Tet1 
from the 5hmC TAB-Seq Kit (Wisegene) corresponding to ref. 54. After 3 h 
incubation at 37 °C and proteinase K treatment, the oxidized plasmids were 
purified with GeneJET PCR Purification Kit from Thermo Scientific and 
eluted in 25 μl water. Samples were then subjected to LC/MS/MS analysis as 
described42. The results are compiled in Supplementary Note 3.
Correlation and cluster analyses. Statistical data analysis was performed using 
IBM SPSS Statistics 19. Results of bivariate correlation analyses are summarized 
in Supplementary Note 5. Unsupervised clustering of species with respect to 
its correlation coefficients was applied by average linkage hierarchical cluster-
ing using a squared Euclidean distance measure.
Pulldown assay. For the pulldown assay, 250 μg (50 μl) of the crude nuclear 
protein extracts were filled up to 500 μl with 50 mM TEAB and 1 mM MgCl2. 
The binding conditions were 45 mM TEAB, 1.1 mM MgCl2, 2 mM HEPES, 
42 mM NaCl and 20 μM EDTA. Complete Protease Inhibitor Cocktail Tablets 
were used from Roche Diagnostics (Indianapolis, IN, USA). The DNA oligom-
ers with DNA-protein cross-linker were dissolved in neat DMSO, and 1 nmol 
was added to the protein lysate and incubated for 20 min at room temperature. 
Streptavidin-coated magnetic particles (Roche Diagnostics, Indianapolis, IN, 
USA) were washed three times with binding buffer (100 mM NaCl, 10 mM 
Tris, 1 mM EDTA, pH 7.4) before 200 μl of the bead slurry (equal to 2 mg 
beads) were added to the sample. Following 2 h incubation at room tempera-
ture under constant rotating, the beads were washed three times with 50 mM 
TEAB and 1 mM MgCl2. The beads were reconstituted in 50 mM TEAB and 
1 mM MgCl2. Disulfide bonds of the cross linker were cleaved and alkylated in 
the process of enzymatic digestion, and the magnetic particles were removed 
before adding trypsin (described below).
Protein sample preparation. Cell lysis of mouse embryonic stem cells was per-
formed as described in ref. 29. For each lysis, approximately 7.5 × 107 cells were 
used. Protein concentration was determined by Bradford assay. For each exper-
iment 250 μg (50 μl) of the crude nuclear protein extract were used. Protein 
samples for MS analysis were reduced by adding 100 mM TCEP and by incu-
bating on a shaker at 650 r.p.m. for 1 h at 60 °C and subsequently alkylated with 
200 mM iodoacetamide in the dark for 30 min at 25 °C. Protein samples were 
digested with 0.5 μg trypsin (Promega, Madison, MA, USA) for 16 h at 37 °C. 
The reaction was stopped using 1 mM phenylmethylsulphonylfluoride. After 
tryptic digestion, peptide labeling with the TMT2plex reagents (Thermo Fisher 
Scientific, Waltham, MA, USA) was performed according to the manufacturer’s 
instructions. TMT2plex reagents 126 and 127 were used to label the samples. 
When the sample (proteins enriched with hmU- or hmC-containing DNA 
strands) was labeled with TMT126, the control sample (proteins enriched with 
no modified DNA-bases) was labeled with the TMT127 reagent and vice versa. 
Subsequent to the labeling, both sample and control, were combined. This way, 
each experiment was performed twice as a so-called label swap experiment. 
Organic solvent was removed by vacuum centrifugation, and the sample was 
finally reconstituted in 1% (v/v) formic acid for MS analysis.
LC/MS analysis of protein samples. The samples were analyzed using an 
UltiMate 3000 nano liquid chromatography system (Dionex, Fisher Scientific, 
Waltham, MA, USA) coupled to an LTQ-Orbitrap XL (Thermo Fisher 
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identified proteins, the only proteins considered as ‘specific readers’ that were 
enriched in both, the forward and the reverse experiment.
Scientific, Waltham, MA, USA). Of each eluate, 15 μl were injected for the 
analysis. The samples were desalted and concentrated on a μ-precolumn 
cartridge (PepMap100, C18, 5 μM, 100 Å, size 300 μm i.d. x 5 mm) and fur-
ther processed on a custom-made analytical column (ReproSil-Pur, C18, 3 μM, 
120 Å, packed into a 75 μm i.d. x 150 mm and 8 μm picotip emitter). A 57-min 
multistep analytical separation was performed at a flow rate of 300 nl/min. 
In the first 50 min, a linear gradient was ramped up from 5% (v/v) solvent B 
(acetonitrile containing 0.1% formic acid and 5% DMSO) and 95% solvent A 
(water containing 0.1% formic acid and 5% DMSO) to 95% solvent B. This level 
was held for 5 min and then ramped down again to 5% solvent B within 2 min. 
Mass spectrometric analyses were performed starting with a full mass scan in 
the mass range between m/z 300 and m/z 1,650. This survey scan was followed 
by three MS/MS scans using the FTMS mass analyzer and high normalized 
collision energy of 70 in the HCD cell and three additional scans using the ion 
trap mass analyzer and a normalized collision energy of 35.
Protein identification and relative quantification method. The Thermo 
Proteome Discoverer 1.1 software (Thermo Fisher Scientific, Waltham, MA, 
USA) was used for protein identification and for relative quantification. The 
Sequest (Thermo Fisher Scientific, Waltham, MA, USA) search engine was 
used in combination with a Uniprot database (Mus musculus; date of download, 
04/2013). As a limit of detection, a ratio of threefold signal over the noise filter 
was applied. A maximum of two missed cleavage sites was allowed. The mass 
tolerances were 10 p.p.m. for the precursor mass and 0.5 Da for the fragment 
ion mass. Carbamidocysteine was set as static modification. Dynamic modi-
fications were: cation, Na (D, E); the residue of the DNA-protein crosslinker 
(+146.028 Da; K, Y); Oxidation (M) as well as TMT2plex (N-term. and K). 
Identified, nonredundant peptides, which were labeled with the TMT2 reagent, 
were used for relative quantification. The integration window tolerance was 
20 p.p.m., and the integration method was set to ‘most confident centroid’. The 
signals of the TMT2 reporter ions 126 and 127 were used to calculate ratios 
and monitor either preferred or nonpreferred binding of the identified pro-
teins to the modified DNA bases in comparison to the control strand. From the 
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  XII. DNA methylation in the context of oxidized cytidine 
derivatives 
 
Introduction: 
The inheritance of methylation marks is a major process in epigenetics. As described in Chapter 
I.2.2.1 it is carried out by DNMT1 in a conserved mechanism on hemi-methylated CpG loci 
after DNA replication.[1] The correct replication of a methylation mark is very complex and is 
tightly regulated. One of the most important factors is UHRF1, which acts as a molecular 
chaperone and activator for DNMT1.[2] As DNA methylation is involved in many biological 
processes such as transcription and cellular development, aberrant methylation patterns can 
have pathological consequences for a cell (see Chapter I.2.2).[3] 
The recently discovered oxidized cytidine derivatives are supposed to be intermediates in an 
active demethylation process, however it is suggested that these bases might also be involved 
in epigenetic processes such as transcription regulation(see Chapter I.2.3).[4] Therefore, it might 
be necessary for a cell to maintain certain patterns of modifications in the CpG loci. There are 
15 distinct patterns resulting from a DNMT/TET enzymatic cascade, who might alter biological 
processes or the epigenetic status ofa distinct loci.[5] Investigations whether this cascade can 
occur on hemi-modified DNA or these modification are lost by dilution after cell replication 
are necessary.  
While the potential of DNMT1 to methylate opposite of a hemi-hydroxymethylated CpG was 
already investigated in vitro and suggested to be rather low, an in vivo study showed significant 
methylation activity.[6-7] Additionally, the binding of UHRF1 to hmC containing DNA using its 
SRA domain was shown by EMSA studies and proteomic approaches, however this issue 
remains controversial as another study stated the opposite.[7-9] In the latter study FACS was also 
used to determine the dilution of hmC after DNA replication in the S-phase in mESCs.[7] A 
significant reduction of hmC levels was observed and a model was suggested that connects 
hmC predominantly with de novo methylation. A model for replication dependent dilution of 
hmC in PGCs was shown as well as the dilution of fC and caC in embryonic development.[10-
11] Unlike hmC, fC and caC are suggested to be intermediates in active DNA demethylation. 
However as the exact biological functions of these new epigenetic players are yet not fully 
understood, it might be necessary for a cell to copy a formylated or carboxylated mark under 
certain circumstances.   
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Results and discussion: 
To investigate the methyltransferase activity in the context of the newly discovered cytidines, 
different oligonucleotides containing the new cytidine derivatives hmC, fC and caC were 
incubated with the three DNA methyltransferases DNMT1, DNMT3a and DNMT3b in 
presence of radiolabeled SAM using a multiwell assay.[12] The resulting kinetics (Fig. 1) 
showed a strong preference of DNMT1 for hemi-methylated DNA and only 1/10 of its activity 
towards hemi-hydroxymethylated and-formylated DNA. Unmethylated DNA showed an even 
slower activity and hemi-carboxylated DNA did not act as a substrate. This result is consistent 
with earlier studies and supports the idea that demethylation by dilution after DNA replication 
is enhanced by oxidation of mC. However DNMT1 is a tightly regulated enzyme and 
establishing the methylation system in vitro is very challenging. Especially interactions of 
several domains in DNMT1s N-terminal region can influence substrate binding and activity as 
described in Chapter I.2.3.[1]  
 
 
Figure 1: Methylation activity of truncated (A) and kinetics of full length (B) DNMT1 in different 
modification contexts. All datapoints are presented in table 1 and table 3 A) Quantification of the change of 
mC in different contexts by LC-MS/MS. Each context was measured in triplica and the mean values were 
taken, SD is illustrated in black bars. Relative methylation of 1.0 represents full conversion of the single 
CpG to mCpG. This was observed in the mC and hmC context while no significant change in the fC and 
caC context could be detected B) Relative activity of full length DNMT1 in different contexts determined 
by radiolabeling using 3H-SAM. Plotting radio counts and time resulted in a kinetic plot of the enzyme. The 
calculated slope of the hemi-methylated substrate was set as 1 and the slopes of the other modifications set 
relative to it. A clear preference for the mC context was detected, while a CpG in the caC context did not 
act as substrate. 
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To address this issue a truncated version of DNMT1 lacking the N-terminal region was 
expressed by Caterina Brandmayr and a methylation assay was performed to determine the 
activity in the context of the newly discovered cytidine derivatives.[13] Surprisingly the 
truncated enzyme was capable to convert 100% of the available CpG loci into mCpG in an hmC 
context (Fig. 1). 
In contrast, in an fC or caC context only about 10% of conversion was observed, even though 
the kinetics of the full length protein in fC and hmC context are similar. It is therefore possible, 
that a switch for the recognition of hemi-hydroxymethylated CpGs exists, as the catalytic site 
is in principle capable of establishing mC in an hmC context. Interestingly UHRF2, a homolog 
of UHRF1 which is supposed to be responsible for such a switch in the mC context, was 
identified as a specific reader for hmC, which repells mC, and found to enhance hmC levels in 
vivo.[9] In contrast to the hmC context, the CpG loci in the fC and caC context remained in an 
unmethylated state, which supports their role as intermediates in DNA demethylation. This 
observation might result from the different chemical properties of fC and caC that exclude 
binding to DNMT1. 
Even though the low activity of the full length DNMT1 on hmC containing CpG loci could be 
confirmed, this study revealed that in principle hmC can fit unlike fC or caC into the active site 
of the enzyme and contribute to methylation. By using a regulatory switch for DNMT1 followed 
by oxidation by one of the TET enzymes, a fully hydroxymethylated CpG locus could be 
maintained. Therefore further investigations have to be done to gain insights into the role of 
DNMT1 in the maintenance of methylation/hydroxymethylation patterns.  
In the kinetic study DNMT3a did not show a preference for any modification type (Fig. 2A), 
On the other hand DNMT3b showed a strong preference for unmethylated DNA and about 0.2 
times the activity on the other types of CpGs (Fig. 2B). The results for unmodified, 
hemi-methylated and -hydroxymethylated CpG loci are consistent with previous reports. These 
reports suggested a role of DNMT3a/b in maintenance of hydroxymethylation.[6] This study 
could extend the role of DNMT3a to fC and caC CpG sites and offers an enzymatic route to the 
15 distinct patterns of CpG modifications by a DNMT3a/TET cascade. These enzymes have 
already been linked and the distinct patterns could be connected to different biological 
functions.[5] However this study was only performed in vitro and can of course not mimic the 
complex processes of the DNA methylation/demethylation machinery. Additionally, oxidation 
of mC is suggested to take place predominantly at hemi-methylated CpG loci, therefore the 
biological relevance of the distinct patterns is yet not known.[14] Very recently Ji et al. were 
able to show similar effects of the new epigenetic bases on DNMT1 and DNMT3a methylation 
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using LC-MS/MS on ODN containing two repetitive CpG sites.[15] Interestingly the 
modification status of one CpG site has great influence on the methylation of the second site. 
Further studies have to be performed using more complex in vitro and in vivo approaches. 
 
 
Figure 2: Relative activity of DNMT3a (A) and DNMT3b (B) in different contexts determined by 
radiolabeling using 3H-SAM. Plotting radio counts and time resulted in a kinetic plot of the enzyme. The 
calculated slope of the unmethylated substrate was set as 1 and the slopes of the other modifications set 
relative to it. Datapoints were collected in duplica and the mean value was used to calculate the slope. A) No 
preference of DNMT3a is visable. B) A clear preference for unmethylated DNA of DNMT3b was detected. 
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Materials and Methods: 
Enzymatic digestion of DNA samples  
DNA samples isolated after in vitro experiments were resuspended in 25 µL H2O. The first 
digestion step was carried out in 100 µM ZnSO4 with 42 units Nuclease S1 (Aspergillus oryzae, 
Roche) and 5 units antarctic phosphatase (New England Biolabs) and incubated at 37 °C for 3 
h. The second digestion step was performed by addition of [Na]2-EDTA (final concentration 
100 µM) and 0.2 units snake venom phosphodiesterase I (Crotalus adamanteus venom, UBS 
Corporation) and incubation at 37 °C for 3 h.  
  
LC-ESI-MS/MS:  
Acetonitrile (LC-MS grade) was purchased from Carl Roth; formic acid (p.a. grade for MS) 
was purchased from Fluka; water was purified by a Milli-Q Plus system (Merck Millipore); 
general HPLC and source settings for LC-ESI-MS/MS were as previously described.[16]  
 
Methylation assay using truncated DNMT1 
Oligonucleotides (ODN7 – ODN11) bearing a single CpG site (modified or unmodified) where 
annealed by heating to 95 °C for 4 min followed by cooling to 4 °C over a period of 45 min. 
Methylation assay was performed together with Caterina Brandmayr in 1 x Dnmt1 Reaction 
Buffer (New England Biolabs), with double stranded DNA (1 µM), purified truncated mDnmt1 
(1 µM, Caterina Brandmayr), Bovine Serum Albumin (0.1 mg/mL) and with or without SAM 
(160 µM). All experiments were performed in triplicate in a total reaction volume was 20 µL. 
Samples were incubated at 37 °C for 3 h, followed by extraction using Roti- 
Phenol/CHCl3/isoamylalcohol (Roth) and by desalting using ZipTip (Millipore). Purified 
oligonucleotides were subsequently digested to single nucleosides and analyzed by LC-
MS/MS. Mass spectrometry analysis was performed using a method established by Toni 
Pfaffeneder as described.[16] 
 
DNA-Synthesis: 
DNA-Synthesis was performed as described by Schröder et al. or purchased from metabion and 
verified by MALDI-MS and HPLC.[17] 
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Data of methylation assay: 
XpG:CpG mCpG (%) St.Dev. (%) 
mC 104,52 5,50 
hmC 106,07 5,43 
fC 8,55 10,72 
caC 4,08 14,58 
 
Table 1: Change of mC in percent upon incubation with truncated mDnmt1 (with or without SAM) per 
modified CpG site (X = mC, hmC fC or caC). All experiments were performed in triplicate. 
 
Oligonucleotides used: 
ODN Sequence source 
1 5´Bio-TTGCACTCTCCTCCCGGAAGTCCCAGCTTC-3´ metabion 
2 5´-GAAGCTGGGACTTCCGGGAGGAGAGTGCAA-3´ metabion 
3 5´-GAAGCTGGGACTTCmCGGGAGGAGAGTGCAA-3´ metabion 
4 5´-GAAGCTGGGACTTChmCGGGAGGAGAGTGCAA-3´ Arne Schröder 
5 5´-GAAGCTGGGACTTCfCGGGAGGAGAGTGCAA-3´ Arne Schröder 
6 5´-GAAGCTGGGACTTCcaCGGGAGGAGAGTGCAA-3´ Arne Schröder 
7 5´-CCTAGCGCATTAC-3´ metabion 
8 5´-GTAATGmCGCTAGG-3´ metabion 
9 5´-GTAATGhmCGCTAGG-3´ Dr. Martin Muenzel 
10 5´-GTAATGfCGCTAGG-3´ Dr. Martin Muenzel 
11 5´-GTAATGcaCGCTAGG-3´ Dr. Martin Muenzel 
 
Table 2: Oligonucleotides used for methylation assays and kinetics, XpG in red. 
 
Methylation kinetics: 
Methylation kinetics were performed as described by Dr. Renata Jurkowska and colleagues.[12] 
Briefly, methylation reactions using DNMT1 (0.2 µM) were carried out with DNA substrate (2 
µM), [methyl-3H]AdoMet (1.0 µM; PerkinElmer) at 37.8 °C in methylation buffer (20 mM 
HEPES, pH 7.5), EDTA (1 mM), KCl (50 mM)). Methylation reactions using DNMT3b/a (2.5 
µM) were carried out with DNA substrate (1 µM), [methyl-3H]AdoMet (1.0 µM; PerkinElmer) 
at 37.8 °C in methylation buffer (20 mM HEPES, pH 7.5), EDTA (1 mM), KCl (50 mM)). 
DNA substrates for the assay were prepared by annealing an ODN1 with a complementary 
oligonucleotide ODN2-6, to form unmethylated and hemimethylated substrates. Initial rates 
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were determined by linear regression. Methylation assays were calibrated by complete 
methylation of the substrates with M.SssI (CpG methyltransferase; NEB). 
 
Data of methylation kinetics: 
 
DNMT1: 
Time [min] C mC hmC caC fC 
2 54 637 53 14 78 
5 128 1920 149 15 192 
10 224 4162 304 19 393 
15 296 6762 539 13 591 
Slope 19 470 37 0 40 
Rel. activity 1.0 25.4 2.0 0.0 2.1 
 
Table 3: Methylation kinetics measurement results for DNMT1 in radio counts/minute (CPM) for different 
methylation contexts. Unmethylated DNA corresponds to C-context, hemi-methylated DNA to mC-context, 
hemi-hydroxymethylated to hmC-context, hemi-formylated DNA to fC-context, hemi-carboxylated DNA to 
caC. 
 
DNMT3a: 
Time [min] C-1 C-2 C Average mC-1 mC-2 mC Average 
3 79 78 79 78 nd 78 
6 106 89 97 76 82 79 
12 129 100 115 113 124 118 
18 234 221 228 226 243 234 
24 260 341 300 485 342 414 
Slope 10.8 15.7 
Rel. activity 1.00 1.45 
Time [min] hmC-1 hmC-2 hmC Average caC-1 caC-2 caC Average fC-1 fC-2 fC Average 
3 78 81 80 106 80 93 57 62 60 
6 94 125 110 94 83 88,167  117 117 
12 218 173 195 154 155 154,5 141 127 134 
18 278 266 272 277 275 276,1665 240 240 240 
24 nd nd nd nd nd nd 298 301 300 
Slope 13.1 12.6 11.1 
Rel. activity 1.21 1.17 1.03 
 
Table 4: Methylation kinetics measurement results for DNMT3a in radio counts/minute (CPM) for different 
methylation contexts. Unmethylated DNA corresponds to C-context, hemi-methylated DNA to mC-context, 
hemi-hydroxymethylated to hmC-context, hemi-formylated DNA to fC-context, hemi-carboxylated DNA to 
caC. 
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DNMT3b: 
Time [min] C-1 C-2 C Average mC-1 mC-2 mC Average 
3 1250 1185 1217 218 232 225 
6 2348 2144 2246 398 381 390 
12 4212 3685 3949 663 632 648 
18 5877 4949 5413 894 1122 1008 
24 5636 5913 5775 nd 1119 1119 
Slope 246.3 49.2 
Rel. activity 1.00 0.20 
Time [min] hmC-1 hmC-2 hmC Average caC-1 caC-2 caC Average fC-1 fC-2 fC Average 
3 180 211 251 160 163 161 200 204 202 
6 383 367 337 260 288 274 354 402 378 
12 552 564 509 655 523 589 614 603 608 
18 816 790 852 673 782 728 1124 915 1019 
24 1185 898 1042 978 932 955 1020 1164 1092 
Slope 43.0 40.8 49.7 
Rel. activity 0.17 0.17 0.20 
 
Table 6: Methylation kinetics measurement results for DNMT3b in radio counts/minute (CPM) for different 
methylation contexts. Unmethylated DNA corresponds to C-context, hemi-methylated DNA to mC-context, 
hemi-hydroxymethylated to hmC-context, hemi-formylated DNA to fC-context, hemi-carboxylated DNA to 
caC. 
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XIII. Dynamics of pyrimidines during methyltransferase 
treatment 
 
Introduction: 
As described in Chapter I.2.3 deamination of mC to dT is speculated to be a pathway in active 
demethylation. DNMT3a/3b are supposed to be involved in this pathway, as upon saturation of 
the C5-C6 double bond in the pyrimidine ring a nucleophilic attack is possible by for example 
a surrounding water molecule. The resulting in deamination is possible before methylation 
resulting in dU, or after methylation resulting in dT. Next to this conversion of cytidines into 
uridines, DNMTs have been reported to act as demethylases by C-C bond cleavage and also a 
mechanism has been proposed and investigated chemically. The dynamics of pyrimidines is 
therefore a combination of deamination and C-C bond cleavage, which can in principle both be 
catalysed by DNMTs. 
 
Results and discussion: 
For a first investigation of the dynamics of pyrimidine derivatives, the oligonucleotides that 
were used for the kinetics of DNMT3s were incubated in the presence and absence of SAM by 
Dr. Renata Jurkowska and colleagues. The re-isolated DNA was then analysed using LC-
MS/MS and dynamics of pyrimidines evaluated by calculating the change of each modification 
per CpG (Fig. 1).  
The transformation of C to mC catalysed by DNMT3b in C-context correlates with the kinetic 
study, as the amount of C is decreasing and mC is rising by 50% per CpG (Fig. 1a). This 
observation corresponds to methylation and is weaker for the other substrates, which only show 
methylation of about 10% per CpG. Additionally, the amounts of the other pyrimidine-
derivatives did not show significant changes. The dynamics for pyrimidines incubated with 
DNMT3a were controversial (Fig. 1b). While the methylation activity of the enzyme was very 
low, a loss of C of about 20% per CpG and a gain of dT was observed in roughly the same 
amount. This could refer to deamination and could be observed in mC-context 
(hemi-methylated DNA) and hmC-context (hemi-hydroxymethylated DNA). Again no change 
in the other pyrimidine derivatives could be observed. 
Data from chapter XII using truncated DNMT1 was also evaluated in respective to deamination 
but no indications could be found (not shown). 
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Fig.1: Dynamics of pyrimidines in different CpG modification contexts after incubation with DNMT3b (A) 
or DNMT3a (B) as detected by single measurements via LC-MS/MS in the presence of SAM compared to 
the absence of SAM. A) A gain in mC with a combined decrease of C displays in the C context the preference 
of DNMT3b for unmethylated DNA as reported in chapter XII. All other pyrimidines in the other contexts 
did not show dynamic changes. B) No changes of mC, hmC, fC and caC could be detected in any context.in 
the mC and hmC context a loss C and a gain of Tcould be detected after incubation of DNMT3a in the 
presence of SAM. 
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These results therefore do not support the idea of C-C bond cleavage by DNMTs, but suggest 
a deamination activity of DNMT3a under the given conditions. However the absolute changes 
are in the range of the error of the applied method and only single samples were measured.  
In principle two sides can be deaminated in hemi-methylated DNA: the template strand already 
harbouring an mC, or the counterstrand after successful methylation using SAM. In 
hemi-hydroxymethylation, deamination from mC to dT can only occur after methylation. To 
validate the suggestion of deamination an incubation under the same conditions using D3-SAM 
was performed to check if deamination occurs after successful methylation, which would result 
in D3-dT. However this was not the case using DNMT3a and DNMT3b in unmethylated or 
hemimethylated DNA (data not shown). To further investigate the dynamics and to exclude the 
possibility of deamination in the strand already harbouring mC, DNA containing dU instead of 
dT was synthesized, as dU did not show up in any of the earlier experiments and deamination 
of mC to dT would be easier detectable.  
Incubation of these oligonucleotides did not show any deamination activity of DNMT3a (data 
not shown). As the methylation activity was with a maximum of 1.3% per CpG also very low, 
it is possible that the enzyme was not active at all and therefore the experiment has to be 
repeated in the future. 
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Materials and Methods: 
Enzymatic digestion of DNA samples  
DNA samples isolated after in vitro experiments were resuspended in 25 µL H2O. The first 
digestion step was carried out in 100 µM ZnSO4 with 42 units Nuclease S1 (Aspergillus oryzae, 
Roche) and 5 units antarctic phosphatase (New England Biolabs) and incubated at 37 °C for 
3 h. The second digestion step was performed by addition of [Na]2-EDTA (final concentration 
100 µM) and 0.2 units snake venom phosphodiesterase I (Crotalus adamanteus venom, UBS 
Corporation) and incubation at 37 °C for 3 h.  
 
LC-ESI-MS/MS:  
Acetonitrile (LC-MS grade) was purchased from Carl Roth; formic acid (p.a. grade for MS) 
was purchased from Fluka; water was purified by a Milli-Q Plus system (Merck Millipore); 
general HPLC and source settings for LC-ESI-MS/MS were as previously described.[1]  
 
In vitro reactions: 
In vitro reactions were performed as described by Dr. Renata Jurkowska.[2] Briefly, methylation 
reactions were carried out with DNA substrate (1µM), 320µM SAM or D3-SAM and 
recombinant DNMTs (2.5 µM) at 37.8 °C in methylation buffer (20 mM HEPES, pH 7.5), 
EDTA (1 mM), KCl (5.0 mM)) for 1 h. DNA substrates for the assay were prepared by 
annealing an ODN containing one unmethylated CpG site with a complementary 
oligonucleotide, to form unmethylated and hemimethylated substrates. After incubation the 
samples were frozen at -20 °C and then purified by spin columns after addition of 1 x volume 
isopropanol (GeneJET, Thermo Fisher), followed by enzymatic digestion as described above. 
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Data of methylation reactions: 
 T/CpG island C/CpG island mC/CpG island hmC/CpG island fC/CpG island caC/CpG island 
C DNMT3b 0,94% -51,57% 50,62% 0,00% 0,01% 0,00% 
mC DNMT3b 5,95% -14,80% 8,88% 0,00% -0,01% -0,02% 
hmC DNMT3b 5,11% -14,71% 10,25% -0,67% 0,01% 0,00% 
fC DNMT3b -1,05% -8,07% 9,10% 0,03% 0,00% -0,01% 
caC DNMT3b 10,99% -20,72% 9,58% 0,05% 0,03% 0,07% 
C DNMT3a -1% -6,75% 7,63% 0,00% 0,01% -0,01% 
mC DNMT3a 20% -19,09% -1,11% 0,00% 0,01% -0,01% 
hmC DNMT3a 25% -27,41% 3,24% -1,03% 0,02% 0,00% 
fC DNMT3a -12% 6,59% 2,44% 0,02% 2,54% 0,00% 
caC DNMT3a -9% 4,85% 2,87% 0,04% 0,00% 0,81% 
 
Table 1: Change of pyrimidines in (%) per CpG in different methylation contexts after incubation using 
DNMT3a or DNMT3b. 
 
DNA-Synthesis: 
DNA-Synthesis was performed as described by Schröder et al. or purchased from metabion and 
verified by MALDI-MS and HPLC.[3] The phosphoramidite for dU was purchased from Glen 
Research. 
 
ODNs used: 
ODN Sequence Source 
1 5´Bio-TTGCACTCTCCTCCCGGAAGTCCCAGCTTC-3´ Metabion 
2 5´-GAAGCTGGGACTTCCGGGAGGAGAGTGCAA-3´ Metabion 
3 5´-GAAGCTGGGACTTCmCGGGAGGAGAGTGCAA-3´ Metabion 
4 5´-GAAGCTGGGACTTChmCGGGAGGAGAGTGCAA-3´ Arne Schröder 
5 5´-GAAGCTGGGACTTCfCGGGAGGAGAGTGCAA-3´ Arne Schröder 
6 5´-GAAGCTGGGACTTCcaCGGGAGGAGAGTGCAA-3´ Arne Schröder 
7 5´-Bio-UUGCACUCUCCUCCCGGAAGUCCCAGCUUC-3´ Benjamin Hackner 
8 5´-Bio-UUGCACUCUCCUCCmCGGAAGUCCCAGCUUC-3 Benjamin Hackner 
9 5´-GAAGCUGGGACUUCCGGGAGGAGAGUGCAA-3´ Benjamin Hackner 
10 5´-GAAGCUGGGACUUCmCGGGAGGAGAGUGCAA-3´ Benjamin Hackner 
11 5´Bio-TTGCACTCTCCTCCcaCGGAAGTCCCAGCTTC-3´ Benjamin Hackner 
 
Table 2: Oligonucleotides used for dynamics of pyrimidines, XpG sites marked in red.  
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XIV. Abbrevations 
 
AA Amino acid 
AdoMet S-Adenosylmethionine 
AP-site Apurinic/Apyrimidinic site 
ARP Aldehyde reactive probe 
BER Base excision repair 
BS Bisulphite seqeuence 
caC 5-carboxylcytidine 
CGI Cytidine-Guanosine dinucleotide island 
CpG Cytidine-Guanosine dinucleotide 
dA 2´desoxy adenine 
dC 2´desoxy cytidine 
dG 2´desoxy guanidine 
DNA Desoxy-ribonucleic acid 
DNMT DNA 5-Methyltransferase 
dsDNA Double stranded DNA 
dT 2´desoxythymidine 
dU 2´desoxyuridine 
EDTA Ethylenediaminetetraacetaic acid 
EMSA Electromobility shift assay 
ESI Electrion spray ionization 
FACS Fluorescence assisted cell sorting 
fC 5-formylcytidine 
GK repeats Glycine-Lysine repeat 
HAT Histone acetyltransferase 
HDAC Histone deacetalyse 
HEPES 2-(4-(2-Hydroxyethyl)-1-piperazinyl)-ethansulfonic acid 
hmC 5-hydroxymethylcytidine 
HPLC High performance liquid chromatography 
IDCase Isoorotate decarboxylase 
iPSC Induced pluripotent stem cell 
IUPAC International Union of Pure and Applied Chemistry 
LC-MS Liquid chromatography- mass spectrometry 
LC-MS/MS Liquid chromatography-tandem mass spectrometry 
MALDI Matrix assocated LASER desorption ionization 
mC 5-methylcyitidine 
mESC Mouse embryonic stem cell 
mRNA Messenger ribonucleic acid 
ODN Oligonucleotide 
OG 2-oxogluterate 
oligo Oligonucleotide 
PCR Polymerase chain reaction 
PGC Primordial germ cells 
PWWP-domain proline-tryptophane motif 
QQQ Triple quadropole 
SAM S-adenosylmethionine 
ssDNA Single stranded DNA 
TDG Thymidine DNA glycosylase 
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TET Ten eleven translocation 
UV Ultra-Violet  
 
